Paclitaxel
Information
- Drug Name
- Paclitaxel
- Description
- Entry(CIViC)
- 24
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma |
ETS2 p.Pro341= (p.P341=) ( ENST00000360214.8, ENST00000360938.8, ENST00000653642.1, ENST00000662305.1, ENST00000666778.1, ENST00000667466.1 ) ETS2 p.Pro341= (p.P341=) ( ENST00000360214.8, ENST00000360938.8, ENST00000653642.1, ENST00000662305.1, ENST00000666778.1, ENST00000667466.1 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Common Germline | 2 | 26893365 | Detail |
| skin melanoma |
CCND1 AMPLIFICATION ( ENST00000227507.3 ) CCND1 AMPLIFICATION ( ENST00000227507.3 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26307133 | Detail |
| skin melanoma |
RAF1 AMPLIFICATION ( ENST00000251849.9 ) RAF1 AMPLIFICATION ( ENST00000251849.9 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26307133 | Detail |
| cervical adenocarcinoma |
AURKA OVEREXPRESSION ( ENST00000395913.7 ) AURKA OVEREXPRESSION ( ENST00000395913.7 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 12559175 | Detail |
| stomach cancer |
ATM UNDEREXPRESSION ( ENST00000278616.10 ) ATM UNDEREXPRESSION ( ENST00000278616.10 ) |
B |
Predictive
|
Supports
|
N/A
|
1 | 26282658 | Detail | |
| lung non-small cell carcinoma |
RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
Unknown
|
3 | 23038758 | Detail |
| Solid Tumor |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 4 | 28281183 | Detail |
| salivary gland cancer | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 23826550 | Detail |
| breast cancer | PIK3CA MUTATION PIK3CA MUTATION | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 18371219 | Detail |
| ovarian carcinoma |
GSTP1 DELETION ( ENST00000398606.10 ) GSTP1 DELETION ( ENST00000398606.10 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 25010864 | Detail |
| ovary epithelial cancer |
KRAS c.*2626T>G ( ENST00000256078.10, ENST00000688940.1, ENST00000553788.6, ENST00000692768.1, ENST00000685328.1, ENST00000693229.1, ENST00000311936.8 ) KRAS c.*2626T>G ( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1, ENST00000553788.6 ) |
B |
Predictive
|
Supports
|
Resistance | Common Germline | 3 | 22139083 | Detail |
| ovarian cancer |
ABCB1 p.Ser893Thr (p.S893T) ( ENST00000265724.8, ENST00000543898.5, ENST00000622132.5 ) ABCB1 p.Ser893Thr (p.S893T) ( ENST00000265724.8, ENST00000543898.5, ENST00000622132.5 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 3 | 16467099 | Detail |
| lung non-small cell carcinoma |
ERCC2 p.Lys751Gln (p.K751Q) ( ENST00000391944.8, ENST00000391945.10, ENST00000684407.1 ) ERCC2 p.Lys751Gln (p.K751Q) ( ENST00000391944.8, ENST00000391945.10, ENST00000684407.1 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 3 | 19470925 | Detail |
| cancer |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 25672916 | Detail |
| breast cancer |
MYD88 OVEREXPRESSION ( ENST00000417037.8 ) MYD88 OVEREXPRESSION ( ENST00000417037.8 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 26596839 | Detail |
| ovarian cancer |
SYK OVEREXPRESSION ( ENST00000375754.9 ) SYK OVEREXPRESSION ( ENST00000375754.9 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 26096845 | Detail |
| lung non-small cell carcinoma | NRG1 EXPRESSION NRG1 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 23390248 | Detail |
| lung cancer | PDCD4 EXPRESSION PDCD4 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 25928036 | Detail |
| endometrial carcinoma | STMN1 EXPRESSION STMN1 EXPRESSION | B |
Predictive
|
Supports
|
Resistance |
N/A
|
3 | 24587245 | Detail |
| cancer | TUBB3 EXPRESSION TUBB3 EXPRESSION | D |
Predictive
|
Supports
|
Resistance |
N/A
|
2 | 21576762 | Detail |
| breast cancer |
TIMP1 OVEREXPRESSION ( ENST00000218388.9 ) TIMP1 OVEREXPRESSION ( ENST00000218388.9 ) |
B |
Predictive
|
Supports
|
Resistance |
N/A
|
2 | 22544540 | Detail |
| lung non-small cell carcinoma | ABCB1 EXPRESSION ABCB1 EXPRESSION | D |
Predictive
|
Supports
|
Resistance |
N/A
|
2 | 21883677 | Detail |
| breast cancer |
ABCC3 AMPLIFICATION ( ENST00000285238.13 ) ABCC3 AMPLIFICATION ( ENST00000285238.13 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 18593940 | Detail |
| lung non-small cell carcinoma | ABCC10 EXPRESSION ABCC10 EXPRESSION | D |
Predictive
|
Supports
|
Resistance |
N/A
|
3 | 18445659 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Eighty SNPs in miRNA binding sites of cancer relat... | ETS2 |
ETS2 p.Pro341= (p.P341=) ( ENST00000360214.8, ENST00000360938.8, ENST00000653642.1, ENST00000662305.1, ENST00000666778.1, ENST00000667466.1 ) ETS2 p.Pro341= (p.P341=) ( ENST00000360214.8, ENST00000360938.8, ENST00000653642.1, ENST00000662305.1, ENST00000666778.1, ENST00000667466.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| Retrospective analysis of somatic mutations and co... | CCND1 |
CCND1 AMPLIFICATION ( ENST00000227507.3 ) CCND1 AMPLIFICATION ( ENST00000227507.3 ) |
Sensitivity | true | CIViC Evidence | detail |
| Retrospective analysis of somatic mutations and co... | RAF1 |
RAF1 AMPLIFICATION ( ENST00000251849.9 ) RAF1 AMPLIFICATION ( ENST00000251849.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| In the cervial andenocarcinoma cell line HeLa, whe... | AURKA |
AURKA OVEREXPRESSION ( ENST00000395913.7 ) AURKA OVEREXPRESSION ( ENST00000395913.7 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| A randomized phase 2 trial investigating the effic... | ATM |
ATM UNDEREXPRESSION ( ENST00000278616.10 ) ATM UNDEREXPRESSION ( ENST00000278616.10 ) |
N/A | true | CIViC Evidence | detail |
| The study began with a total of 443 patients that ... | RRM1 |
RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| No objective responses were observed in the PTEN d... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Sensitivity | false | CIViC Evidence | detail |
| Case report of a 61-year-old caucasian male with a... | ERBB2 | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| This study of 140 patients with stage II-III breas... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | false | CIViC Evidence | detail |
| Stable GSTP1 knockdown in ovarian carcinoma A2780 ... | GSTP1 |
GSTP1 DELETION ( ENST00000398606.10 ) GSTP1 DELETION ( ENST00000398606.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The functional variant rs61764370 in the KRAS gene... | KRAS |
KRAS c.*2626T>G ( ENST00000256078.10, ENST00000688940.1, ENST00000553788.6, ENST00000692768.1, ENST00000685328.1, ENST00000693229.1, ENST00000311936.8 ) KRAS c.*2626T>G ( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1, ENST00000553788.6 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| The ABCB1 G2677T/A (S893T, rs2032582) homozygous v... | ABCB1 |
ABCB1 p.Ser893Thr (p.S893T) ( ENST00000265724.8, ENST00000543898.5, ENST00000622132.5 ) ABCB1 p.Ser893Thr (p.S893T) ( ENST00000265724.8, ENST00000543898.5, ENST00000622132.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| The ERCC2 K751Q variant is significantly correlate... | ERCC2 |
ERCC2 p.Lys751Gln (p.K751Q) ( ENST00000391944.8, ENST00000391945.10, ENST00000684407.1 ) ERCC2 p.Lys751Gln (p.K751Q) ( ENST00000391944.8, ENST00000391945.10, ENST00000684407.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| All three patients with PTEN loss had benefit from... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this retrospective analysis of 211 breast cance... | MYD88 |
MYD88 OVEREXPRESSION ( ENST00000417037.8 ) MYD88 OVEREXPRESSION ( ENST00000417037.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Overexpression and high p-SYK/SYK ratio were assoc... | SYK |
SYK OVEREXPRESSION ( ENST00000375754.9 ) SYK OVEREXPRESSION ( ENST00000375754.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In-vivo studies of residual NSCLC tumors (xenograf... | NRG1 | NRG1 EXPRESSION NRG1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| PDCD4 expression was associated with response to p... | PDCD4 | PDCD4 EXPRESSION PDCD4 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| 33 patients were retrospectively analyzed for Stat... | STMN1 | STMN1 EXPRESSION STMN1 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| High expression of class 3 beta-tubulin led to dec... | TUBB3 | TUBB3 EXPRESSION TUBB3 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| High expression of TIMP-1 was assessed by IHC in 9... | TIMP1 |
TIMP1 OVEREXPRESSION ( ENST00000218388.9 ) TIMP1 OVEREXPRESSION ( ENST00000218388.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| mRNA expression of ABCB1 in 17 NSCLC cell lines wa... | ABCB1 | ABCB1 EXPRESSION ABCB1 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 44 cell lines and 145 patient samples were utilize... | ABCC3 |
ABCC3 AMPLIFICATION ( ENST00000285238.13 ) ABCC3 AMPLIFICATION ( ENST00000285238.13 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Increased expression of ABCC10 in 17 NSCLC cell li... | ABCC10 | ABCC10 EXPRESSION ABCC10 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| MITF amplification does not predict chemosensitivi... | MITF | MITF AMP | Resitance or Non-Reponse | true | MMMP | detail |
| Blocking the expression of APP by RNA interference... | APP | APP UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Pretreatment of melanoma cells with the JNK inhibi... | MAPK8 | MAPK8 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Inhibition of ATF-2 phosphorylation by retinoic ac... | ATF2 | ATF2 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| HM30181A: P-gp inhibitor. P-gp in the brain microe... | ABCB1 | ABCB1 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Elesclomol is believed to act by increasing reacti... | ROS1 | ROS1 OVEREXPRESSION | Sensitivity | true | MMMP | detail |
| Dasatinib does not act synergically with paclitaxe... | SRC | SRC UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| ABCB8 mediates the resistance to doxorubicin (but ... | ABCB8 | ABCB8 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| 20% of samples were TUBB3 negative and HDAC inhibi... | TUBB3 | TUBB3 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Paclitaxel is selectively targeted to melanoma cel... | AMFR | AMFR UNKNOWN | Sensitivity | true | MMMP | detail |
| Results based on both expression and forced expres... | DCT | DCT EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| The findings identify p38, TNFalpha and NFkB as ke... | TRAF2 | TRAF2 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| The results indicate that although Muc4(+) cells e... | MUC4 | MUC4 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| The findings suggest that the use of taxane in ant... | MYC | MYC EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Various chemotherapy regimens: gemcitabine + treos... | MITF | MITF AMP | Resitance or Non-Reponse | true | MMMP | detail |
| Non melanoma specific model (miscellany). Increase... | ABCB1 | ABCB1 UNKNOWN | toxicity increased | true | MMMP | detail |
| Non melanoma specific model (breast cancer) | ABCB1 | ABCB1 UNKNOWN | toxicity unchanged | true | MMMP | detail |
| Non melanoma specific model (breast cancer) | ABCB1 | ABCB1 UNKNOWN | toxicity unchanged | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04175912 | Active, not recruiting | Phase 2 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | March 16, 2020 | October 1, 2024 |
| NCT02876302 | Active, not recruiting | Phase 2 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | January 24, 2018 | August 2024 |
| NCT03719924 | Active, not recruiting | Phase 2 | Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma | March 7, 2019 | April 15, 2025 |
| NCT03716180 | Active, not recruiting | Phase 1 | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | November 5, 2018 | September 1, 2030 |
| NCT03694002 | Active, not recruiting | Phase 2 | Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | March 20, 2019 | November 30, 2024 |
| NCT02876107 | Active, not recruiting | Phase 2 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | October 6, 2016 | October 31, 2025 |
| NCT04908787 | Active, not recruiting | Phase 3 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | June 11, 2021 | December 2024 |
| NCT03635567 | Active, not recruiting | Phase 3 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | October 25, 2018 | June 4, 2024 |
| NCT02794571 | Active, not recruiting | Phase 1 | Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors | May 23, 2016 | October 5, 2024 |
| NCT04172259 | Active, not recruiting | Phase 2 | ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | January 10, 2019 | September 30, 2026 |
| NCT00770809 | Active, not recruiting | Phase 3 | Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | December 1, 2008 | July 10, 2024 |
| NCT03957590 | Active, not recruiting | Phase 3 | Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC | June 12, 2019 | December 30, 2024 |
| NCT02779855 | Active, not recruiting | Phase 1/Phase 2 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | May 2, 2017 | August 31, 2024 |
| NCT06212752 | Active, not recruiting | Phase 3 | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension | June 13, 2023 | May 22, 2028 |
| NCT02734290 | Active, not recruiting | Phase 1/Phase 2 | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | February 23, 2016 | December 2025 |
| NCT04781088 | Active, not recruiting | Phase 2 | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | September 1, 2021 | February 9, 2025 |
| NCT04166487 | Active, not recruiting | Phase 2 | Plasma-Adapted First-Line Pembro In NSCLC | January 13, 2020 | December 1, 2024 |
| NCT05173987 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | February 3, 2022 | May 27, 2027 |
| NCT04770272 | Active, not recruiting | Phase 2 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy | March 1, 2021 | August 31, 2024 |
| NCT04380636 | Active, not recruiting | Phase 3 | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | July 6, 2020 | February 15, 2027 |
| NCT04895358 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | June 18, 2021 | July 21, 2028 |
| NCT03631199 | Active, not recruiting | Phase 3 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects | December 21, 2018 | June 7, 2027 |
| NCT04374630 | Active, not recruiting | Phase 2 | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian | June 9, 2020 | June 28, 2024 |
| NCT03918278 | Active, not recruiting | Phase 1 | A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) | June 19, 2019 | February 19, 2025 |
| NCT00411138 | Active, not recruiting | Phase 3 | Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer | November 23, 2006 | December 31, 2024 |
| NCT03916419 | Active, not recruiting | Phase 2 | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer | June 20, 2019 | September 30, 2025 |
| NCT02726997 | Active, not recruiting | Phase 1/Phase 2 | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) | July 6, 2016 | December 31, 2025 |
| NCT02654119 | Active, not recruiting | Phase 2 | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery | December 11, 2015 | November 20, 2026 |
| NCT05113251 | Active, not recruiting | Phase 3 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | October 25, 2021 | April 30, 2027 |
| NCT02621398 | Active, not recruiting | Phase 1 | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | August 4, 2016 | December 30, 2042 |
| NCT04165070 | Active, not recruiting | Phase 2 | KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | December 19, 2019 | February 13, 2039 |
| NCT04092283 | Active, not recruiting | Phase 3 | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | April 29, 2020 | December 31, 2028 |
| NCT02617849 | Active, not recruiting | Phase 2 | Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | May 19, 2016 | December 2025 |
| NCT03914612 | Active, not recruiting | Phase 3 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | July 16, 2019 | May 10, 2024 |
| NCT04764227 | Active, not recruiting | Phase 2 | Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) | May 30, 2020 | March 30, 2027 |
| NCT00433420 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer | April 2003 | December 2025 |
| NCT00433511 | Active, not recruiting | Phase 3 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | November 2, 2007 | February 22, 2025 |
| NCT02608216 | Active, not recruiting | Phase 1 | [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer | November 2015 | November 2024 |
| NCT03616886 | Active, not recruiting | Phase 1/Phase 2 | Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC | December 28, 2018 | April 2025 |
| NCT04739800 | Active, not recruiting | Phase 2 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | June 10, 2021 | January 8, 2025 |
| NCT02603679 | Active, not recruiting | Phase 2 | Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases | February 2015 | December 31, 2031 |
| NCT03609047 | Active, not recruiting | Phase 2 | Adjuvant Palbociclib in Elderly Patients With Breast Cancer | June 14, 2019 | September 30, 2032 |
| NCT04339738 | Active, not recruiting | Phase 2 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | November 4, 2020 | September 30, 2024 |
| NCT00861705 | Active, not recruiting | Phase 2 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | May 15, 2009 | February 22, 2025 |
| NCT04090398 | Active, not recruiting | Phase 2 | Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones | August 4, 2020 | June 30, 2025 |
| NCT04736173 | Active, not recruiting | Phase 3 | Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer | February 8, 2021 | July 1, 2027 |
| NCT04083963 | Active, not recruiting | Phase 2 | Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | August 9, 2019 | September 27, 2026 |
| NCT03603184 | Active, not recruiting | Phase 3 | Atezolizumab Trial in Endometrial Cancer - AtTEnd | October 2, 2018 | May 2025 |
| NCT04729387 | Active, not recruiting | Phase 3 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | July 2, 2021 | January 31, 2026 |
| NCT02593175 | Active, not recruiting | Phase 2 | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | August 26, 2016 | August 31, 2025 |
| NCT03598270 | Active, not recruiting | Phase 3 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer | November 21, 2018 | January 2024 |
| NCT03595592 | Active, not recruiting | Phase 3 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | September 7, 2018 | March 15, 2027 |
| NCT03595059 | Active, not recruiting | Phase 1 | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | July 13, 2018 | December 31, 2024 |
| NCT03587311 | Active, not recruiting | Phase 2 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | October 12, 2018 | October 21, 2024 |
| NCT05275777 | Active, not recruiting | Phase 1/Phase 2 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | May 19, 2022 | February 2030 |
| NCT05386888 | Active, not recruiting | Phase 2 | A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | September 9, 2022 | January 31, 2025 |
| NCT04634877 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | January 10, 2021 | June 18, 2025 |
| NCT04047862 | Active, not recruiting | Phase 1 | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | August 26, 2019 | August 2024 |
| NCT03579784 | Active, not recruiting | Phase 2 | Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer | November 26, 2018 | December 31, 2024 |
| NCT04564157 | Active, not recruiting | Phase 3 | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy | January 13, 2021 | April 1, 2031 |
| NCT05116189 | Active, not recruiting | Phase 3 | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | December 13, 2021 | August 31, 2027 |
| NCT06107868 | Active, not recruiting | Phase 1 | Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer | March 20, 2024 | December 4, 2026 |
| NCT04556773 | Active, not recruiting | Phase 1 | A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer | December 17, 2020 | November 28, 2025 |
| NCT04554771 | Active, not recruiting | Phase 2 | Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy | January 27, 2021 | January 1, 2024 |
| NCT02584478 | Active, not recruiting | Phase 3 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | December 2015 | December 2024 |
| NCT05446870 | Active, not recruiting | Phase 2 | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | July 25, 2022 | December 26, 2024 |
| NCT02560298 | Active, not recruiting | Phase 2 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer | August 23, 2016 | August 2023 |
| NCT02546232 | Active, not recruiting | Phase 2 | Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting | April 1, 2015 | December 31, 2028 |
| NCT03568422 | Active, not recruiting | Phase 1/Phase 2 | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | February 5, 2019 | December 31, 2023 |
| NCT04034251 | Active, not recruiting | Phase 2 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | June 9, 2020 | January 30, 2027 |
| NCT00942357 | Active, not recruiting | Phase 3 | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | June 29, 2009 | July 28, 2024 |
| NCT00070564 | Active, not recruiting | Phase 3 | S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer | November 2003 | January 2027 |
| NCT02525757 | Active, not recruiting | Phase 2 | MPDL3280A With Chemoradiation for Lung Cancer | January 26, 2016 | January 31, 2026 |
| NCT03884101 | Active, not recruiting | Phase 3 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) | April 11, 2019 | January 15, 2025 |
| NCT03564691 | Active, not recruiting | Phase 1 | Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | July 11, 2018 | September 28, 2025 |
| NCT00494182 | Active, not recruiting | Phase 2 | Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | April 25, 2007 | December 31, 2025 |
| NCT02520154 | Active, not recruiting | Phase 2 | Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | July 5, 2016 | July 31, 2024 |
| NCT02509286 | Active, not recruiting | Phase 3 | Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus | January 2016 | December 31, 2024 |
| NCT03871036 | Active, not recruiting | Phase 1/Phase 2 | Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | May 1, 2019 | January 31, 2025 |
| NCT02502266 | Active, not recruiting | Phase 2/Phase 3 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | May 3, 2016 | June 30, 2024 |
| NCT02488967 | Active, not recruiting | Phase 3 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | July 26, 2015 | October 31, 2026 |
| NCT00003042 | Active, not recruiting | Phase 2 | Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer | May 30, 1997 | December 30, 2024 |
| NCT02477826 | Active, not recruiting | Phase 3 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | August 5, 2015 | August 30, 2024 |
| NCT04025879 | Active, not recruiting | Phase 3 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | November 5, 2019 | September 30, 2024 |
| NCT03556839 | Active, not recruiting | Phase 3 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix | September 25, 2018 | November 2024 |
| NCT03554044 | Active, not recruiting | Phase 1 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | February 5, 2020 | April 30, 2025 |
| NCT04331067 | Active, not recruiting | Phase 1/Phase 2 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer | November 19, 2020 | May 31, 2026 |
| NCT03517449 | Active, not recruiting | Phase 3 | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | June 11, 2018 | October 7, 2024 |
| NCT03509012 | Active, not recruiting | Phase 1 | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors | May 2, 2018 | December 31, 2024 |
| NCT02446600 | Active, not recruiting | Phase 3 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 28, 2016 | August 9, 2024 |
| NCT03503786 | Active, not recruiting | Phase 2 | Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer | April 1, 2018 | December 2023 |
| NCT00977574 | Active, not recruiting | Phase 2 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | September 14, 2009 | March 6, 2025 |
| NCT04310007 | Active, not recruiting | Phase 2 | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | July 13, 2020 | September 30, 2024 |
| NCT00980954 | Active, not recruiting | Phase 3 | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | September 2009 | August 31, 2028 |
| NCT06110195 | Active, not recruiting | Phase 1 | Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | January 24, 2024 | October 2027 |
| NCT04269200 | Active, not recruiting | Phase 3 | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer | May 5, 2020 | March 5, 2025 |
| NCT04001829 | Active, not recruiting | Phase 2 | Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | August 9, 2019 | March 31, 2027 |
| NCT05543629 | Active, not recruiting | Phase 1/Phase 2 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | October 4, 2022 | November 1, 2026 |
| NCT04245085 | Active, not recruiting | Phase 2 | ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma | September 29, 2020 | December 2024 |
| NCT00997009 | Active, not recruiting | Phase 2 | Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer | October 2009 | December 2024 |
| NCT00997906 | Active, not recruiting | Phase 2/Phase 3 | Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC | September 15, 2009 | December 31, 2023 |
| NCT04222972 | Active, not recruiting | Phase 3 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | July 24, 2020 | June 30, 2025 |
| NCT02436993 | Active, not recruiting | Phase 2 | Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | April 2015 | June 2024 |
| NCT04220827 | Active, not recruiting | Phase 1 | Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer | December 6, 2019 | October 30, 2028 |
| NCT03997123 | Active, not recruiting | Phase 3 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC | June 25, 2019 | March 18, 2024 |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT05017012 | Active, not recruiting | Phase 1 | A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18) | September 21, 2021 | September 26, 2026 |
| NCT02390427 | Active, not recruiting | Phase 1 | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | April 20, 2015 | May 2024 |
| NCT03858322 | Active, not recruiting | Phase 1 | 'ADVANCE' (A Pilot Trial) | March 21, 2019 | June 21, 2024 |
| NCT03838159 | Active, not recruiting | Phase 2 | NADIM II: Neo-Adjuvant Immunotherapy | May 15, 2019 | November 30, 2028 |
| NCT03498521 | Active, not recruiting | Phase 2 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | July 10, 2018 | June 9, 2024 |
| NCT03490292 | Active, not recruiting | Phase 1/Phase 2 | Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer | May 29, 2018 | March 2023 |
| NCT02375204 | Active, not recruiting | Phase 3 | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors | August 5, 2015 | June 2024 |
| NCT03991403 | Active, not recruiting | Phase 3 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | August 27, 2019 | March 11, 2024 |
| NCT03474107 | Active, not recruiting | Phase 3 | A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | June 27, 2018 | August 31, 2024 |
| NCT03829722 | Active, not recruiting | Phase 2 | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | September 5, 2019 | September 2024 |
| NCT02364713 | Active, not recruiting | Phase 2 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | March 13, 2015 | February 28, 2028 |
| NCT03440437 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | April 16, 2018 | June 2024 |
| NCT02344472 | Active, not recruiting | Phase 3 | Detect V / CHEVENDO (Chemo vs. Endo) | September 2015 | January 31, 2025 |
| NCT03982485 | Active, not recruiting | Phase 2 | Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer | October 16, 2018 | March 29, 2031 |
| NCT02315196 | Active, not recruiting | Phase 2 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | February 25, 2015 | July 2041 |
| NCT02279134 | Active, not recruiting | Phase 2/Phase 3 | Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma | October 2014 | December 2024 |
| NCT02259621 | Active, not recruiting | Phase 2 | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC | September 2014 | October 2027 |
| NCT03423979 | Active, not recruiting | Phase 2 | Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter | December 19, 2017 | March 30, 2024 |
| NCT04964960 | Active, not recruiting | Phase 2 | Pembro+Chemo in Brain Mets | May 19, 2022 | May 2033 |
| NCT02258659 | Active, not recruiting | Phase 2 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer | September 22, 2014 | December 2025 |
| NCT03800134 | Active, not recruiting | Phase 3 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer | December 6, 2018 | September 11, 2028 |
| NCT03416153 | Active, not recruiting | Phase 2 | Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer | May 21, 2018 | May 2024 |
| NCT03393884 | Active, not recruiting | Phase 1/Phase 2 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) | September 5, 2018 | December 31, 2024 |
| NCT03390686 | Active, not recruiting | Phase 3 | A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients | November 15, 2019 | July 2024 |
| NCT02221999 | Active, not recruiting | Phase 2/Phase 3 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients | September 2013 | January 2029 |
| NCT04215146 | Active, not recruiting | Phase 2 | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | June 10, 2020 | July 2024 |
| NCT04540211 | Active, not recruiting | Phase 3 | A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma | October 30, 2020 | August 14, 2025 |
| NCT01081262 | Active, not recruiting | Phase 3 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | October 12, 2010 | March 1, 2025 |
| NCT01081951 | Active, not recruiting | Phase 2 | Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer | February 4, 2010 | December 31, 2024 |
| NCT02214381 | Active, not recruiting | Phase 3 | A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response | July 2014 | October 2024 |
| NCT04958785 | Active, not recruiting | Phase 2 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer | December 14, 2021 | January 2025 |
| NCT02213497 | Active, not recruiting | Phase 1 | Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer | April 2014 | December 31, 2024 |
| NCT02187991 | Active, not recruiting | Phase 2 | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | February 12, 2015 | December 2023 |
| NCT05267470 | Active, not recruiting | Phase 1 | A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) | March 29, 2022 | May 31, 2024 |
| NCT03309150 | Active, not recruiting | Phase 1 | ATRi Transition Rollover Study | January 10, 2018 | December 15, 2023 |
| NCT03981796 | Active, not recruiting | Phase 3 | A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer | July 18, 2019 | November 26, 2026 |
| NCT05226598 | Active, not recruiting | Phase 3 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) | March 24, 2022 | September 27, 2027 |
| NCT03281369 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | October 13, 2017 | April 30, 2025 |
| NCT03279237 | Active, not recruiting | Phase 1 | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers | October 24, 2017 | September 2023 |
| NCT04956692 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | August 5, 2021 | October 14, 2026 |
| NCT02186847 | Active, not recruiting | Phase 2 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | August 2014 | April 16, 2025 |
| NCT02135042 | Active, not recruiting | Phase 2/Phase 3 | Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | April 21, 2014 | February 2031 |
| NCT03798626 | Active, not recruiting | Phase 1 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | May 22, 2019 | December 30, 2024 |
| NCT03794778 | Active, not recruiting | Phase 4 | Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer | March 19, 2019 | March 31, 2024 |
| NCT02124421 | Active, not recruiting | Phase 2 | HOT: HIPEC in Ovarian Cancer as Initial Treatment | April 2014 | April 2028 |
| NCT02101788 | Active, not recruiting | Phase 2/Phase 3 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | February 27, 2014 | October 11, 2024 |
| NCT01142388 | Active, not recruiting | Phase 2 | Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | September 21, 2010 | March 7, 2025 |
| NCT02037048 | Active, not recruiting | Phase 2 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | February 10, 2014 | October 1, 2025 |
| NCT05498896 | Active, not recruiting | Phase 2 | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | December 19, 2018 | January 30, 2026 |
| NCT02009449 | Active, not recruiting | Phase 1 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | November 15, 2013 | August 25, 2024 |
| NCT01154920 | Active, not recruiting | Phase 2 | Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | July 9, 2010 | December 31, 2025 |
| NCT01993810 | Active, not recruiting | Phase 3 | Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer | February 3, 2014 | October 2025 |
| NCT01970722 | Active, not recruiting | Phase 1 | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | May 19, 2014 | December 22, 2024 |
| NCT00295893 | Active, not recruiting | Phase 2 | Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer | September 27, 2005 | December 15, 2024 |
| NCT01898117 | Active, not recruiting | Phase 2 | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer | July 2013 | December 2030 |
| NCT00565851 | Active, not recruiting | Phase 3 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | December 6, 2007 | January 1, 2028 |
| NCT03215706 | Active, not recruiting | Phase 3 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | August 24, 2017 | January 19, 2026 |
| NCT01167712 | Active, not recruiting | Phase 3 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | September 27, 2010 | June 7, 2024 |
| NCT01897441 | Active, not recruiting | N/A | Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer | June 2013 | December 2026 |
| NCT04538742 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer | December 28, 2020 | January 31, 2025 |
| NCT03199885 | Active, not recruiting | Phase 3 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | April 5, 2019 | May 15, 2025 |
| NCT03181100 | Active, not recruiting | Phase 2 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | July 27, 2017 | July 31, 2025 |
| NCT01873326 | Active, not recruiting | Phase 2 | Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors | June 2013 | June 2024 |
| NCT04931342 | Active, not recruiting | Phase 2 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | October 7, 2021 | December 31, 2028 |
| NCT05722015 | Active, not recruiting | Phase 3 | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) | February 14, 2023 | May 22, 2028 |
| NCT01187199 | Active, not recruiting | Phase 1 | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | August 19, 2010 | April 30, 2026 |
| NCT01853748 | Active, not recruiting | Phase 2 | T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | May 2013 | May 2024 |
| NCT04929392 | Active, not recruiting | Phase 2 | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer | January 25, 2022 | April 25, 2027 |
| NCT04527991 | Active, not recruiting | Phase 3 | Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer | January 13, 2021 | October 2024 |
| NCT04499924 | Active, not recruiting | Phase 2/Phase 3 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer | March 22, 2021 | March 31, 2027 |
| NCT04209855 | Active, not recruiting | Phase 3 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | December 31, 2019 | April 2024 |
| NCT04623775 | Active, not recruiting | Phase 2 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | February 17, 2021 | September 16, 2025 |
| NCT01820858 | Active, not recruiting | Phase 3 | The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma | November 2012 | December 2026 |
| NCT03179904 | Active, not recruiting | Phase 2 | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | August 3, 2017 | July 30, 2024 |
| NCT03177291 | Active, not recruiting | Phase 1 | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | September 26, 2017 | June 2024 |
| NCT01802749 | Active, not recruiting | Phase 3 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | November 2013 | December 2023 |
| NCT03141359 | Active, not recruiting | Phase 2 | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | May 12, 2017 | July 2027 |
| NCT04498117 | Active, not recruiting | Phase 3 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | August 25, 2020 | August 26, 2027 |
| NCT01796197 | Active, not recruiting | Phase 2 | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | August 2013 | July 2024 |
| NCT04494425 | Active, not recruiting | Phase 3 | Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | July 24, 2020 | June 19, 2026 |
| NCT03125928 | Active, not recruiting | Phase 2 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | June 13, 2017 | December 2024 |
| NCT01779206 | Active, not recruiting | Phase 2/Phase 3 | ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer | May 2012 | October 2024 |
| NCT01750073 | Active, not recruiting | Phase 2 | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | December 7, 2012 | June 2026 |
| NCT01706120 | Active, not recruiting | Phase 4 | Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab | October 2012 | December 2024 |
| NCT03977194 | Active, not recruiting | Phase 3 | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | July 23, 2019 | December 2026 |
| NCT00104676 | Active, not recruiting | Phase 3 | Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors | November 26, 2003 | December 2024 |
| NCT03107182 | Active, not recruiting | Phase 2 | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer | June 27, 2017 | July 2025 |
| NCT04492033 | Active, not recruiting | Phase 1/Phase 2 | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | June 22, 2020 | July 31, 2025 |
| NCT03783442 | Active, not recruiting | Phase 3 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | December 11, 2018 | June 30, 2024 |
| NCT01676649 | Active, not recruiting | Phase 2 | Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma | November 2012 | May 2026 |
| NCT03101748 | Active, not recruiting | Phase 1/Phase 2 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | January 29, 2018 | January 1, 2026 |
| NCT03088540 | Active, not recruiting | Phase 3 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | May 29, 2017 | June 30, 2025 |
| NCT03085056 | Active, not recruiting | Early Phase 1 | Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | March 15, 2017 | September 2024 |
| NCT03047265 | Active, not recruiting | Phase 2 | Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | February 4, 2017 | June 1, 2027 |
| NCT01612351 | Active, not recruiting | Phase 2 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | June 2012 | November 2031 |
| NCT03044613 | Active, not recruiting | Phase 1 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | July 11, 2017 | February 2025 |
| NCT03760822 | Active, not recruiting | Phase 2 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | November 16, 2018 | September 2024 |
| NCT00326456 | Active, not recruiting | Phase 3 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | January 1, 2003 | December 2023 |
| NCT03036488 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | March 7, 2017 | September 30, 2025 |
| NCT04879368 | Active, not recruiting | Phase 3 | RegoNivo vs Standard of Care Chemotherapy in AGOC | June 1, 2021 | June 1, 2026 |
| NCT01566240 | Active, not recruiting | Phase 3 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer | November 8, 2012 | December 2026 |
| NCT01275677 | Active, not recruiting | Phase 3 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | January 6, 2011 | July 12, 2024 |
| NCT03747120 | Active, not recruiting | Phase 2 | Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab | January 25, 2019 | July 2025 |
| NCT01386385 | Active, not recruiting | Phase 1/Phase 2 | Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | June 20, 2011 | December 31, 2024 |
| NCT03976362 | Active, not recruiting | Phase 3 | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | June 28, 2019 | March 12, 2025 |
| NCT00657878 | Active, not recruiting | Phase 3 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval | November 2008 | December 2023 |
| NCT01281176 | Active, not recruiting | Phase 1 | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | February 9, 2011 | April 22, 2025 |
| NCT00660842 | Active, not recruiting | Phase 3 | Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer | November 2008 | November 2024 |
| NCT03740165 | Active, not recruiting | Phase 3 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | December 18, 2018 | May 29, 2026 |
| NCT02998528 | Active, not recruiting | Phase 3 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | March 4, 2017 | November 8, 2028 |
| NCT02957968 | Active, not recruiting | Phase 2 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | January 24, 2017 | February 28, 2025 |
| NCT04489888 | Active, not recruiting | Phase 4 | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) | October 27, 2020 | July 25, 2024 |
| NCT01366144 | Active, not recruiting | Phase 1 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | June 20, 2011 | March 5, 2025 |
| NCT04603183 | Active, not recruiting | Phase 2 | ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL | June 2, 2021 | June 30, 2025 |
| NCT02931890 | Active, not recruiting | Phase 2 | Multicentric Randomised Trial for Resectable Gastric Cancer | December 21, 2017 | March 2029 |
| NCT04472429 | Active, not recruiting | Phase 3 | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | January 12, 2021 | October 27, 2024 |
| NCT01358877 | Active, not recruiting | Phase 3 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | November 8, 2011 | November 28, 2024 |
| NCT03965689 | Active, not recruiting | Phase 2 | Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | April 16, 2020 | March 20, 2025 |
| NCT02892123 | Active, not recruiting | Phase 1 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | September 30, 2016 | July 1, 2024 |
| NCT04865289 | Active, not recruiting | Phase 3 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study | October 22, 2019 | January 15, 2025 |
| NCT04832854 | Active, not recruiting | Phase 2 | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | April 23, 2021 | April 30, 2028 |
| NCT04425018 | Active, not recruiting | Phase 2 | MARGetuximab Or Trastuzumab (MARGOT) | July 13, 2020 | July 1, 2027 |
| NCT04205812 | Active, not recruiting | Phase 3 | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | September 11, 2020 | April 15, 2025 |
| NCT03734029 | Active, not recruiting | Phase 3 | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | December 27, 2018 | October 1, 2025 |
| NCT03725436 | Active, not recruiting | Phase 1 | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | January 24, 2019 | April 30, 2025 |
| NCT04194203 | Active, not recruiting | Phase 3 | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | April 9, 2020 | June 28, 2024 |
| NCT02883062 | Active, not recruiting | Phase 2 | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | August 2, 2017 | January 23, 2025 |
| NCT01345851 | Active, not recruiting | N/A | Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | March 23, 2011 | January 31, 2026 |
| NCT05342636 | Active, not recruiting | Phase 1/Phase 2 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | July 27, 2022 | September 21, 2026 |
| NCT05298592 | Active, not recruiting | Phase 1 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | March 31, 2022 | July 15, 2024 |
| NCT00031694 | Completed | Phase 2 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | March 2002 | April 2010 |
| NCT00031876 | Completed | Phase 1/Phase 2 | Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer | May 2000 | September 2004 |
| NCT00031954 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | August 2001 | |
| NCT00032032 | Completed | Phase 1 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | May 2002 | January 2010 |
| NCT00033410 | Completed | Phase 1 | Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | March 2002 | |
| NCT00033553 | Completed | Phase 2 | Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer | March 2002 | June 2010 |
| NCT00033657 | Completed | Phase 2 | Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer | August 15, 2002 | October 2009 |
| NCT00033696 | Completed | Phase 2 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | September 2001 | April 2009 |
| NCT00034346 | Completed | Phase 2 | ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) | January 2002 | |
| NCT00034541 | Completed | Phase 1/Phase 2 | Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer | December 2000 | May 2003 |
| NCT00038545 | Completed | Phase 2 | A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | May 18, 2001 | April 27, 2004 |
| NCT00040794 | Completed | Phase 2 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | May 2002 | |
| NCT00041119 | Completed | Phase 3 | Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer | May 2002 | June 2014 |
| NCT00042809 | Completed | Phase 1 | Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors | May 2002 | |
| NCT00043108 | Completed | Phase 2 | Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | July 2002 | February 2018 |
| NCT00045630 | Completed | Phase 2 | S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium | January 2003 | December 2011 |
| NCT00049257 | Completed | Phase 2 | Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | October 2002 | March 2009 |
| NCT00049790 | Completed | Phase 2 | Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer | December 2004 | |
| NCT00050167 | Completed | Phase 1 | Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | November 2002 | August 2011 |
| NCT00052312 | Completed | Phase 2 | Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer | September 2002 | |
| NCT00052351 | Completed | Phase 2 | Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer | September 2002 | October 2007 |
| NCT00054028 | Completed | Phase 1/Phase 2 | Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer | December 2002 | March 2008 |
| NCT00054548 | Completed | Phase 1 | Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors | October 2002 | |
| NCT00055601 | Completed | Phase 2 | Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer | December 2002 | May 14, 2018 |
| NCT00055835 | Completed | Phase 2 | S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium | November 2002 | June 2006 |
| NCT00057863 | Completed | Phase 2 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | January 2003 | March 2010 |
| NCT00059787 | Completed | Phase 2 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | April 2003 | May 2010 |
| NCT00062010 | Completed | Phase 2 | Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | May 26, 2004 | August 2012 |
| NCT00062062 | Completed | Phase 2 | Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer | October 2004 | November 2010 |
| NCT00062179 | Completed | Phase 2 | Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | March 2003 | November 2006 |
| NCT00063401 | Completed | Phase 2 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | September 2003 | June 2006 |
| NCT00063999 | Completed | Phase 3 | Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | August 25, 2003 | January 5, 2021 |
| NCT00064077 | Completed | Phase 3 | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix | May 2003 | January 30, 2018 |
| NCT00066716 | Completed | Phase 2 | Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus | June 2003 | |
| NCT00068757 | Completed | Phase 1 | Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | August 2003 | |
| NCT00069953 | Completed | Phase 2 | Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | September 2003 | December 2016 |
| NCT00071188 | Completed | Phase 2 | ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | February 2004 | October 2007 |
| NCT00072319 | Completed | Phase 2 | Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer | August 2003 | November 2006 |
| NCT00075270 | Completed | Phase 3 | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | January 2004 | March 2012 |
| NCT00075712 | Completed | Phase 2/Phase 3 | Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | September 2003 | |
| NCT00077129 | Completed | Phase 2 | Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer | June 1, 2006 | |
| NCT00079287 | Completed | Phase 3 | Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer | March 2001 | November 2008 |
| NCT00079430 | Completed | Phase 1 | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | June 2004 | |
| NCT00081302 | Completed | Phase 2 | Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | March 2004 | November 2013 |
| NCT00083057 | Completed | Phase 1 | Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck | May 2004 | November 2010 |
| NCT00084214 | Completed | Phase 1/Phase 2 | STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma | May 2004 | |
| NCT00085358 | Completed | Phase 1 | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) | May 2004 | |
| NCT00085501 | Completed | Phase 2 | S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | July 2004 | July 2011 |
| NCT00087217 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor | May 2004 | |
| NCT00088088 | Completed | Phase 1/Phase 2 | STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | March 2004 | March 2005 |
| NCT00088556 | Completed | Phase 1/Phase 2 | Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer | August 2004 | May 2009 |
| NCT00089297 | Completed | Phase 2 | Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer | January 6, 2005 | February 2011 |
| NCT00091039 | Completed | N/A | Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery | August 2004 | February 2006 |
| NCT00091377 | Completed | Phase 1/Phase 2 | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | August 2004 | March 2008 |
| NCT00093756 | Completed | Phase 1/Phase 2 | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer | September 2004 | May 2013 |
| NCT00093795 | Completed | Phase 3 | Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | October 2004 | June 2016 |
| NCT00094835 | Completed | Phase 1/Phase 2 | Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | January 2005 | March 2007 |
| NCT00094861 | Completed | Phase 2 | Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | January 2005 | January 2014 |
| NCT00095914 | Completed | Phase 1 | Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors | September 2004 | March 2009 |
| NCT00095927 | Completed | Phase 2 | Randomized Amifostine For SCCHN | May 2003 | June 2008 |
| NCT00096200 | Completed | Phase 2 | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | August 2004 | August 2011 |
| NCT00096343 | Completed | Phase 2 | Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer | October 2002 | March 2005 |
| NCT00097227 | Completed | Phase 2 | Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | November 2004 | April 2007 |
| NCT00100789 | Completed | Phase 2 | S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | January 2005 | February 2008 |
| NCT00107250 | Completed | Phase 1 | AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) | January 21, 2005 | January 18, 2011 |
| NCT00107341 | Completed | Phase 2 | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction | August 2005 | May 2008 |
| NCT00110019 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | June 2005 | August 2012 |
| NCT00111787 | Completed | Phase 2 | Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer | April 11, 2005 | November 1, 2006 |
| NCT00112489 | Completed | Phase 2 | Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer | May 2005 | |
| NCT00113516 | Completed | Phase 2 | A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer | September 2005 | March 2009 |
| NCT00117442 | Completed | Phase 2 | A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood | August 2002 | December 2004 |
| NCT00119262 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer | October 2005 | September 2009 |
| NCT00126581 | Completed | Phase 2 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | August 15, 2005 | November 28, 2017 |
| NCT00128856 | Completed | Phase 2 | Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | March 2003 | January 2015 |
| NCT00129389 | Completed | Phase 3 | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | September 19, 2003 | October 1, 2013 |
| NCT00129727 | Completed | Phase 2 | Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) | June 2005 | February 2009 |
| NCT00129922 | Completed | Phase 3 | Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer | November 1999 | December 2007 |
| NCT00131963 | Completed | A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel | October 2003 | October 2014 | |
| NCT00136175 | Completed | Phase 2 | Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder | November 1999 | October 2007 |
| NCT00146549 | Completed | Phase 3 | Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer | August 2001 | December 2007 |
| NCT00146562 | Completed | Phase 2 | Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | July 2003 | May 2007 |
| NCT00147537 | Completed | Phase 1/Phase 2 | Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer | February 2005 | August 2011 |
| NCT00148681 | Completed | Phase 2 | Preoperative Herceptin and Navelbine for Breast Cancer | May 2001 | May 2003 |
| NCT00151034 | Completed | Phase 2 | Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | September 2000 | October 2007 |
| NCT00151060 | Completed | Phase 2 | Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate | December 1998 | June 2006 |
| NCT00152477 | Completed | Phase 2 | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer | August 15, 2005 | June 25, 2009 |
| NCT00158379 | Completed | Phase 2 | Taxol Carboplatin and Erythropoetin | July 2003 | June 2008 |
| NCT00170664 | Completed | Phase 2 | Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer | January 1999 | September 2004 |
| NCT00174356 | Completed | Phase 1 | PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients | December 2002 | October 2005 |
| NCT00174434 | Completed | Phase 1 | Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer | September 2005 | August 2007 |
| NCT00176254 | Completed | Phase 2 | Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer | May 2000 | October 2012 |
| NCT00176267 | Completed | Phase 2 | Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer | September 2002 | January 31, 2017 |
| NCT00178256 | Completed | Phase 1/Phase 2 | Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer | June 1998 | December 2012 |
| NCT00181701 | Completed | Phase 2 | Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | October 2004 | May 2006 |
| NCT00189553 | Completed | Phase 3 | Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse | April 2005 | June 2012 |
| NCT00189566 | Completed | Phase 2 | Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | April 2004 | April 2009 |
| NCT00191256 | Completed | Phase 2 | Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer | June 2001 | July 2006 |
| NCT00191646 | Completed | Phase 3 | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | October 2002 | August 2009 |
| NCT00191672 | Completed | Phase 2 | A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer | December 2003 | November 2006 |
| NCT00191854 | Completed | Phase 2 | Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line | March 2005 | November 2009 |
| NCT00193141 | Completed | Phase 2 | Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer | October 1999 | July 2007 |
| NCT00193193 | Completed | Phase 2 | Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | August 2000 | February 2007 |
| NCT00193297 | Completed | Phase 2 | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma | February 2002 | June 2006 |
| NCT00193310 | Completed | Phase 2 | Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer | November 2000 | January 2009 |
| NCT00193362 | Completed | Phase 3 | Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer | June 2004 | September 2007 |
| NCT00193531 | Completed | Phase 2 | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | December 1998 | January 2007 |
| NCT00193596 | Completed | Phase 3 | Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site | September 2003 | June 2009 |
| NCT00194753 | Completed | Phase 2 | Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12 | December 2001 | March 2011 |
| NCT00194779 | Completed | Phase 2 | Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery | October 2003 | June 2011 |
| NCT00217607 | Completed | Phase 2 | Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery | February 2005 | January 2012 |
| NCT00226590 | Completed | Phase 2 | Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC | April 2003 | July 2008 |
| NCT00228319 | Completed | Phase 1/Phase 2 | Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants | October 2002 | August 2007 |
| NCT00230451 | Completed | Phase 2 | Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma | November 1997 | July 2008 |
| NCT00231075 | Completed | Phase 2 | Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV | January 2001 | May 2007 |
| NCT00231582 | Completed | Phase 2 | High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II | September 2004 | January 2010 |
| NCT00236899 | Completed | Phase 3 | Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC | September 2005 | August 2010 |
| NCT00238420 | Completed | Phase 1/Phase 2 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | July 26, 2005 | May 20, 2022 |
| NCT00245154 | Completed | Phase 2/Phase 3 | Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer | November 3, 2005 | January 10, 2013 |
| NCT00252798 | Completed | Phase 1 | ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | July 2002 | October 2005 |
| NCT00255762 | Completed | Phase 2 | Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | December 2005 | |
| NCT00256243 | Completed | Phase 2 | Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | April 2004 | July 2012 |
| NCT00262847 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | September 2005 | April 2015 |
| NCT00270491 | Completed | Phase 2 | Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer. | December 2005 | October 2010 |
| NCT00276588 | Completed | Phase 2 | Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | July 2005 | |
| NCT00276796 | Completed | Phase 2 | Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | ||
| NCT00278148 | Completed | Phase 1/Phase 2 | Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer | October 2005 | February 2011 |
| NCT00280150 | Completed | Phase 1/Phase 2 | Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | January 2006 | January 2013 |
| NCT00280787 | Completed | Phase 2 | Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | November 2003 | October 2010 |
| NCT00281788 | Completed | Phase 1 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer | September 2003 | July 2007 |
| NCT00287937 | Completed | Phase 1 | Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors | July 2005 | |
| NCT00287989 | Completed | Phase 2 | Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer | November 2004 | May 2009 |
| NCT00288041 | Completed | Phase 2 | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma | October 2005 | |
| NCT00294762 | Completed | Phase 2 | Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC | January 2006 | March 2009 |
| NCT00301028 | Completed | Phase 2 | Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer | April 2006 | September 2011 |
| NCT00301730 | Completed | Phase 1 | Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung | October 2005 | |
| NCT00310011 | Completed | Phase 2 | Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium | June 1998 | August 2009 |
| NCT00311636 | Completed | Phase 3 | Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery | September 2003 | April 2008 |
| NCT00313599 | Completed | Phase 1 | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | February 2006 | December 2013 |
| NCT00314678 | Completed | Phase 2 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | September 2005 | April 2007 |
| NCT00316199 | Completed | Phase 2 | Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer | April 2006 | April 2008 |
| NCT00316407 | Completed | Phase 1/Phase 2 | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients | August 2005 | November 2009 |
| NCT00317200 | Completed | Phase 2 | A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | April 2006 | November 2007 |
| NCT00318136 | Completed | Phase 2 | A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE) | September 2005 | July 2009 |
| NCT00320541 | Completed | Phase 2 | A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer | May 2006 | August 2012 |
| NCT00322400 | Completed | Phase 1 | Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | March 2006 | January 2012 |
| NCT00322452 | Completed | Phase 3 | First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia | March 2006 | June 2010 |
| NCT00329641 | Completed | Phase 2 | Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye | February 2011 | November 2012 |
| NCT00334321 | Completed | Phase 1 | Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients | April 2006 | September 2015 |
| NCT00334802 | Completed | Phase 2 | Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer | June 2006 | March 2010 |
| NCT00336791 | Completed | Phase 3 | Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer | September 2003 | September 2010 |
| NCT00337532 | Completed | Phase 2/Phase 3 | A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer | May 2005 | June 2007 |
| NCT00343291 | Completed | Phase 2 | A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC | December 2006 | December 2010 |
| NCT00344552 | Completed | Phase 2 | Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer | June 2006 | March 2008 |
| NCT00347412 | Completed | Phase 3 | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | November 2006 | February 2010 |
| NCT00350025 | Completed | Phase 2 | Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer | August 2006 | September 2012 |
| NCT00352300 | Completed | Phase 1 | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | June 2006 | |
| NCT00360360 | Completed | Phase 2 | Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site | July 2006 | March 2009 |
| NCT00001383 | Completed | Phase 1 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | March 1994 | January 2001 |
| NCT00368875 | Completed | Phase 1/Phase 2 | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | July 2006 | December 2011 |
| NCT00368992 | Completed | Phase 2 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | August 2006 | October 2010 |
| NCT00373256 | Completed | Phase 3 | A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer | November 2006 | August 2011 |
| NCT00387374 | Completed | Phase 2 | Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab | October 2006 | |
| NCT00388076 | Completed | Phase 1 | Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) | April 28, 2006 | July 21, 2009 |
| NCT00390611 | Completed | Phase 2 | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | October 2006 | April 2014 |
| NCT00391118 | Completed | Phase 2 | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | November 2006 | July 2012 |
| NCT00392704 | Completed | Phase 2 | Treatment of Head & Neck Cancer With Chemotherapy and Radiation | December 2006 | May 2012 |
| NCT00393068 | Completed | Phase 2 | Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer | February 2007 | August 2011 |
| NCT00399126 | Completed | Phase 1 | Phase I Trial of Paclitaxel With Perifosine | November 2004 | October 2011 |
| NCT00401674 | Completed | Phase 2 | MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer | June 2003 | June 2008 |
| NCT00403130 | Completed | Phase 2 | Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer | February 2006 | November 2012 |
| NCT00408460 | Completed | Phase 2 | Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | February 2006 | October 2012 |
| NCT00408655 | Completed | Phase 1 | Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors | February 2007 | |
| NCT00421889 | Completed | Phase 1/Phase 2 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | August 2005 | February 2009 |
| NCT00423852 | Completed | Phase 1/Phase 2 | Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin | August 2006 | February 2013 |
| NCT00426556 | Completed | Phase 1 | Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | July 2007 | March 2014 |
| NCT00429299 | Completed | Phase 2 | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | August 2006 | June 2012 |
| NCT00431080 | Completed | Phase 3 | Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | August 2004 | October 2007 |
| NCT00432094 | Completed | Phase 2 | Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | December 19, 2006 | March 2021 |
| NCT00434252 | Completed | Phase 2 | A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | February 2007 | April 2009 |
| NCT00436566 | Completed | Phase 2 | Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | March 16, 2007 | July 22, 2019 |
| NCT00445458 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | September 11, 2007 | February 7, 2018 |
| NCT00448305 | Completed | Phase 2 | EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients | January 2007 | March 2011 |
| NCT00453167 | Completed | Phase 2 | Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer | December 2005 | March 2010 |
| NCT00455533 | Completed | Phase 2 | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | October 2007 | December 2009 |
| NCT00467012 | Completed | Phase 2 | Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer | April 2007 | September 2011 |
| NCT00467051 | Completed | Phase 2 | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | November 5, 2007 | June 30, 2018 |
| NCT00470301 | Completed | Phase 1/Phase 2 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | April 2007 | September 2013 |
| NCT00470366 | Completed | Phase 2 | Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors | March 2007 | June 2016 |
| NCT00478361 | Completed | Phase 2 | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | April 2007 | June 2015 |
| NCT00479817 | Completed | Phase 2 | Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer | July 5, 2007 | December 9, 2019 |
| NCT00480831 | Completed | Phase 2 | A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) | June 2007 | August 2010 |
| NCT00481078 | Completed | Phase 2 | Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | May 2007 | July 2009 |
| NCT00482391 | Completed | Phase 2 | Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | March 2007 | July 2011 |
| NCT00483782 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | April 2006 | |
| NCT00486954 | Completed | Phase 3 | Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer | July 2007 | October 2012 |
| NCT00490711 | Completed | Phase 2 | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | July 2003 | April 2005 |
| NCT00491855 | Completed | Phase 1 | Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis | June 2007 | December 2012 |
| NCT00495170 | Completed | Phase 2 | Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | April 14, 2006 | June 14, 2017 |
| NCT00496028 | Completed | Phase 1 | Phase I Study in Patients With Solid Tumours | March 2007 | March 2010 |
| NCT00499083 | Completed | Phase 2 | Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) | May 1, 2006 | January 28, 2010 |
| NCT00502203 | Completed | Phase 2 | Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus | August 2001 | November 2010 |
| NCT00508326 | Completed | Phase 1 | Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement | October 2005 | October 2010 |
| NCT00508625 | Completed | Phase 2 | A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab | June 2006 | November 2011 |
| NCT00511459 | Completed | Phase 2 | Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients | July 2007 | May 2014 |
| NCT00511992 | Completed | Phase 2 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | July 2007 | August 3, 2015 |
| NCT00513292 | Completed | Phase 3 | Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery | July 2007 | February 21, 2013 |
| NCT00513383 | Completed | Phase 1 | Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck | April 2006 | October 2012 |
| NCT00513695 | Completed | Phase 2 | Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | June 2007 | October 16, 2017 |
| NCT00513786 | Completed | Phase 2 | Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma | August 1, 2007 | January 3, 2017 |
| NCT00515073 | Completed | Phase 2 | Papillary Serous Carcinoma of the Endometrium | April 2001 | May 2013 |
| NCT00516724 | Completed | Phase 1 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel | June 22, 2007 | April 11, 2024 |
| NCT00517621 | Completed | Phase 2 | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | February 2006 | October 2010 |
| NCT00520013 | Completed | Phase 2 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | August 2007 | November 2013 |
| NCT00524303 | Completed | Phase 2 | Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | August 2007 | August 2015 |
| NCT00527735 | Completed | Phase 2 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | February 2008 | December 2011 |
| NCT00533585 | Completed | Phase 1 | BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) | May 2006 | January 2016 |
| NCT00533949 | Completed | Phase 3 | High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | November 2007 | May 20, 2022 |
| NCT00535119 | Completed | Phase 1 | Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer | September 2007 | |
| NCT00540514 | Completed | Phase 3 | Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer | November 1, 2007 | February 1, 2013 |
| NCT00542451 | Completed | Phase 2 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | October 2007 | August 30, 2022 |
| NCT00544167 | Completed | N/A | Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer | May 2007 | April 2011 |
| NCT00546156 | Completed | Phase 2 | Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer | October 2007 | December 2012 |
| NCT00550537 | Completed | Phase 2 | Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | October 2007 | December 2013 |
| NCT00550784 | Completed | Phase 1 | Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | January 2001 | October 2014 |
| NCT00553358 | Completed | Phase 3 | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | January 5, 2008 | December 23, 2019 |
| NCT00559845 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer | February 2008 | July 2015 |
| NCT00561795 | Completed | Phase 2 | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | September 2007 | April 2008 |
| NCT00563784 | Completed | Phase 2 | TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | November 2007 | May 30, 2018 |
| NCT00564733 | Completed | Phase 2 | FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer | October 2007 | March 2012 |
| NCT00567554 | Completed | Phase 3 | Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer | October 2007 | October 2015 |
| NCT00574587 | Completed | Phase 1/Phase 2 | Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | December 2007 | May 2014 |
| NCT00575952 | Completed | Phase 1 | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer | January 17, 2008 | July 16, 2016 |
| NCT00578149 | Completed | Phase 2 | Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer | May 2006 | August 2007 |
| NCT00580333 | Completed | Phase 2 | Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer | September 2007 | June 2020 |
| NCT00580983 | Completed | N/A | Optimized Intensity Modulated Irradiation for Head and Neck Cancer | August 2003 | June 2010 |
| NCT00581971 | Completed | Phase 1/Phase 2 | Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer | September 2002 | March 2012 |
| NCT00583830 | Completed | Phase 2 | A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer | January 2007 | February 2011 |
| NCT00600821 | Completed | Phase 2 | A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. | April 2008 | October 2012 |
| NCT00602797 | Completed | Phase 2 | Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer | December 17, 2007 | August 1, 2014 |
| NCT00606515 | Completed | Phase 4 | Pharmacokinetics Study of Liposomal Paclitaxel in Humans | February 2008 | October 2008 |
| NCT00610714 | Completed | Phase 2 | AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer | April 2008 | January 2012 |
| NCT00617409 | Completed | Phase 2 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | October 2, 2007 | January 31, 2019 |
| NCT00618826 | Completed | Phase 2 | A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer | November 2006 | February 2014 |
| NCT00637897 | Completed | Phase 1 | Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer | March 2008 | March 2013 |
| NCT00645177 | Completed | Phase 2 | Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer | July 2008 | December 2009 |
| NCT00653939 | Completed | Phase 2 | A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer | March 2008 | October 2011 |
| NCT00655850 | Completed | Phase 2 | Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer | March 2008 | September 2016 |
| NCT00655876 | Completed | Phase 3 | Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer | June 2008 | May 20, 2022 |
| NCT00661193 | Completed | Phase 2 | S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer | December 2008 | December 2016 |
| NCT00667251 | Completed | Phase 3 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | October 7, 2008 | July 27, 2022 |
| NCT00667641 | Completed | Phase 1 | Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | March 2007 | February 2009 |
| NCT00680758 | Completed | Phase 1 | Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer | May 2008 | December 2010 |
| NCT00683059 | Completed | Phase 2 | Single Agent Abraxane as Second Line Therapy in Bladder Cancer | March 2008 | June 2012 |
| NCT00686959 | Completed | Phase 3 | Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer | September 2008 | November 2014 |
| NCT00687687 | Completed | Phase 2 | Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma | May 2008 | December 2011 |
| NCT00691379 | Completed | Phase 1/Phase 2 | Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer | April 2008 | March 2016 |
| NCT00702299 | Completed | Phase 1 | Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer | September 2007 | October 2012 |
| NCT00707707 | Completed | Phase 1 | Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | September 15, 2008 | February 19, 2018 |
| NCT00716534 | Completed | Phase 2 | Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | June 2008 | April 2012 |
| NCT00724386 | Completed | Phase 1 | Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer | June 1999 | November 2012 |
| NCT00730353 | Completed | Phase 2 | Sutent + Taxol for Advanced Esophageal Cancer | August 2008 | March 2010 |
| NCT00735696 | Completed | Phase 2 | A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer | January 2009 | January 2012 |
| NCT00737243 | Completed | Phase 2 | Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site | August 2008 | December 2012 |
| NCT00750386 | Completed | Phase 1/Phase 2 | Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas | January 2008 | March 2011 |
| NCT00753038 | Completed | Phase 2 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma | August 2008 | May 2013 |
| NCT00753909 | Completed | Phase 2 | Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer | November 2008 | October 2016 |
| NCT00756847 | Completed | Phase 1 | Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors | September 2008 | October 2012 |
| NCT00762034 | Completed | Phase 3 | A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer | December 2008 | December 2014 |
| NCT00768469 | Completed | Phase 1 | Study Evaluating Safety And Tolerability, Solid Tumor | October 2008 | January 2011 |
| NCT00773695 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer | November 7, 2008 | November 9, 2022 |
| NCT00785291 | Completed | Phase 3 | Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer | October 13, 2008 | June 15, 2017 |
| NCT00788931 | Completed | Phase 1 | A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer | December 2008 | |
| NCT00793897 | Completed | Phase 1 | Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors | April 2009 | June 2012 |
| NCT00795340 | Completed | Phase 3 | Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | February 4, 2009 | January 16, 2014 |
| NCT00795678 | Completed | Chemotherapeutic Agents in Brain/Breast | September 2008 | April 2013 | |
| NCT00796991 | Completed | Phase 1 | Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine | February 2009 | October 2012 |
| NCT00798252 | Completed | Phase 1 | Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | March 2009 | May 2015 |
| NCT00800202 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis | April 2009 | October 2012 |
| NCT00803062 | Completed | Phase 3 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | April 2009 | February 2013 |
| NCT00803556 | Completed | Phase 1 | Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy | January 2006 | August 2009 |
| NCT00806286 | Completed | Phase 2 | Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer | December 2008 | August 2012 |
| NCT00807573 | Completed | Phase 2 | Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment | December 2008 | April 2014 |
| NCT00809133 | Completed | Phase 1 | Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours | May 2007 | February 2015 |
| NCT00814086 | Completed | Phase 1 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | February 2009 | |
| NCT00815308 | Completed | Phase 2 | Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma | January 2009 | July 2010 |
| NCT00821028 | Completed | N/A | Local Paclitaxel Delivery for SFA Disease | January 2009 | April 2012 |
| NCT00828009 | Completed | Phase 2 | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | January 17, 2011 | May 22, 2019 |
| NCT00828841 | Completed | Phase 2 | Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC | December 2008 | August 2012 |
| NCT00832819 | Completed | Phase 1 | E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC) | February 2009 | October 2011 |
| NCT00846027 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer | January 2009 | January 2013 |
| NCT00848718 | Completed | Phase 1 | A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) | March 17, 2009 | May 17, 2012 |
| NCT00855764 | Completed | Phase 2 | Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer | October 2005 | October 2006 |
| NCT00861627 | Completed | Phase 2 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | March 2009 | November 2015 |
| NCT00864318 | Completed | Phase 2 | Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis | March 13, 2009 | October 5, 2020 |
| NCT00866528 | Completed | Phase 1 | Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | July 9, 2009 | October 25, 2012 |
| NCT00874107 | Completed | Phase 2 | Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | June 2009 | May 2016 |
| NCT00874848 | Completed | Phase 2 | Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | August 2009 | August 2015 |
| NCT00876395 | Completed | Phase 3 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer | September 10, 2009 | October 23, 2017 |
| NCT00887575 | Completed | Phase 1/Phase 2 | Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer | June 2009 | September 2014 |
| NCT00888615 | Completed | Phase 2 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | December 13, 2010 | August 31, 2016 |
| NCT00889382 | Completed | Phase 1/Phase 2 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | August 5, 2009 | August 25, 2014 |
| NCT00891072 | Completed | Phase 1 | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | July 2009 | April 2011 |
| NCT00891605 | Completed | Phase 1 | Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors | July 2009 | July 2012 |
| NCT00897026 | Completed | Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344 | July 2008 | April 27, 2012 | |
| NCT00898417 | Completed | Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab | March 14, 2008 | April 14, 2008 | |
| NCT00900172 | Completed | Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel | March 15, 2008 | April 15, 2009 | |
| NCT00900627 | Completed | Phase 1/Phase 2 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) | June 2009 | February 2015 |
| NCT00915005 | Completed | Phase 2 | Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence | June 2009 | February 24, 2020 |
| NCT00915018 | Completed | Phase 2 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer | August 21, 2009 | June 28, 2018 |
| NCT00915603 | Completed | Phase 2 | Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer | July 2009 | July 2014 |
| NCT00918203 | Completed | Phase 2 | A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | January 2010 | November 17, 2017 |
| NCT00919880 | Completed | Phase 2 | Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer | July 2009 | December 2010 |
| NCT00930930 | Completed | Phase 2 | Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer | June 2009 | October 2014 |
| NCT00936702 | Completed | Phase 2 | Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary | September 2009 | August 2013 |
| NCT00937560 | Completed | Phase 2 | A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer | June 25, 2009 | July 1, 2013 |
| NCT00945191 | Completed | Phase 2 | Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer | October 6, 2009 | August 23, 2011 |
| NCT00948675 | Completed | Phase 3 | Study of Participants With Advanced Non-Small Cell Lung Cancer | September 1, 2009 | November 6, 2020 |
| NCT00951496 | Completed | Phase 3 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | August 11, 2009 | January 11, 2016 |
| NCT00951665 | Completed | Phase 1/Phase 2 | A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer | August 2009 | June 2013 |
| NCT00954642 | Completed | Phase 1 | A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | August 2009 | December 2011 |
| NCT00960960 | Completed | Phase 1 | A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | August 2009 | December 2015 |
| NCT00971841 | Completed | Phase 2 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer | March 2008 | April 2012 |
| NCT00971867 | Completed | Phase 2 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer | August 4, 2006 | November 26, 2008 |
| NCT00971945 | Completed | Phase 2 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer | June 30, 2005 | March 31, 2008 |
| NCT00972205 | Completed | N/A | Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors | December 2007 | June 2009 |
| NCT00974584 | Completed | Phase 1 | A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | October 2009 | March 2015 |
| NCT00976573 | Completed | Phase 2 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | April 2010 | September 2015 |
| NCT00976911 | Completed | Phase 3 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | October 29, 2009 | July 9, 2014 |
| NCT00979212 | Completed | Phase 2 | Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | February 2011 | May 20, 2022 |
| NCT00984464 | Completed | Phase 2 | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | September 2009 | October 2014 |
| NCT00986674 | Completed | Phase 2 | Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer | September 2009 | December 2013 |
| NCT00989651 | Completed | Phase 1 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | October 28, 2009 | April 10, 2020 |
| NCT00991796 | Completed | Phase 2 | CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC) | June 2009 | December 2011 |
| NCT00993655 | Completed | Phase 2 | Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer | March 3, 2010 | July 11, 2016 |
| NCT00998192 | Completed | Phase 2 | A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung | October 2009 | August 2015 |
| NCT01003158 | Completed | Phase 1 | Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. | October 2009 | April 2012 |
| NCT01005329 | Completed | Phase 2 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | November 6, 2009 | September 22, 2013 |
| NCT01008150 | Completed | Phase 2 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | October 2010 | November 25, 2016 |
| NCT01011075 | Completed | Phase 2 | Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | August 2009 | July 2012 |
| NCT01014351 | Completed | Phase 2 | Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | February 2010 | August 2013 |
| NCT01015118 | Completed | Phase 3 | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer | November 17, 2009 | September 15, 2016 |
| NCT01015222 | Completed | Phase 1 | Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | November 2009 | May 27, 2021 |
| NCT01023204 | Completed | Phase 2 | Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer | October 2002 | July 2005 |
| NCT01024062 | Completed | Phase 2 | Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC) | December 2002 | March 2005 |
| NCT01024101 | Completed | Phase 2 | Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer | January 2004 | December 2005 |
| NCT01026116 | Completed | Phase 3 | A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old | December 2009 | December 23, 2016 |
| NCT01031446 | Completed | Phase 1/Phase 2 | Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer | October 2009 | August 2017 |
| NCT01042925 | Completed | Phase 1/Phase 2 | Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | February 2010 | December 2012 |
| NCT01051934 | Completed | Phase 1 | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | December 29, 2009 | September 28, 2011 |
| NCT01057342 | Completed | Phase 2 | Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer | January 2010 | July 2012 |
| NCT01063517 | Completed | Phase 2 | Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | February 2, 2010 | June 29, 2023 |
| NCT01066832 | Completed | Phase 4 | The Valentines Trial | February 2010 | March 2011 |
| NCT01069328 | Completed | Phase 1 | Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) | July 2006 | October 2011 |
| NCT01075464 | Completed | Phase 1 | A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | February 2010 | April 2013 |
| NCT01077999 | Completed | Phase 2 | Chemoradiation and Panitumumab for Esophageal Cancer | January 2010 | April 2012 |
| NCT01084083 | Completed | Phase 2 | Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer | August 11, 2010 | January 2015 |
| NCT01091428 | Completed | Phase 2 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | April 16, 2010 | July 19, 2017 |
| NCT01094184 | Completed | Phase 4 | A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer | March 2010 | December 2015 |
| NCT01097746 | Completed | Phase 2 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | April 14, 2010 | September 13, 2022 |
| NCT01100931 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) | February 2010 | December 2012 |
| NCT01106898 | Completed | Phase 2 | Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery | March 24, 2010 | September 28, 2015 |
| NCT01107626 | Completed | Phase 3 | Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | October 25, 2010 | August 17, 2021 |
| NCT01108055 | Completed | Phase 2 | Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer | April 2010 | July 2015 |
| NCT01120184 | Completed | Phase 3 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | July 31, 2010 | September 16, 2016 |
| NCT01121406 | Completed | Phase 2 | BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | April 2010 | June 2014 |
| NCT01146795 | Completed | Phase 2 | Neoadjuvant Therapy for Ovarian Cancer | May 17, 2010 | April 13, 2015 |
| NCT01160185 | Completed | Meta-analysis of Efficacy of Topotecan | June 2009 | July 2009 | |
| NCT01165216 | Completed | Phase 1 | Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer | September 2010 | June 2013 |
| NCT01166542 | Completed | Phase 3 | Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers | June 2010 | May 2014 |
| NCT01170663 | Completed | Phase 3 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma | December 2010 | February 2017 |
| NCT01172223 | Completed | Phase 1/Phase 2 | Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer | September 2007 | December 2013 |
| NCT01174238 | Completed | Phase 2 | A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma | July 2010 | December 2013 |
| NCT01183559 | Completed | Phase 1 | A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery | August 7, 2008 | August 2011 |
| NCT01186991 | Completed | Phase 2 | Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer | March 2011 | March 2016 |
| NCT01196390 | Completed | Phase 3 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | February 14, 2011 | August 15, 2023 |
| NCT01196429 | Completed | Phase 2 | Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer | August 2010 | January 2015 |
| NCT01196741 | Completed | Phase 2/Phase 3 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer | March 2011 | January 2014 |
| NCT01199055 | Completed | Phase 1 | CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | March 2010 | July 2011 |
| NCT01199263 | Completed | Phase 2 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | December 6, 2010 | July 17, 2020 |
| NCT01204125 | Completed | Phase 2 | Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients | September 2010 | February 2017 |
| NCT01204749 | Completed | Phase 3 | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer | November 2010 | December 2016 |
| NCT01209195 | Completed | Phase 1 | A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers | October 2010 | July 2014 |
| NCT01209520 | Completed | N/A | Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy | July 2009 | |
| NCT01218516 | Completed | Phase 2 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | June 27, 2011 | November 1, 2013 |
| NCT01219777 | Completed | Phase 1 | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | September 2010 | May 2015 |
| NCT01225302 | Completed | Phase 1 | A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) | September 2010 | June 2012 |
| NCT01229930 | Completed | Phase 2 | Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery | June 2010 | December 2012 |
| NCT01234038 | Completed | Phase 1/Phase 2 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel | November 2010 | January 2013 |
| NCT01235897 | Completed | Phase 1 | MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | March 2011 | November 2013 |
| NCT01236547 | Completed | Phase 2 | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | October 28, 2010 | May 20, 2022 |
| NCT01239732 | Completed | Phase 3 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | December 2010 | March 2015 |
| NCT01240655 | Completed | Phase 1 | A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors | April 2011 | January 2015 |
| NCT01248403 | Completed | Phase 3 | A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy | October 2011 | October 2019 |
| NCT01248949 | Completed | Phase 1 | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | October 2010 | October 2015 |
| NCT01253525 | Completed | Phase 1 | Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas | November 2010 | October 2011 |
| NCT01254526 | Completed | Phase 1 | Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer | December 2010 | April 2013 |
| NCT01256268 | Completed | Phase 1 | Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids | June 13, 2011 | August 3, 2017 |
| NCT01256762 | Completed | Phase 2 | Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer | November 2010 | December 2012 |
| NCT01263145 | Completed | Phase 1 | MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer | January 5, 2011 | October 19, 2012 |
| NCT01276496 | Completed | Phase 1 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | December 2010 | |
| NCT01280058 | Completed | Phase 2 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | December 2010 | January 20, 2016 |
| NCT01281150 | Completed | Phase 1 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | January 2011 | |
| NCT01281852 | Completed | Phase 1 | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | March 14, 2011 | February 11, 2017 |
| NCT01285609 | Completed | Phase 3 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | January 16, 2011 | August 22, 2017 |
| NCT01288261 | Completed | Phase 1 | Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer | January 2011 | July 2015 |
| NCT01293630 | Completed | Phase 1 | A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors | January 2011 | October 2013 |
| NCT01294293 | Completed | Phase 1 | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | March 2011 | |
| NCT01301716 | Completed | Phase 1 | A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors | September 2011 | August 2014 |
| NCT01301729 | Completed | Phase 4 | A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment | March 2011 | July 2014 |
| NCT01303497 | Completed | Phase 2 | Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas | September 10, 2010 | January 29, 2019 |
| NCT01306942 | Completed | Phase 1/Phase 2 | Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | July 2011 | March 15, 2019 |
| NCT01316757 | Completed | Phase 2 | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | February 16, 2011 | October 3, 2017 |
| NCT01317615 | Completed | Phase 4 | RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation | April 2011 | March 2015 |
| NCT01320111 | Completed | Phase 2 | Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment | July 1, 2010 | August 31, 2014 |
| NCT01320592 | Completed | Phase 1 | PD0332991/Paclitaxel in Advanced Breast Cancer | March 2011 | May 2019 |
| NCT01325441 | Completed | Phase 1/Phase 2 | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | April 2011 | June 1, 2021 |
| NCT01332656 | Completed | Phase 2 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel | May 2011 | July 2014 |
| NCT01333033 | Completed | Phase 2 | PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy | July 2011 | April 1, 2023 |
| NCT01333085 | Completed | Phase 1/Phase 2 | Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery | October 2009 | May 2013 |
| NCT01345279 | Completed | Indirect Comparison Topotecan Cervical Carcinoma | June 2009 | July 2009 | |
| NCT01351350 | Completed | Phase 1 | Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies | February 28, 2011 | September 15, 2017 |
| NCT01357161 | Completed | Phase 2 | A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | July 26, 2011 | August 8, 2016 |
| NCT00367471 | Completed | Phase 1 | Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. | December 7, 2006 | September 12, 2019 |
| NCT00001384 | Completed | Phase 2 | A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients | May 1994 | February 2001 |
| NCT00001387 | Completed | Phase 1 | Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy | September 1994 | July 2000 |
| NCT00001426 | Completed | Phase 2 | A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer | February 3, 1995 | November 7, 2013 |
| NCT00001450 | Completed | Phase 2 | Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC | September 1995 | June 2000 |
| NCT00001498 | Completed | Phase 2 | A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | February 1996 | December 2000 |
| NCT00001499 | Completed | Phase 2 | Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | March 1996 | June 2000 |
| NCT00001569 | Completed | Phase 1 | Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis | January 1997 | December 2002 |
| NCT00002189 | Completed | Phase 2 | Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals | ||
| NCT00002519 | Completed | Phase 1 | Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer | January 1997 | January 2000 |
| NCT00002558 | Completed | Phase 1/Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | January 1994 | April 2009 |
| NCT00002559 | Completed | Phase 1/Phase 2 | Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin | January 1994 | January 2003 |
| NCT00002562 | Completed | Phase 2 | Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer | March 1994 | August 2004 |
| NCT00002568 | Completed | Phase 3 | Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer | June 1994 | |
| NCT00002587 | Completed | Phase 1 | Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors | September 1994 | December 2000 |
| NCT00002632 | Completed | Phase 2 | Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | May 30, 1995 | |
| NCT00002662 | Completed | Phase 3 | Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer | August 1994 | June 2004 |
| NCT00002679 | Completed | Phase 2 | Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer | February 1994 | January 2002 |
| NCT00002684 | Completed | Phase 2 | Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer | May 1995 | October 2007 |
| NCT00002711 | Completed | Phase 1 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus | October 1995 | October 2000 |
| NCT00002717 | Completed | Phase 3 | Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer | March 1996 | |
| NCT00002734 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer | March 1996 | |
| NCT00002814 | Completed | Phase 2 | Combination Chemotherapy for Patients With Brain Cancer | August 1996 | December 2001 |
| NCT00002826 | Completed | Phase 2 | Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer | August 14, 1997 | |
| NCT00002837 | Completed | Phase 1/Phase 2 | High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer | September 1995 | January 2002 |
| NCT00002852 | Completed | Phase 3 | Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer | October 1996 | |
| NCT00002854 | Completed | Phase 1 | High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer | December 1994 | August 2015 |
| NCT00002888 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer | March 1997 | August 2004 |
| NCT00002894 | Completed | Phase 3 | Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer | March 1996 | June 2003 |
| NCT00002913 | Completed | Phase 1 | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer | December 1996 | |
| NCT00002917 | Completed | Phase 1/Phase 2 | Paclitaxel in Treating Patients With Early-Stage Bladder Cancer | November 1996 | May 2004 |
| NCT00002922 | Completed | Phase 2 | Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | February 21, 1997 | |
| NCT00002928 | Completed | Phase 2 | Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer | January 1997 | August 2001 |
| NCT00002931 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer | February 1997 | December 2014 |
| NCT00002937 | Completed | Phase 2 | Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer | June 1996 | November 2005 |
| NCT00002939 | Completed | Phase 1 | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer | November 1996 | April 2002 |
| NCT00002949 | Completed | Phase 1 | Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis | July 1996 | May 2001 |
| NCT00002953 | Completed | Phase 3 | Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer | December 1996 | November 2005 |
| NCT00002969 | Completed | Phase 2 | S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | May 1997 | January 2007 |
| NCT00002972 | Completed | Phase 2 | Paclitaxel in Treating Patients With Lung Cancer | January 1997 | |
| NCT00002984 | Completed | Phase 1/Phase 2 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus | March 1997 | January 2007 |
| NCT00003004 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors | July 1997 | October 2001 |
| NCT00003008 | Completed | Phase 2 | Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma | December 15, 1997 | |
| NCT00003013 | Completed | Phase 3 | Chemotherapy Plus Surgery in Treating Women With Breast Cancer | October 1996 | March 2009 |
| NCT00003035 | Completed | Phase 2 | Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer | March 1997 | June 2001 |
| NCT00003050 | Completed | Phase 2 | Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer | April 1997 | March 2000 |
| NCT00003065 | Completed | Phase 2 | Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix | January 1997 | February 2004 |
| NCT00003072 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer | May 1997 | October 1998 |
| NCT00003084 | Completed | Phase 2 | Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer | December 1997 | November 2002 |
| NCT00003087 | Completed | Phase 2 | Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus | August 1997 | February 2005 |
| NCT00003088 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Breast Cancer | September 1997 | June 2003 |
| NCT00003089 | Completed | Phase 2 | Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | July 1997 | February 2004 |
| NCT00003092 | Completed | Phase 3 | Paclitaxel in Treating Older Patients With Solid Tumors | September 1997 | June 2006 |
| NCT00003105 | Completed | Phase 1/Phase 2 | Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer | September 1997 | August 2004 |
| NCT00003111 | Completed | Phase 2 | Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | April 1997 | April 2004 |
| NCT00003117 | Completed | Phase 3 | Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer | October 1997 | January 2006 |
| NCT00003120 | Completed | Phase 3 | S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | November 1997 | November 2012 |
| NCT00003127 | Completed | Phase 2 | S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer | February 1998 | July 2004 |
| NCT00003128 | Completed | Phase 3 | Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus | November 1997 | |
| NCT00003130 | Completed | Phase 2 | Paclitaxel in Treating Women With Recurrent Solid Tumors | November 1997 | January 2006 |
| NCT00003133 | Completed | Phase 1 | Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer | September 1997 | January 2003 |
| NCT00003158 | Completed | Phase 2 | S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer | February 1998 | December 2007 |
| NCT00003159 | Completed | Phase 3 | Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer | August 1997 | June 2007 |
| NCT00003193 | Completed | Phase 1/Phase 2 | Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer | January 1998 | September 2005 |
| NCT00003206 | Completed | Phase 2 | Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer | October 6, 1999 | |
| NCT00003214 | Completed | Phase 3 | Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer | July 1996 | April 2000 |
| NCT00003230 | Completed | Phase 1/Phase 2 | Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia | January 1998 | July 2000 |
| NCT00003235 | Completed | Phase 3 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed | June 1, 1998 | |
| NCT00003237 | Completed | Phase 2 | Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach | June 22, 1998 | |
| NCT00003242 | Completed | Phase 1 | Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors | February 1998 | October 2001 |
| NCT00003281 | Completed | Phase 2 | Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer | April 1998 | March 2006 |
| NCT00003294 | Completed | Phase 1 | Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer | May 1997 | May 2004 |
| NCT00003298 | Completed | Phase 2 | Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer | June 1, 1999 | May 2011 |
| NCT00003299 | Completed | Phase 3 | Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer | April 1998 | January 2006 |
| NCT00003313 | Completed | Phase 3 | Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer | September 1998 | June 2010 |
| NCT00003317 | Completed | Phase 3 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | May 1998 | August 2005 |
| NCT00003322 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer | March 1998 | |
| NCT00003334 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | March 1997 | |
| NCT00003342 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer | December 1997 | July 2007 |
| NCT00003350 | Completed | Phase 3 | Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma | March 1999 | |
| NCT00003376 | Completed | Phase 3 | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | December 3, 1998 | |
| NCT00003377 | Completed | Phase 1 | Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix | November 1999 | July 2009 |
| NCT00003379 | Completed | Phase 1/Phase 2 | Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer | November 1999 | |
| NCT00003385 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | March 1999 | |
| NCT00003387 | Completed | Phase 3 | Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery | July 1998 | April 2009 |
| NCT00003392 | Completed | Phase 2 | High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer | September 1997 | January 2003 |
| NCT00003394 | Completed | Phase 1/Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer | April 1998 | April 2003 |
| NCT00003397 | Completed | Phase 2 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | September 1998 | December 2002 |
| NCT00003399 | Completed | Phase 2 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma | September 1998 | September 2002 |
| NCT00003401 | Completed | Phase 2 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma | January 1999 | September 2002 |
| NCT00003402 | Completed | Phase 2 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | January 1999 | December 2002 |
| NCT00003413 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | September 1998 | February 2001 |
| NCT00003440 | Completed | Phase 3 | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | July 1998 | |
| NCT00003449 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | May 1998 | February 2004 |
| NCT00003518 | Completed | Phase 2 | Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors | January 25, 1999 | |
| NCT00003539 | Completed | Phase 2 | Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer | April 1998 | February 2003 |
| NCT00003555 | Completed | Phase 1 | Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors | July 1998 | May 2003 |
| NCT00003569 | Completed | Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel | March 1998 | ||
| NCT00003582 | Completed | Phase 1/Phase 2 | Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer | May 1988 | December 1996 |
| NCT00003587 | Completed | Phase 2 | S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | October 1998 | January 2007 |
| NCT00003589 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | August 1998 | |
| NCT00003591 | Completed | Phase 2 | Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer | November 1998 | October 2005 |
| NCT00003592 | Completed | Phase 3 | Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | April 22, 1999 | March 2, 2004 |
| NCT00003612 | Completed | Phase 2 | Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer | April 1999 | March 15, 2019 |
| NCT00003614 | Completed | Phase 2 | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | February 4, 1999 | |
| NCT00003644 | Completed | Phase 3 | Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | October 1998 | |
| NCT00003691 | Completed | Phase 3 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | December 1998 | |
| NCT00003701 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Bladder Cancer | April 2, 1999 | June 15, 2007 |
| NCT00003732 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer | September 1998 | September 2005 |
| NCT00003742 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors | October 1998 | August 2001 |
| NCT00003812 | Completed | Phase 2 | Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | March 1999 | March 2006 |
| NCT00003862 | Completed | Phase 2 | Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer | November 1999 | |
| NCT00003877 | Completed | Phase 1/Phase 2 | Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer | September 1998 | December 2000 |
| NCT00003881 | Completed | Phase 2 | Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | May 1999 | July 2004 |
| NCT00003896 | Completed | Phase 2 | S9912 Combination Chemo in Stage III Ovarian Cancer, | September 1999 | February 2008 |
| NCT00003899 | Completed | Phase 1 | Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors | January 1999 | November 2001 |
| NCT00003927 | Completed | Phase 1 | Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | May 18, 1999 | March 21, 2023 |
| NCT00003930 | Completed | Phase 1/Phase 2 | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | September 1999 | November 2013 |
| NCT00003943 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. | September 1998 | February 2003 |
| NCT00003944 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | August 1998 | February 2003 |
| NCT00003957 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | December 1998 | August 2001 |
| NCT00003972 | Completed | Phase 3 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer | July 1998 | March 2003 |
| NCT00003992 | Completed | Phase 2 | Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 | August 1999 | March 2009 |
| NCT00003998 | Completed | Phase 3 | Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer | October 1998 | December 2004 |
| NCT00004011 | Completed | Phase 3 | S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer | October 1999 | November 2012 |
| NCT00004013 | Completed | Phase 2 | Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer | January 1999 | October 2001 |
| NCT00004054 | Completed | Phase 3 | Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer | January 2000 | November 2013 |
| NCT00004055 | Completed | Phase 2 | Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer | November 1999 | July 2004 |
| NCT00004057 | Completed | Phase 1 | Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas | December 1998 | December 2000 |
| NCT00004077 | Completed | Phase 2 | Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer | May 1996 | July 2005 |
| NCT00004089 | Completed | Phase 2 | Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer | August 1999 | April 2002 |
| NCT00004092 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer | May 1999 | December 2013 |
| NCT00004105 | Completed | Phase 1/Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Cancer | September 1998 | |
| NCT00004125 | Completed | Phase 3 | Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes | November 16, 1999 | November 2016 |
| NCT00004126 | Completed | Phase 2 | Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer | November 1999 | August 2003 |
| NCT00004137 | Completed | Phase 2 | S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer | October 1999 | November 2008 |
| NCT00004160 | Completed | Phase 1/Phase 2 | Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed | February 2000 | May 2004 |
| NCT00004174 | Completed | Phase 1 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer | October 1999 | May 2008 |
| NCT00004202 | Completed | Phase 2 | Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer | October 1998 | January 2003 |
| NCT00004863 | Completed | Phase 1 | Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors | July 1999 | August 2001 |
| NCT00004865 | Completed | Phase 2 | Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy | November 1999 | |
| NCT00004916 | Completed | Phase 1/Phase 2 | Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | February 1999 | October 2002 |
| NCT00004921 | Completed | Phase 3 | High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery | September 1998 | September 2007 |
| NCT00004924 | Completed | Phase 2 | Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer | March 1999 | February 2006 |
| NCT00004934 | Completed | Phase 3 | Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | August 1999 | May 2003 |
| NCT00004979 | Completed | Phase 1/Phase 2 | Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors | September 2000 | |
| NCT00005021 | Completed | Phase 1 | Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma | July 1996 | May 2003 |
| NCT00005026 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | February 2000 | |
| NCT00005028 | Completed | Phase 2 | Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer | May 2000 | July 2006 |
| NCT00005032 | Completed | Phase 1/Phase 2 | Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | April 2000 | September 2001 |
| NCT00005046 | Completed | Phase 1 | Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | April 2000 | |
| NCT00005048 | Completed | Phase 1 | Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | April 1997 | |
| NCT00005051 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer | August 1999 | |
| NCT00005059 | Completed | Phase 2 | Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer | January 2000 | April 2006 |
| NCT00005065 | Completed | Phase 1 | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | January 2000 | |
| NCT00005078 | Completed | Phase 1 | Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors | March 2000 | July 2012 |
| NCT00005087 | Completed | Phase 2 | Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer | March 2000 | November 2013 |
| NCT00005599 | Completed | Phase 2 | Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer | February 2000 | August 2004 |
| NCT00005635 | Completed | Phase 2 | Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | January 2000 | |
| NCT00005644 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | January 2, 2001 | June 15, 2007 |
| NCT00005646 | Completed | Phase 2 | Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer | April 2000 | February 2008 |
| NCT00005647 | Completed | Phase 1 | SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck | May 2000 | October 2003 |
| NCT00005649 | Completed | Phase 2 | Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer | July 1998 | July 4, 2002 |
| NCT00005806 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | September 1999 | March 2002 |
| NCT00005819 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | April 2000 | August 2006 |
| NCT00005831 | Completed | Phase 2 | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | March 2000 | |
| NCT00005838 | Completed | Phase 3 | Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery | March 2000 | |
| NCT00005840 | Completed | Phase 1 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00005847 | Completed | Phase 2 | Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | April 5, 2001 | |
| NCT00005849 | Completed | Phase 2 | Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer | April 2000 | November 2003 |
| NCT00005970 | Completed | Phase 3 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | May 19, 2000 | January 27, 2010 |
| NCT00006004 | Completed | Phase 2 | Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer | August 22, 2000 | |
| NCT00006011 | Completed | Phase 3 | Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00006012 | Completed | Phase 1/Phase 2 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | February 2001 | May 2006 |
| NCT00006018 | Completed | Phase 1 | Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors | July 2000 | April 2002 |
| NCT00006027 | Completed | Phase 3 | Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer | August 2000 | |
| NCT00006108 | Completed | Phase 1/Phase 2 | Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer | August 1999 | July 2002 |
| NCT00006110 | Completed | Phase 2 | Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer | December 1998 | April 2013 |
| NCT00006227 | Completed | Phase 2 | Paclitaxel in Treating Patients With Ovarian Stromal Cancer | November 20, 2000 | July 16, 2016 |
| NCT00006229 | Completed | Phase 2/Phase 3 | Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer | April 4, 2000 | February 10, 2009 |
| NCT00006245 | Completed | Phase 2 | Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel | July 2000 | August 2007 |
| NCT00006248 | Completed | Phase 2 | S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | November 2000 | June 2005 |
| NCT00006256 | Completed | Phase 2 | Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer | June 8, 2000 | November 20, 2023 |
| NCT00006257 | Completed | Phase 1 | SU5416 and Paclitaxel in Treating Patients With Advanced Cancer | November 2000 | |
| NCT00006377 | Completed | Phase 2 | Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer | June 2000 | January 2003 |
| NCT00006378 | Completed | Phase 2 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | December 1999 | April 2003 |
| NCT00006454 | Completed | Phase 3 | Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer | December 1999 | August 2006 |
| NCT00006459 | Completed | Phase 3 | Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer | July 2000 | October 2005 |
| NCT00006469 | Completed | Phase 2 | Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer | August 1999 | January 30, 2006 |
| NCT00006484 | Completed | Phase 3 | Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | November 2000 | April 2006 |
| NCT00006929 | Completed | Phase 2 | Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | September 2000 | |
| NCT00007904 | Completed | Phase 2 | Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes | July 2000 | September 2012 |
| NCT00008138 | Completed | Phase 2 | S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer | March 2001 | November 2009 |
| NCT00009802 | Completed | Phase 1 | Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors | June 1998 | June 2005 |
| NCT00009880 | Completed | Phase 2 | Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach | April 2001 | |
| NCT00009997 | Completed | Phase 1 | Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer | March 1999 | |
| NCT00010257 | Completed | Phase 2 | Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma | June 19, 2001 | August 2012 |
| NCT00011960 | Completed | Phase 2 | Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery | May 2001 | |
| NCT00011986 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | January 2001 | January 28, 2013 |
| NCT00011999 | Completed | Phase 2 | Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer | March 2001 | June 2010 |
| NCT00014118 | Completed | Phase 2 | Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer | June 6, 2001 | May 2009 |
| NCT00014222 | Completed | Phase 3 | Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | December 4, 2000 | March 17, 2014 |
| NCT00014573 | Completed | Phase 2 | Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer | August 1998 | October 2004 |
| NCT00014599 | Completed | Phase 2 | Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva | February 2001 | |
| NCT00016315 | Completed | Phase 1 | Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer | May 2001 | June 2010 |
| NCT00016406 | Completed | Phase 3 | S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer | May 2001 | February 2012 |
| NCT00016874 | Completed | Phase 1 | 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer | December 2000 | January 2008 |
| NCT00016913 | Completed | Phase 2 | Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | May 2001 | May 2008 |
| NCT00017407 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer | October 13, 2000 | September 9, 2002 |
| NCT00019019 | Completed | Phase 1 | Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas | October 1994 | July 2006 |
| NCT00019812 | Completed | Phase 2 | Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 | August 1999 | February 2004 |
| NCT00020007 | Completed | Phase 1 | Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery | December 1999 | |
| NCT00020449 | Completed | Phase 2 | Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | January 2001 | May 2004 |
| NCT00020761 | Completed | Phase 2 | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach | April 2000 | August 2005 |
| NCT00021060 | Completed | Phase 2/Phase 3 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | August 2002 | |
| NCT00021320 | Completed | Phase 2 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer | May 2000 | April 2009 |
| NCT00021333 | Completed | Phase 2 | Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer | September 1999 | May 2008 |
| NCT00021372 | Completed | Phase 2 | Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | February 1996 | September 2006 |
| NCT00022139 | Completed | Phase 2 | Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | January 2002 | January 2009 |
| NCT00022191 | Completed | Phase 3 | Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer | May 2001 | |
| NCT00022620 | Completed | Phase 2 | Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer | June 2001 | |
| NCT00023673 | Completed | Phase 1/Phase 2 | Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer | July 2001 | November 2013 |
| NCT00025389 | Completed | Phase 2 | Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer | November 2001 | August 2007 |
| NCT00025480 | Completed | Phase 1 | Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | August 2001 | |
| NCT00026104 | Completed | Phase 2 | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | November 2001 | |
| NCT00027937 | Completed | Phase 2 | Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma | August 2001 | November 2007 |
| NCT00028535 | Completed | Phase 1 | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors | November 2001 | |
| NCT00028587 | Completed | Phase 1 | PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | December 2001 | |
| NCT00028743 | Completed | Phase 3 | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | August 31, 2001 | January 10, 2013 |
| NCT00028769 | Completed | Phase 2 | S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer | December 2001 | July 2011 |
| NCT00028860 | Completed | Phase 2 | Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer | October 2001 | October 2004 |
| NCT00028873 | Completed | Phase 2 | R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy | September 2001 | |
| NCT00028938 | Completed | Phase 3 | Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | January 1, 2002 | November 10, 2002 |
| NCT00028990 | Completed | Phase 3 | Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | January 29, 2002 | May 2009 |
| NCT00030368 | Completed | Phase 1 | Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | November 2001 | |
| NCT00030654 | Completed | Phase 3 | Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer | October 2002 | February 4, 2005 |
| NCT01362374 | Completed | Phase 1 | Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors | July 11, 2011 | October 16, 2020 |
| NCT01364012 | Completed | Phase 3 | A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy | May 23, 2011 | August 17, 2017 |
| NCT01366131 | Completed | Phase 2 | Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) | June 2011 | |
| NCT01374620 | Completed | Phase 1 | Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel | June 2011 | April 2013 |
| NCT01402271 | Completed | Phase 1/Phase 2 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | July 2012 | July 13, 2020 |
| NCT01411410 | Completed | Phase 1 | Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer | August 24, 2011 | June 29, 2015 |
| NCT01414608 | Completed | Phase 3 | Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer | January 9, 2012 | July 9, 2021 |
| NCT01421472 | Completed | Phase 2 | A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer | August 2011 | June 2014 |
| NCT01423123 | Completed | Phase 1 | Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer | May 2011 | March 2014 |
| NCT01433614 | Completed | Phase 3 | Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer | December 2002 | December 2013 |
| NCT01440998 | Completed | Phase 1 | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | September 20, 2011 | December 31, 2015 |
| NCT01446016 | Completed | Phase 2 | Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) | September 2011 | March 1, 2019 |
| NCT01447706 | Completed | Phase 2 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | October 2011 | June 2015 |
| NCT01454102 | Completed | Phase 1 | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | December 16, 2011 | July 23, 2021 |
| NCT01454778 | Completed | N/A | Effects of Paclitaxel on Intimal Hyperplasia | April 2011 | April 2015 |
| NCT01462890 | Completed | Phase 3 | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer | November 2011 | December 2021 |
| NCT01468909 | Completed | Phase 2 | Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | December 12, 2011 | January 27, 2018 |
| NCT01484080 | Completed | Phase 1/Phase 2 | Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates | October 2011 | April 2014 |
| NCT01485848 | Completed | Phase 2 | EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer | February 2012 | May 2014 |
| NCT01486602 | Completed | Phase 1 | Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | March 2012 | January 16, 2018 |
| NCT01493843 | Completed | Phase 2 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | January 20, 2012 | March 30, 2016 |
| NCT01494688 | Completed | Phase 1 | A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors | December 20, 2011 | February 7, 2018 |
| NCT01496742 | Completed | Phase 2 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer | April 2012 | November 2015 |
| NCT01505569 | Completed | N/A | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | October 20, 2011 | February 1, 2024 |
| NCT01506609 | Completed | Phase 2 | Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer | January 23, 2012 | September 2, 2020 |
| NCT01515306 | Completed | Phase 2 | A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors | July 19, 2012 | February 22, 2021 |
| NCT01519804 | Completed | Phase 2 | A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | April 2012 | September 2015 |
| NCT01523678 | Completed | Phase 2 | Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | February 2012 | August 14, 2018 |
| NCT01525602 | Completed | Phase 1 | Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors | May 2012 | February 2018 |
| NCT01526369 | Completed | Phase 3 | A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer | February 13, 2012 | February 17, 2023 |
| NCT01560104 | Completed | Phase 2 | A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | February 2012 | September 2014 |
| NCT01572038 | Completed | Phase 3 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer | June 1, 2012 | September 20, 2019 |
| NCT01572727 | Completed | Phase 2/Phase 3 | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation | August 2012 | June 2015 |
| NCT01583426 | Completed | Phase 3 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) | July 2012 | December 2018 |
| NCT01593020 | Completed | Phase 2 | Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | August 3, 2012 | November 4, 2020 |
| NCT01593228 | Completed | Phase 3 | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | May 2012 | September 2016 |
| NCT01594177 | Completed | Phase 2 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy | May 2012 | March 2014 |
| NCT01616303 | Completed | Phase 2 | A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | June 15, 2012 | October 12, 2018 |
| NCT01617668 | Completed | Phase 2 | A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer | August 2012 | September 2014 |
| NCT01617928 | Completed | Phase 1 | A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors | May 2012 | July 2013 |
| NCT01633970 | Completed | Phase 1 | A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | July 11, 2012 | February 26, 2020 |
| NCT01636622 | Completed | Phase 1 | Study of Vemurafenib, Carboplatin, and Paclitaxel | July 9, 2012 | April 21, 2020 |
| NCT01644825 | Completed | Phase 2 | Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer | December 2010 | December 29, 2015 |
| NCT01644890 | Completed | Phase 3 | A Phase III Study of NK105 in Patients With Breast Cancer | July 2012 | January 2017 |
| NCT01649947 | Completed | Phase 2 | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II | December 23, 2011 | June 30, 2015 |
| NCT01653470 | Completed | Phase 1 | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | October 12, 2012 | May 8, 2017 |
| NCT01656538 | Completed | Phase 2 | A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | February 20, 2013 | February 14, 2018 |
| NCT01663727 | Completed | Phase 3 | Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer | August 27, 2012 | November 21, 2017 |
| NCT01688609 | Completed | Phase 2 | Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | July 2012 | August 15, 2016 |
| NCT01704287 | Completed | Phase 2 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | November 20, 2012 | January 31, 2019 |
| NCT01705691 | Completed | Phase 2 | Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer | September 2012 | October 2015 |
| NCT01711541 | Completed | Phase 1/Phase 2 | Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | October 22, 2012 | May 15, 2023 |
| NCT01711970 | Completed | Phase 1/Phase 2 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | November 2012 | May 3, 2017 |
| NCT01716715 | Completed | Phase 2 | Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | November 6, 2012 | February 9, 2019 |
| NCT01721746 | Completed | Phase 3 | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | December 21, 2012 | December 29, 2020 |
| NCT01722968 | Completed | Phase 2 | A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel | November 2012 | |
| NCT01726452 | Completed | Phase 3 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | January 24, 2013 | August 4, 2022 |
| NCT01739218 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable | February 1, 2013 | August 17, 2016 |
| NCT01740336 | Completed | Phase 2 | A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer | February 6, 2013 | December 10, 2015 |
| NCT01745757 | Completed | Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer | June 2012 | December 2022 | |
| NCT01746771 | Completed | Phase 1/Phase 2 | A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer | November 2012 | August 2015 |
| NCT01755897 | Completed | N/A | A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients | November 2012 | December 2020 |
| NCT01757288 | Completed | Phase 1/Phase 2 | Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC | March 25, 2013 | June 3, 2019 |
| NCT01763645 | Completed | Phase 3 | A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer | October 2012 | November 2014 |
| NCT01763671 | Completed | Phase 3 | Paclitaxel-bevacizumab in Advanced Lung Cancer | May 2013 | April 2017 |
| NCT01764022 | Completed | Phase 3 | A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients | October 2012 | December 2017 |
| NCT01769391 | Completed | Phase 2 | A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer | January 2013 | July 2017 |
| NCT01770301 | Completed | Phase 2 | Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) | February 2013 | April 2021 |
| NCT01778803 | Completed | Phase 1 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | February 26, 2013 | February 23, 2015 |
| NCT01779479 | Completed | Phase 2 | Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) | February 2013 | February 2016 |
| NCT01783197 | Completed | Phase 1 | Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC | June 4, 2013 | April 2, 2019 |
| NCT01792050 | Completed | Phase 2 | Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer | February 2013 | July 7, 2017 |
| NCT01797900 | Completed | Phase 2 | The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | March 2013 | September 2014 |
| NCT01803282 | Completed | Phase 1 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | March 29, 2013 | April 23, 2019 |
| NCT01816594 | Completed | Phase 2 | NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer | September 3, 2013 | February 18, 2015 |
| NCT01818063 | Completed | Phase 2 | Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | April 25, 2013 | December 10, 2018 |
| NCT01821833 | Completed | N/A | Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel | May 24, 2016 | August 3, 2022 |
| NCT01822314 | Completed | Phase 3 | Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer | April 2013 | March 2023 |
| NCT01822613 | Completed | Phase 1 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | July 26, 2013 | June 3, 2016 |
| NCT01827163 | Completed | Phase 2 | Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer | April 2013 | January 2019 |
| NCT01835236 | Completed | Phase 2 | Trastuzumab & Pertuzumab Followed by T-DM1 in MBC | March 3, 2013 | May 26, 2020 |
| NCT01836679 | Completed | Phase 2 | Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer | April 2013 | December 2015 |
| NCT01839773 | Completed | Phase 3 | A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy | March 2013 | August 2015 |
| NCT01847001 | Completed | Phase 2 | Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | October 2012 | October 16, 2019 |
| NCT01855828 | Completed | Phase 2 | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | September 2013 | August 2018 |
| NCT01862081 | Completed | Phase 1 | A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer | July 16, 2013 | June 9, 2017 |
| NCT01862328 | Completed | Phase 1 | Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors | June 10, 2013 | May 21, 2018 |
| NCT01868022 | Completed | Phase 1 | Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | October 9, 2013 | October 24, 2017 |
| NCT01901146 | Completed | Phase 3 | Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer | April 29, 2013 | January 27, 2017 |
| NCT01911598 | Completed | Phase 1 | A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) | September 19, 2013 | June 22, 2017 |
| NCT01918254 | Completed | Phase 1 | A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein | August 6, 2013 | October 7, 2016 |
| NCT01924533 | Completed | Phase 3 | Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | September 3, 2013 | March 27, 2023 |
| NCT01938846 | Completed | Phase 1 | BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors | September 5, 2013 | June 22, 2017 |
| NCT01940497 | Completed | Phase 3 | A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | November 15, 2013 | March 27, 2018 |
| NCT01946074 | Completed | Phase 1 | A Study of ABT-165 in Subjects With Solid Tumors | August 8, 2013 | September 28, 2022 |
| NCT01954355 | Completed | Phase 1 | LDE225 and Paclitaxel in Solid Tumors | September 2013 | November 2016 |
| NCT01959490 | Completed | Phase 2 | Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer | September 24, 2013 | March 29, 2017 |
| NCT01964391 | Completed | Phase 3 | A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer | February 21, 2014 | November 25, 2018 |
| NCT01966003 | Completed | Phase 3 | Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | November 11, 2013 | July 23, 2015 |
| NCT01966471 | Completed | Phase 3 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | January 31, 2014 | June 4, 2021 |
| NCT01968915 | Completed | Phase 1 | Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors | November 2013 | June 2015 |
| NCT01971034 | Completed | Phase 2 | Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure. | June 2011 | |
| NCT01973660 | Completed | Phase 2 | PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | October 2013 | December 2017 |
| NCT01982448 | Completed | Phase 2 | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | April 2014 | August 2020 |
| NCT01989676 | Completed | Phase 3 | A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) | February 24, 2014 | June 27, 2020 |
| NCT01989780 | Completed | Phase 2 | Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | January 2014 | June 2019 |
| NCT01992341 | Completed | Phase 1 | AMG 386 Drug-Drug Interaction Study With Paclitaxel | July 2012 | September 2014 |
| NCT01998906 | Completed | Phase 3 | A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer | May 2002 | July 2012 |
| NCT02004093 | Completed | Phase 2 | A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | December 2005 | September 2008 |
| NCT02013154 | Completed | Phase 1 | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | May 5, 2014 | January 11, 2021 |
| NCT02015676 | Completed | Phase 1/Phase 2 | A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer | July 2001 | September 2009 |
| NCT02019277 | Completed | Phase 3 | A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | December 5, 2013 | November 4, 2016 |
| NCT02032277 | Completed | Phase 3 | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | April 2, 2014 | November 12, 2020 |
| NCT02033551 | Completed | Phase 1 | A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | December 2013 | September 2016 |
| NCT02033993 | Completed | Phase 2 | Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen. | March 11, 2014 | October 28, 2020 |
| NCT02038647 | Completed | Phase 2 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | May 12, 2014 | July 10, 2017 |
| NCT02039674 | Completed | Phase 1/Phase 2 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | February 21, 2014 | October 18, 2021 |
| NCT02041429 | Completed | Phase 1/Phase 2 | Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca | February 2014 | January 2021 |
| NCT02041533 | Completed | Phase 3 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | March 27, 2014 | May 27, 2022 |
| NCT02048020 | Completed | Phase 2 | Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer | December 26, 2013 | January 9, 2017 |
| NCT02051751 | Completed | Phase 1 | A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer | March 5, 2014 | August 19, 2016 |
| NCT02057380 | Completed | Phase 2 | A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | April 16, 2014 | December 21, 2016 |
| NCT02060253 | Completed | Phase 1 | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | April 2014 | June 2018 |
| NCT02066103 | Completed | N/A | Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients | July 2014 | June 2016 |
| NCT02069158 | Completed | Phase 1 | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor | April 2014 | May 2019 |
| NCT02073487 | Completed | Phase 2 | Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel | February 2014 | January 2019 |
| NCT02073968 | Completed | Phase 2 | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer | July 2013 | November 2020 |
| NCT02106546 | Completed | Phase 3 | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | April 10, 2014 | November 20, 2019 |
| NCT02109328 | Completed | Phase 2 | Alisertib in Chemotherapy-pretreated Urothelial Cancer | August 28, 2014 | October 12, 2016 |
| NCT02122770 | Completed | Phase 1 | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors | April 1, 2014 | June 5, 2017 |
| NCT02124707 | Completed | Phase 2 | Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | June 16, 2014 | October 1, 2019 |
| NCT02125344 | Completed | Phase 3 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | December 2014 | January 30, 2017 |
| NCT02132949 | Completed | Phase 2 | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | July 14, 2014 | August 25, 2020 |
| NCT02142738 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | August 25, 2014 | May 27, 2021 |
| NCT02152137 | Completed | Phase 2 | Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer | September 2014 | April 15, 2023 |
| NCT02162719 | Completed | Phase 2 | A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors | August 19, 2014 | August 31, 2019 |
| NCT02163694 | Completed | Phase 3 | A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | July 17, 2014 | January 25, 2024 |
| NCT02172846 | Completed | Phase 1 | Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer | May 22, 2014 | October 2, 2017 |
| NCT02178956 | Completed | Phase 3 | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer | October 2014 | September 20, 2017 |
| NCT02182232 | Completed | Phase 1 | A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer | June 2005 | |
| NCT02182245 | Completed | Phase 1 | Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies | October 2005 | |
| NCT02194166 | Completed | Phase 3 | A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration | July 18, 2014 | July 12, 2018 |
| NCT02199418 | Completed | Phase 2 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer | January 2013 | October 2016 |
| NCT02220894 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | October 30, 2014 | September 12, 2022 |
| NCT02240212 | Completed | Phase 1 | Study of Afuresertib Combined With Paclitaxel in Gastric Cancer | October 2014 | February 7, 2017 |
| NCT02256436 | Completed | Phase 3 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | October 22, 2014 | October 1, 2020 |
| NCT02263495 | Completed | Phase 2 | Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer | December 19, 2014 | June 17, 2019 |
| NCT02264990 | Completed | Phase 3 | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers | September 30, 2014 | February 21, 2020 |
| NCT02269293 | Completed | Phase 1 | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | October 13, 2014 | April 20, 2021 |
| NCT02272790 | Completed | Phase 2 | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | January 30, 2015 | March 8, 2023 |
| NCT02279732 | Completed | Phase 3 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin | October 13, 2014 | May 3, 2018 |
| NCT02280252 | Completed | Phase 2 | Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response | March 2005 | December 20, 2018 |
| NCT02287129 | Completed | Phase 2 | Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction | December 5, 2014 | August 7, 2020 |
| NCT02301988 | Completed | Phase 2 | A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer | February 17, 2015 | August 2, 2017 |
| NCT02302807 | Completed | Phase 3 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | January 13, 2015 | November 8, 2018 |
| NCT02307227 | Completed | Phase 2 | Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors | April 2006 | April 2014 |
| NCT02308553 | Completed | Phase 1/Phase 2 | Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma | March 17, 2015 | November 2019 |
| NCT02311907 | Completed | Phase 3 | Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | December 2009 | August 2012 |
| NCT02312245 | Completed | Phase 2 | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | July 21, 2015 | April 24, 2023 |
| NCT02312661 | Completed | Phase 1 | Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer | October 5, 2015 | November 2017 |
| NCT02317874 | Completed | Phase 1 | Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer | September 8, 2015 | May 3, 2022 |
| NCT02327169 | Completed | Phase 1 | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies | January 14, 2015 | July 2, 2018 |
| NCT02341456 | Completed | Phase 1 | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | January 16, 2015 | July 9, 2018 |
| NCT02364999 | Completed | Phase 3 | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | April 2015 | December 2017 |
| NCT02365935 | Completed | N/A | 4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery | February 2007 | September 2014 |
| NCT02366143 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | March 31, 2015 | December 7, 2020 |
| NCT02366949 | Completed | Phase 1 | Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel | February 27, 2015 | April 18, 2019 |
| NCT02367794 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] | June 11, 2015 | February 17, 2021 |
| NCT02370238 | Completed | Phase 2 | A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | July 29, 2015 | March 23, 2020 |
| NCT02370498 | Completed | Phase 3 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | May 11, 2015 | June 10, 2021 |
| NCT02383212 | Completed | Phase 1 | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | February 2, 2015 | November 18, 2019 |
| NCT02383251 | Completed | Phase 2 | Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer | June 15, 2015 | December 31, 2020 |
| NCT02389751 | Completed | Phase 1 | Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | April 10, 2015 | July 16, 2019 |
| NCT02393898 | Completed | BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older | April 23, 2015 | June 14, 2019 | |
| NCT02406170 | Completed | Phase 1/Phase 2 | Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma | April 2015 | October 2019 |
| NCT02412722 | Completed | Phase 1 | A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | March 26, 2015 | May 31, 2018 |
| NCT02413320 | Completed | Phase 2 | Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer | July 2015 | February 1, 2020 |
| NCT02414685 | Completed | Phase 2 | First Line TIP in Poor Prognosis TGCTs. | April 2015 | June 2020 |
| NCT02419742 | Completed | Phase 4 | Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen | August 18, 2015 | June 24, 2021 |
| NCT02420314 | Completed | Phase 2 | Pharmacological Ascorbate for Lung Cancer | April 2015 | August 27, 2022 |
| NCT02429622 | Completed | Phase 1/Phase 2 | Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma | January 2015 | December 2016 |
| NCT02430311 | Completed | Phase 1 | The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. | June 10, 2015 | April 28, 2017 |
| NCT02440425 | Completed | Phase 2 | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | October 20, 2015 | May 27, 2021 |
| NCT02442063 | Completed | Phase 1 | Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions | August 2015 | October 2016 |
| NCT02446574 | Completed | Phase 1/Phase 2 | Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma | July 2007 | December 2016 |
| NCT02448329 | Completed | Phase 2 | Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy | January 14, 2015 | April 19, 2021 |
| NCT02450058 | Completed | Phase 3 | Adjuvant FEC Versus EP in Breast Cancer (MIG5) | November 1996 | May 2012 |
| NCT02451956 | Completed | Phase 2 | Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy | January 7, 2015 | May 24, 2019 |
| NCT02467907 | Completed | Phase 2 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | July 28, 2015 | January 15, 2019 |
| NCT02472964 | Completed | Phase 3 | Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. | July 2012 | August 2018 |
| NCT02474186 | Completed | Phase 2 | Phase II Study for Solid Metastatic Tumors | April 2003 | July 2015 |
| NCT02483104 | Completed | Phase 1 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | July 2015 | July 2016 |
| NCT02483247 | Completed | Phase 1 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | September 2015 | May 2019 |
| NCT02489903 | Completed | Phase 2 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | June 2015 | December 6, 2021 |
| NCT02492867 | Completed | N/A | A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer | January 14, 2016 | April 21, 2022 |
| NCT02501603 | Completed | Phase 2 | Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer | July 2016 | December 20, 2022 |
| NCT02501954 | Completed | Phase 3 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | March 2015 | November 2023 |
| NCT02503358 | Completed | Phase 1 | Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | July 21, 2016 | July 16, 2020 |
| NCT02513563 | Completed | Phase 2 | AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | October 30, 2015 | November 28, 2023 |
| NCT02514551 | Completed | Phase 2 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | October 12, 2015 | December 28, 2018 |
| NCT02539225 | Completed | Phase 2 | A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | October 5, 2015 | March 10, 2021 |
| NCT02549209 | Completed | Phase 2 | Pembro/Carbo/Taxol in Endometrial Cancer | August 22, 2017 | February 10, 2022 |
| NCT02562898 | Completed | Phase 1/Phase 2 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | October 12, 2015 | September 1, 2020 |
| NCT02564263 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | December 1, 2015 | March 14, 2022 |
| NCT02567799 | Completed | Phase 1/Phase 2 | BIO 300 Non-Small Cell Lung Cancer Study | November 2015 | September 2020 |
| NCT02574078 | Completed | Phase 1/Phase 2 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) | November 23, 2015 | April 15, 2020 |
| NCT02576574 | Completed | Phase 3 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | October 29, 2015 | January 29, 2024 |
| NCT02581943 | Completed | Phase 2 | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | June 17, 2016 | December 28, 2022 |
| NCT02581982 | Completed | Phase 2 | Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | April 6, 2016 | December 19, 2022 |
| NCT02591615 | Completed | Phase 2 | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | March 2016 | July 4, 2020 |
| NCT02597036 | Completed | Phase 1 | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | November 6, 2015 | May 24, 2020 |
| NCT02597946 | Completed | Phase 2 | Afatinib in NSCLC With HER2 Mutation | March 18, 2016 | July 22, 2018 |
| NCT02599324 | Completed | Phase 1/Phase 2 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | December 1, 2015 | August 20, 2021 |
| NCT02599363 | Completed | Phase 1 | A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer | January 2016 | March 12, 2019 |
| NCT02607332 | Completed | Phase 2 | Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | November 2015 | January 2018 |
| NCT02607982 | Completed | Phase 2 | CCRT for Esophageal Cancer. | January 2005 | November 2015 |
| NCT02613208 | Completed | A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer | December 9, 2015 | December 3, 2018 | |
| NCT02614833 | Completed | Phase 2 | IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma | December 2015 | May 2021 |
| NCT02615730 | Completed | Phase 1/Phase 2 | PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma | February 2016 | March 31, 2021 |
| NCT02622074 | Completed | Phase 1 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | January 27, 2016 | November 18, 2019 |
| NCT02625623 | Completed | Phase 3 | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | December 28, 2015 | November 13, 2019 |
| NCT02628132 | Completed | Phase 1/Phase 2 | Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients | November 2016 | March 24, 2020 |
| NCT02628951 | Completed | Phase 2 | Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis | May 26, 2016 | January 2, 2019 |
| NCT02630199 | Completed | Phase 1 | Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer | December 2015 | April 19, 2021 |
| NCT02631876 | Completed | Phase 3 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | March 2, 2016 | January 2020 |
| NCT02640053 | Completed | N/A | Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome | December 23, 2015 | October 5, 2018 |
| NCT02640755 | Completed | Phase 1 | Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase | January 28, 2016 | July 6, 2017 |
| NCT02672475 | Completed | Phase 1 | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | March 2016 | August 2023 |
| NCT02684227 | Completed | Phase 2 | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | August 24, 2016 | September 27, 2023 |
| NCT02689427 | Completed | Phase 2 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | September 22, 2016 | November 15, 2023 |
| NCT02698891 | Completed | Phase 2 | Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer | April 7, 2016 | November 2021 |
| NCT02725268 | Completed | Phase 2 | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer | April 1, 2016 | October 30, 2020 |
| NCT02728492 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | August 2013 | January 2016 |
| NCT02730546 | Completed | Phase 1/Phase 2 | Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | June 24, 2016 | October 31, 2023 |
| NCT02735239 | Completed | Phase 1/Phase 2 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | June 24, 2016 | June 16, 2022 |
| NCT02739698 | Completed | Phase 2 | Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia | July 2012 | March 2017 |
| NCT02754882 | Completed | Phase 3 | A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | July 5, 2016 | October 9, 2018 |
| NCT02766582 | Completed | Phase 2 | Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | October 2016 | December 30, 2023 |
| NCT02775435 | Completed | Phase 3 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | June 9, 2016 | September 14, 2023 |
| NCT02788708 | Completed | Phase 1 | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | May 27, 2016 | March 31, 2022 |
| NCT02789657 | Completed | Phase 2 | Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | November 21, 2016 | March 27, 2020 |
| NCT02810457 | Completed | Phase 3 | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer | September 7, 2016 | January 26, 2022 |
| NCT02819518 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | July 27, 2016 | October 30, 2023 |
| NCT02835586 | Completed | Phase 3 | STREAMER : STent Restenosis And MEdicaments Release | May 2013 | November 2015 |
| NCT02881125 | Completed | Phase 1 | Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma | November 3, 2016 | November 30, 2019 |
| NCT02890511 | Completed | Phase 1/Phase 2 | A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer | August 2010 | October 2012 |
| NCT02898077 | Completed | Phase 3 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | March 2, 2017 | April 12, 2021 |
| NCT02911350 | Completed | Phase 1 | Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer | May 2000 | December 2016 |
| NCT02915744 | Completed | Phase 3 | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | November 2016 | July 2020 |
| NCT02916511 | Completed | Phase 2 | Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma | September 1, 2016 | July 1, 2023 |
| NCT02944396 | Completed | Phase 1 | Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | December 23, 2016 | October 2, 2019 |
| NCT02948075 | Completed | Phase 2 | Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | September 2015 | June 16, 2017 |
| NCT02954055 | Completed | Phase 2 | MEtronomic TrEatment Option in Advanced bReast cAncer | September 13, 2017 | November 23, 2022 |
| NCT02978495 | Completed | Phase 2 | Neoadjuvant Carboplatin in Triple Negative Breast Cancer | May 17, 2017 | October 22, 2021 |
| NCT03018080 | Completed | Phase 2 | Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer | June 12, 2017 | August 5, 2022 |
| NCT03030287 | Completed | Phase 1 | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | December 2016 | April 2020 |
| NCT03038100 | Completed | Phase 3 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 8, 2017 | August 12, 2022 |
| NCT03056833 | Completed | Phase 1 | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | June 10, 2017 | August 1, 2022 |
| NCT03057366 | Completed | Phase 1 | A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors | May 11, 2017 | November 5, 2018 |
| NCT03057600 | Completed | Phase 2 | Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) | May 1, 2017 | November 25, 2019 |
| NCT03064126 | Completed | Phase 3 | RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty | March 2, 2017 | October 25, 2023 |
| NCT03072992 | Completed | Phase 2 | "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer | March 20, 2017 | June 30, 2019 |
| NCT03083613 | Completed | Phase 2 | Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma | May 2015 | December 1, 2018 |
| NCT03085914 | Completed | Phase 1/Phase 2 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | May 2, 2017 | July 13, 2020 |
| NCT03087864 | Completed | Phase 2 | PDL-1 Targeting in Resectable Oesophageal Cancer | June 28, 2017 | July 1, 2019 |
| NCT03092986 | Completed | Phase 4 | Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer | January 1, 2017 | December 2018 |
| NCT03095209 | Completed | Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery | February 24, 2017 | January 18, 2021 | |
| NCT03096418 | Completed | Phase 4 | Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response | March 13, 2017 | August 16, 2022 |
| NCT03112590 | Completed | Phase 1/Phase 2 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | June 23, 2017 | February 20, 2023 |
| NCT03117049 | Completed | Phase 3 | Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) | June 13, 2017 | December 4, 2023 |
| NCT03117933 | Completed | Phase 2 | Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | March 9, 2017 | December 31, 2023 |
| NCT03125902 | Completed | Phase 3 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) | August 25, 2017 | January 17, 2023 |
| NCT03126812 | Completed | Phase 1/Phase 2 | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | November 1, 2017 | March 5, 2024 |
| NCT03128008 | Completed | Phase 2 | Locally Advanced NSCLC Hyperfractionated RT | December 7, 2017 | January 27, 2021 |
| NCT03132532 | Completed | Phase 2 | Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | July 31, 2017 | December 31, 2023 |
| NCT03136055 | Completed | Phase 2 | Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas | June 20, 2017 | October 31, 2021 |
| NCT03165994 | Completed | Phase 2 | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | October 6, 2017 | February 21, 2023 |
| NCT03169335 | Completed | Phase 3 | Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer | March 28, 2017 | July 13, 2018 |
| NCT03189446 | Completed | Phase 2 | Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer | October 2, 2017 | October 6, 2021 |
| NCT03193918 | Completed | Phase 1 | Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma | April 14, 2017 | July 15, 2020 |
| NCT03248427 | Completed | Phase 2 | Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. | July 13, 2017 | July 20, 2019 |
| NCT03272477 | Completed | Phase 2 | Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients | October 5, 2017 | March 4, 2024 |
| NCT03296163 | Completed | Phase 3 | A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | February 6, 2018 | February 27, 2020 |
| NCT03301350 | Completed | Phase 2 | Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer | November 7, 2017 | February 7, 2022 |
| NCT03314935 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | November 21, 2017 | November 28, 2022 |
| NCT03328494 | Completed | Phase 1 | Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies | October 13, 2017 | March 16, 2021 |
| NCT03329911 | Completed | Phase 3 | A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer | October 20, 2017 | May 27, 2021 |
| NCT03330028 | Completed | Phase 1 | Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | October 27, 2017 | April 18, 2023 |
| NCT03330106 | Completed | Phase 1 | A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors | November 15, 2017 | June 21, 2021 |
| NCT03337724 | Completed | Phase 3 | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer | January 6, 2018 | January 4, 2023 |
| NCT03342911 | Completed | Phase 2 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | November 13, 2017 | October 6, 2020 |
| NCT03356860 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. | April 13, 2017 | December 31, 2023 |
| NCT03394885 | Completed | Phase 1/Phase 2 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer | June 19, 2018 | July 20, 2020 |
| NCT03395080 | Completed | Phase 2 | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | March 5, 2018 | January 27, 2021 |
| NCT03411161 | Completed | Phase 1/Phase 2 | S 81694 Plus Paclitaxel in Metastatic Breast Cancer | January 4, 2018 | June 8, 2020 |
| NCT03430843 | Completed | Phase 3 | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | January 26, 2018 | December 28, 2022 |
| NCT03430882 | Completed | Phase 1 | Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors | March 12, 2018 | June 8, 2022 |
| NCT03432598 | Completed | Phase 2 | Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer | August 24, 2017 | December 21, 2020 |
| NCT03486314 | Completed | Phase 1 | A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors | August 13, 2018 | February 28, 2021 |
| NCT03492047 | Completed | Phase 1/Phase 2 | N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients | April 1, 2018 | June 30, 2019 |
| NCT03493854 | Completed | Phase 3 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | June 14, 2018 | June 2, 2023 |
| NCT03498716 | Completed | Phase 3 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | August 2, 2018 | August 14, 2023 |
| NCT03535701 | Completed | N/A | Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer | October 20, 2017 | May 1, 2020 |
| NCT03556358 | Completed | Phase 3 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | June 28, 2018 | February 4, 2021 |
| NCT03573947 | Completed | Phase 2 | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC | October 2, 2018 | June 15, 2023 |
| NCT03594747 | Completed | Phase 3 | A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer | July 30, 2018 | April 28, 2023 |
| NCT03600090 | Completed | Phase 1 | Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer | October 16, 2018 | December 25, 2021 |
| NCT03601897 | Completed | Phase 1/Phase 2 | A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors | October 25, 2018 | May 23, 2022 |
| NCT03618758 | Completed | Phase 1/Phase 2 | Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 | December 24, 2018 | December 2, 2023 |
| NCT03635489 | Completed | Phase 3 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | August 15, 2018 | May 12, 2023 |
| NCT03644186 | Completed | Phase 2 | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) | April 16, 2019 | April 14, 2023 |
| NCT03691090 | Completed | Phase 3 | Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer | December 3, 2018 | April 30, 2022 |
| NCT03693612 | Completed | Phase 1/Phase 2 | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | November 26, 2018 | September 16, 2021 |
| NCT03726879 | Completed | Phase 3 | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | January 11, 2019 | August 24, 2023 |
| NCT03748134 | Completed | Phase 3 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) | December 24, 2018 | July 29, 2023 |
| NCT03756818 | Completed | Phase 1 | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | March 5, 2019 | February 23, 2023 |
| NCT03762564 | Completed | Phase 2 | Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy | March 8, 2019 | November 25, 2022 |
| NCT03783949 | Completed | Phase 2 | European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | November 30, 2018 | September 1, 2023 |
| NCT03800836 | Completed | Phase 1 | A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | February 13, 2018 | March 15, 2022 |
| NCT03814005 | Completed | Phase 1 | A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | July 10, 2019 | April 19, 2022 |
| NCT03840915 | Completed | Phase 1/Phase 2 | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | April 2, 2019 | July 29, 2022 |
| NCT03850444 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study | August 1, 2016 | September 8, 2022 |
| NCT03853707 | Completed | Phase 1/Phase 2 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | March 4, 2019 | September 19, 2023 |
| NCT03866993 | Completed | Phase 3 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | December 20, 2018 | January 14, 2022 |
| NCT03875092 | Completed | Phase 3 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | April 21, 2017 | September 14, 2023 |
| NCT03887130 | Completed | Phase 2 | Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer | March 27, 2007 | April 18, 2013 |
| NCT03901118 | Completed | Phase 2 | Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer | July 1, 2019 | December 18, 2020 |
| NCT03933449 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | December 29, 2016 | March 14, 2022 |
| NCT03940196 | Completed | Phase 3 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | March 22, 2019 | May 18, 2023 |
| NCT03943667 | Completed | Phase 3 | Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma | May 23, 2019 | April 26, 2022 |
| NCT04031703 | Completed | Phase 3 | Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN) | January 1, 2011 | April 20, 2016 |
| NCT04046016 | Completed | Early Phase 1 | A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor | July 3, 2018 | December 24, 2018 |
| NCT04081389 | Completed | Phase 1 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | December 6, 2019 | February 27, 2023 |
| NCT04110288 | Completed | VQI DELTA Paclitaxel Device Safety Analysis | January 1, 2017 | April 1, 2020 | |
| NCT04127019 | Completed | Phase 3 | Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) | June 1, 2010 | June 15, 2017 |
| NCT04177108 | Completed | Phase 3 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | November 25, 2019 | February 28, 2023 |
| NCT04224922 | Completed | Phase 2 | Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer | May 2015 | May 2017 |
| NCT04261218 | Completed | Phase 1 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer | August 25, 2020 | July 4, 2022 |
| NCT04299880 | Completed | Phase 1 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | February 24, 2020 | May 30, 2021 |
| NCT04324346 | Completed | N/A | Central Catheters Used for Chemotherapy in Women With Breast Cancer | April 1, 2016 | February 1, 2021 |
| NCT04408118 | Completed | Phase 2 | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC | October 5, 2020 | December 7, 2023 |
| NCT04551950 | Completed | Phase 1 | Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) | October 19, 2020 | June 30, 2022 |
| NCT04568200 | Completed | Phase 2 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma | June 19, 2020 | January 1, 2024 |
| NCT04572100 | Completed | Phase 1 | Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer | October 1, 2020 | January 9, 2023 |
| NCT04632992 | Completed | Phase 2 | A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | January 13, 2021 | February 27, 2024 |
| NCT04647643 | Completed | Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease | November 20, 2020 | December 31, 2021 | |
| NCT04672772 | Completed | Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data. | December 18, 2020 | January 17, 2022 | |
| NCT04672928 | Completed | Phase 1 | A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | December 14, 2020 | January 31, 2023 |
| NCT04694183 | Completed | Phase 2 | The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer | August 17, 2020 | May 6, 2023 |
| NCT04742036 | Completed | Phase 1 | Capivasertib China PK Study | February 22, 2021 | July 29, 2022 |
| NCT04868708 | Completed | Phase 2 | A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer | April 1, 2021 | February 28, 2024 |
| NCT05112536 | Completed | Phase 2 | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | March 3, 2022 | March 13, 2023 |
| NCT05128617 | Completed | Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study | November 4, 2021 | May 30, 2023 | |
| NCT05189535 | Completed | Phase 2/Phase 3 | "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients" | October 3, 2021 | September 28, 2023 |
| NCT05318443 | Completed | Phase 3 | A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | April 17, 2020 | January 12, 2023 |
| NCT06062602 | Completed | Early Phase 1 | PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC | July 26, 2021 | November 15, 2022 |
| NCT06303583 | Enrolling by invitation | Phase 1/Phase 2 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma | June 1, 2022 | December 31, 2026 |
| NCT02307812 | No longer available | Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France | |||
| NCT06445972 | Not yet recruiting | Phase 1/Phase 2 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | July 1, 2024 | October 27, 2028 |
| NCT06279364 | Not yet recruiting | Phase 3 | A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | February 2024 | July 2026 |
| NCT05522894 | Not yet recruiting | Phase 2 | AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC | October 1, 2022 | October 1, 2024 |
| NCT06204614 | Not yet recruiting | Early Phase 1 | Drug Screening Using IMD in Bladder Cancer | February 14, 2024 | July 1, 2025 |
| NCT05487391 | Not yet recruiting | Phase 3 | A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | October 1, 2022 | October 1, 2031 |
| NCT05741021 | Not yet recruiting | Phase 2 | A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | March 1, 2023 | October 25, 2024 |
| NCT06055348 | Not yet recruiting | Phase 1/Phase 2 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | October 30, 2023 | November 30, 2025 |
| NCT05131893 | Not yet recruiting | Neoadjuvant Treatment of Breast Cancer | March 2022 | December 2031 | |
| NCT05247684 | Not yet recruiting | Phase 2 | AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC | February 20, 2022 | January 20, 2025 |
| NCT06463028 | Not yet recruiting | Phase 2 | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer | September 30, 2024 | September 2029 |
| NCT05821452 | Not yet recruiting | Phase 2 | Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma | May 25, 2023 | May 30, 2026 |
| NCT05900921 | Not yet recruiting | Phase 2 | Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer | July 1, 2023 | December 31, 2025 |
| NCT05826015 | Not yet recruiting | Phase 1 | AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | October 31, 2024 | June 4, 2034 |
| NCT06341335 | Not yet recruiting | Phase 3 | A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | May 2024 | July 2027 |
| NCT05489848 | Not yet recruiting | Phase 2/Phase 3 | Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation | August 20, 2022 | August 20, 2030 |
| NCT02422563 | Not yet recruiting | Phase 3 | NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB | October 2015 | October 2025 |
| NCT06066216 | Not yet recruiting | Phase 2 | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer | February 1, 2024 | October 31, 2026 |
| NCT06447662 | Not yet recruiting | Phase 1 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | July 28, 2024 | July 12, 2028 |
| NCT05921149 | Not yet recruiting | N/A | Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer | May 25, 2024 | June 1, 2031 |
| NCT05411237 | Not yet recruiting | Phase 3 | Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma | March 15, 2024 | September 2028 |
| NCT05841381 | Not yet recruiting | Phase 3 | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | May 6, 2023 | May 6, 2033 |
| NCT04301375 | Not yet recruiting | Phase 2 | Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) | June 15, 2020 | July 15, 2027 |
| NCT05966441 | Not yet recruiting | Phase 2 | Role of Curcumin in Paclitaxel Induced PN | August 30, 2023 | March 10, 2024 |
| NCT06439693 | Not yet recruiting | Phase 2 | The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | November 2024 | March 30, 2033 |
| NCT06434610 | Not yet recruiting | Phase 2 | A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. | June 30, 2024 | December 31, 2026 |
| NCT05715840 | Not yet recruiting | Phase 3 | Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) | January 31, 2023 | May 31, 2026 |
| NCT06297811 | Not yet recruiting | Phase 2 | Myeloprotection With Trilaciclib in Pan-cancer Population | March 1, 2024 | December 31, 2027 |
| NCT06340568 | Not yet recruiting | Phase 3 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer | August 2024 | December 2028 |
| NCT05287308 | Not yet recruiting | N/A | Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | March 2022 | September 2027 |
| NCT06139211 | Not yet recruiting | Phase 1/Phase 2 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | November 30, 2023 | April 30, 2026 |
| NCT05111444 | Not yet recruiting | Phase 2 | Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | December 31, 2021 | June 30, 2024 |
| NCT05990127 | Not yet recruiting | Phase 3 | A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | November 14, 2023 | November 28, 2026 |
| NCT06238843 | Not yet recruiting | Phase 3 | A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma | March 29, 2024 | June 30, 2027 |
| NCT05872412 | Not yet recruiting | Phase 2 | Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer | June 1, 2023 | April 30, 2024 |
| NCT06412471 | Not yet recruiting | Phase 2 | A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients | June 2024 | August 2025 |
| NCT06364917 | Not yet recruiting | Phase 2 | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | October 31, 2024 | June 2027 |
| NCT05067530 | Not yet recruiting | Phase 2 | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study | January 1, 2022 | December 6, 2026 |
| NCT06136988 | Not yet recruiting | Phase 1/Phase 2 | A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. | December 2023 | April 2028 |
| NCT05322499 | Not yet recruiting | Phase 2 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | April 15, 2022 | April 15, 2025 |
| NCT05794659 | Not yet recruiting | Phase 2 | Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer | November 15, 2023 | November 15, 2027 |
| NCT06023862 | Not yet recruiting | Phase 2 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | January 22, 2024 | December 31, 2029 |
| NCT06407310 | Not yet recruiting | Phase 2 | Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | July 1, 2024 | December 1, 2027 |
| NCT05628610 | Not yet recruiting | Phase 2 | Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer | November 30, 2022 | December 1, 2027 |
| NCT05730777 | Not yet recruiting | Phase 4 | Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics | February 15, 2023 | December 31, 2023 |
| NCT06394492 | Not yet recruiting | Phase 3 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | May 31, 2024 | December 31, 2026 |
| NCT05798819 | Not yet recruiting | Phase 3 | A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | May 1, 2023 | December 1, 2026 |
| NCT06363708 | Not yet recruiting | N/A | Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer | June 1, 2024 | June 30, 2026 |
| NCT06393751 | Not yet recruiting | Phase 1/Phase 2 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | June 21, 2024 | February 9, 2028 |
| NCT06197438 | Not yet recruiting | Phase 2 | Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer | January 1, 2024 | April 1, 2025 |
| NCT05316376 | Not yet recruiting | Phase 2 | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial | May 1, 2022 | April 30, 2025 |
| NCT05715229 | Recruiting | Phase 2 | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | September 29, 2023 | April 28, 2026 |
| NCT04296175 | Recruiting | Phase 3 | Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) | March 5, 2020 | June 2025 |
| NCT04278092 | Recruiting | Phase 2 | Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | February 10, 2020 | July 2024 |
| NCT04016389 | Recruiting | N/A | FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery | February 11, 2020 | June 2025 |
| NCT05420636 | Recruiting | Phase 2 | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | December 21, 2022 | August 7, 2026 |
| NCT06312176 | Recruiting | Phase 3 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | April 14, 2024 | April 12, 2031 |
| NCT04274426 | Recruiting | Phase 2 | Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer | October 13, 2021 | December 2026 |
| NCT04267848 | Recruiting | Phase 3 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial | June 16, 2020 | December 15, 2024 |
| NCT06317311 | Recruiting | Phase 2 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | May 7, 2024 | August 31, 2027 |
| NCT04046575 | Recruiting | Phase 1 | Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer | November 7, 2019 | September 30, 2027 |
| NCT05420948 | Recruiting | Phase 2 | A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer | October 17, 2022 | December 1, 2026 |
| NCT04266249 | Recruiting | Phase 2 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | March 13, 2020 | December 31, 2038 |
| NCT06333951 | Recruiting | Phase 1 | AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | June 28, 2024 | November 3, 2029 |
| NCT04055649 | Recruiting | Phase 2 | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | January 21, 2020 | May 28, 2026 |
| NCT04069273 | Recruiting | Phase 2 | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma | December 1, 2020 | December 10, 2025 |
| NCT04253964 | Recruiting | Phase 2 | Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | July 1, 2020 | June 2025 |
| NCT04243616 | Recruiting | Phase 2 | Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer | March 5, 2020 | January 1, 2026 |
| NCT06318897 | Recruiting | Phase 2 | Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer | May 29, 2024 | September 30, 2027 |
| NCT04083599 | Recruiting | Phase 1/Phase 2 | GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | September 17, 2019 | October 2025 |
| NCT06328738 | Recruiting | Phase 1 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | June 1, 2024 | July 2028 |
| NCT04209686 | Recruiting | Phase 2 | Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | July 31, 2020 | April 2028 |
| NCT04205968 | Recruiting | Phase 2 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | June 1, 2020 | June 16, 2025 |
| NCT04095364 | Recruiting | Phase 3 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | September 20, 2019 | February 1, 2028 |
| NCT06320405 | Recruiting | Phase 1/Phase 2 | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors | May 31, 2024 | April 1, 2029 |
| NCT06321068 | Recruiting | Phase 2/Phase 3 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer | April 9, 2024 | October 2027 |
| NCT04205903 | Recruiting | Phase 1 | Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer | December 11, 2020 | January 2, 2024 |
| NCT05183126 | Recruiting | Phase 4 | Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer | March 28, 2022 | May 2024 |
| NCT05307705 | Recruiting | Phase 1 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | May 11, 2022 | May 2025 |
| NCT05158062 | Recruiting | Phase 2 | Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer | April 20, 2022 | November 30, 2024 |
| NCT06323460 | Recruiting | Phase 2 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | April 1, 2024 | December 31, 2025 |
| NCT05721755 | Recruiting | Phase 3 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | June 8, 2023 | March 31, 2030 |
| NCT04193059 | Recruiting | Phase 3 | Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer | August 1, 2018 | July 2024 |
| NCT05298423 | Recruiting | Phase 3 | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006) | May 3, 2022 | September 4, 2029 |
| NCT05142189 | Recruiting | Phase 1 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | June 17, 2022 | August 2027 |
| NCT05459129 | Recruiting | Phase 1/Phase 2 | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | April 13, 2023 | August 11, 2024 |
| NCT05739981 | Recruiting | Phase 1/Phase 2 | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | February 10, 2023 | January 30, 2028 |
| NCT05482893 | Recruiting | Phase 1/Phase 2 | PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) | March 15, 2023 | April 2026 |
| NCT05136846 | Recruiting | Phase 1 | Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer | December 6, 2021 | December 31, 2025 |
| NCT05296798 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | July 4, 2022 | September 30, 2032 |
| NCT05747794 | Recruiting | Phase 2/Phase 3 | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy | May 22, 2023 | July 31, 2027 |
| NCT06441890 | Recruiting | Phase 2 | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer | June 2024 | June 2028 |
| NCT05116462 | Recruiting | Phase 3 | Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | March 15, 2024 | October 14, 2028 |
| NCT05112965 | Recruiting | Phase 3 | An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | December 1, 2021 | December 31, 2025 |
| NCT03048942 | Recruiting | Phase 2 | Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer | November 2014 | August 2025 |
| NCT05751668 | Recruiting | Phase 2 | Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) | November 2, 2023 | May 31, 2030 |
| NCT05768932 | Recruiting | Phase 1 | BAL0891 in Patients With Advanced Solid Tumors | December 14, 2022 | March 24, 2026 |
| NCT05775289 | Recruiting | Phase 2 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | March 15, 2023 | March 30, 2028 |
| NCT05781308 | Recruiting | Phase 2 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | April 26, 2023 | June 2026 |
| NCT02619448 | Recruiting | Early Phase 1 | Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC | December 2014 | December 2025 |
| NCT03081143 | Recruiting | Phase 2/Phase 3 | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | May 10, 2017 | March 2025 |
| NCT05381909 | Recruiting | Phase 1 | A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors | July 6, 2022 | November 2026 |
| NCT05799612 | Recruiting | Phase 1 | Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma | March 22, 2024 | December 31, 2029 |
| NCT05485766 | Recruiting | Phase 2 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | February 29, 2024 | September 30, 2027 |
| NCT05800015 | Recruiting | Phase 2/Phase 3 | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | August 8, 2023 | December 23, 2031 |
| NCT03094884 | Recruiting | Phase 1 | Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer | February 24, 2017 | May 1, 2025 |
| NCT05108870 | Recruiting | Phase 1/Phase 2 | TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers | March 27, 2024 | January 1, 2026 |
| NCT05800587 | Recruiting | Phase 2 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | February 22, 2023 | August 1, 2029 |
| NCT02305654 | Recruiting | Phase 3 | International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | May 12, 2017 | November 30, 2027 |
| NCT05107674 | Recruiting | Phase 1 | A Study of NX-1607 in Adults With Advanced Malignancies | September 29, 2021 | February 28, 2026 |
| NCT05819892 | Recruiting | Phase 1 | Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | July 17, 2023 | March 1, 2028 |
| NCT05828459 | Recruiting | Phase 1 | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | July 10, 2023 | July 2027 |
| NCT05832827 | Recruiting | Phase 2 | First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) | September 4, 2023 | June 30, 2028 |
| NCT05834348 | Recruiting | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | June 26, 2023 | February 3, 2025 | |
| NCT05840211 | Recruiting | Phase 3 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | May 8, 2023 | December 2028 |
| NCT05382286 | Recruiting | Phase 3 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | July 25, 2022 | February 2027 |
| NCT05319730 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | May 16, 2023 | September 20, 2028 |
| NCT05092360 | Recruiting | Phase 3 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) | January 10, 2022 | May 2027 |
| NCT05853172 | Recruiting | Phase 2 | Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer | March 21, 2023 | December 21, 2025 |
| NCT05870748 | Recruiting | Phase 2/Phase 3 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | July 12, 2023 | February 2026 |
| NCT05502237 | Recruiting | Phase 3 | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | October 12, 2022 | September 2027 |
| NCT05283226 | Recruiting | Phase 2 | Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | September 30, 2022 | January 2, 2025 |
| NCT05879068 | Recruiting | Phase 2 | A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | May 27, 2022 | April 30, 2026 |
| NCT05065021 | Recruiting | Phase 2 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | February 23, 2023 | June 6, 2025 |
| NCT02639650 | Recruiting | Phase 3 | Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor | March 1, 2016 | March 1, 2026 |
| NCT05054439 | Recruiting | Phase 2 | A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC | December 22, 2021 | June 2024 |
| NCT05506943 | Recruiting | Phase 2/Phase 3 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | January 9, 2023 | December 2025 |
| NCT03233139 | Recruiting | Phase 1 | Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies | June 21, 2017 | March 27, 2030 |
| NCT05039801 | Recruiting | Phase 1 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | September 9, 2021 | May 29, 2026 |
| NCT05889390 | Recruiting | Phase 2/Phase 3 | Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer | February 20, 2023 | April 30, 2025 |
| NCT05020860 | Recruiting | Phase 2 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | April 18, 2023 | November 2029 |
| NCT05012254 | Recruiting | Phase 2 | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | November 18, 2021 | December 15, 2026 |
| NCT05900206 | Recruiting | Phase 2 | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | October 26, 2023 | April 30, 2032 |
| NCT05009082 | Recruiting | Phase 3 | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | September 13, 2022 | September 2030 |
| NCT05007106 | Recruiting | Phase 2 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | September 16, 2021 | February 22, 2027 |
| NCT05002127 | Recruiting | Phase 2/Phase 3 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | January 15, 2022 | August 2028 |
| NCT02194738 | Recruiting | N/A | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | September 26, 2014 | September 28, 2026 |
| NCT03287271 | Recruiting | Phase 1/Phase 2 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | February 6, 2018 | October 2024 |
| NCT04982237 | Recruiting | Phase 3 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | August 27, 2021 | December 30, 2025 |
| NCT05904379 | Recruiting | Phase 1/Phase 2 | AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | July 13, 2023 | January 31, 2027 |
| NCT04974944 | Recruiting | Phase 2 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer | July 30, 2021 | December 2024 |
| NCT04949256 | Recruiting | Phase 3 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) | July 28, 2021 | December 29, 2025 |
| NCT04943653 | Recruiting | Phase 1/Phase 2 | Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis | June 8, 2021 | December 2025 |
| NCT03321188 | Recruiting | Phase 2 | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients | December 15, 2017 | December 15, 2024 |
| NCT04938583 | Recruiting | Phase 1/Phase 2 | Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | March 17, 2021 | December 31, 2025 |
| NCT05929768 | Recruiting | Phase 3 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | September 15, 2023 | April 2033 |
| NCT05281003 | Recruiting | Phase 2 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004) | February 20, 2023 | September 1, 2026 |
| NCT05977998 | Recruiting | Phase 2 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | September 8, 2023 | October 31, 2030 |
| NCT05978648 | Recruiting | Phase 2 | Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy | September 20, 2023 | December 31, 2027 |
| NCT05983276 | Recruiting | Phase 2 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | November 16, 2023 | August 28, 2031 |
| NCT05984277 | Recruiting | Phase 3 | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | October 24, 2023 | May 16, 2029 |
| NCT04921527 | Recruiting | Phase 3 | Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer | December 20, 2021 | July 31, 2025 |
| NCT05276973 | Recruiting | Phase 1 | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | September 8, 2022 | June 30, 2024 |
| NCT05382299 | Recruiting | Phase 3 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | July 20, 2022 | May 2027 |
| NCT05383196 | Recruiting | Phase 1/Phase 2 | Onvansertib + Paclitaxel In TNBC | September 30, 2022 | February 15, 2029 |
| NCT05552807 | Recruiting | Phase 1 | SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | June 15, 2022 | September 2023 |
| NCT06005324 | Recruiting | Phase 1 | Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer | December 18, 2023 | December 2026 |
| NCT06018337 | Recruiting | Phase 3 | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | January 18, 2024 | May 2028 |
| NCT04893109 | Recruiting | Phase 2 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | June 16, 2021 | May 1, 2028 |
| NCT03410784 | Recruiting | Phase 2 | Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer | April 1, 2018 | December 2024 |
| NCT04892953 | Recruiting | Phase 2 | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | July 7, 2021 | September 30, 2024 |
| NCT06437353 | Recruiting | Phase 2 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | May 25, 2024 | October 30, 2027 |
| NCT06038578 | Recruiting | Phase 2 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | October 4, 2023 | August 31, 2025 |
| NCT06043427 | Recruiting | Phase 2 | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | April 16, 2024 | June 30, 2026 |
| NCT06047379 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | November 1, 2023 | August 31, 2026 |
| NCT05256225 | Recruiting | Phase 2/Phase 3 | Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | November 16, 2022 | October 31, 2027 |
| NCT03462212 | Recruiting | Phase 1/Phase 2 | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination | March 17, 2021 | March 1, 2025 |
| NCT04862650 | Recruiting | Phase 2 | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | November 30, 2021 | December 31, 2024 |
| NCT05554380 | Recruiting | Phase 2 | Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial | September 22, 2023 | August 31, 2025 |
| NCT04862585 | Recruiting | Phase 2/Phase 3 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | October 7, 2021 | December 31, 2024 |
| NCT06052839 | Recruiting | Phase 2 | Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC | October 3, 2023 | September 2026 |
| NCT05357846 | Recruiting | Phase 3 | PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) | November 1, 2022 | January 2031 |
| NCT06058377 | Recruiting | Phase 3 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | November 27, 2023 | May 31, 2026 |
| NCT04858269 | Recruiting | Phase 2 | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | May 27, 2021 | June 2027 |
| NCT05319639 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | February 16, 2023 | December 31, 2024 |
| NCT05564377 | Recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | April 7, 2023 | July 1, 2030 |
| NCT04856176 | Recruiting | Phase 2 | A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy | January 3, 2022 | December 2024 |
| NCT05358548 | Recruiting | Phase 2 | ATATcH Alternating Treatment Plans for Advanced Cancer | April 28, 2022 | December 1, 2025 |
| NCT03534713 | Recruiting | Phase 3 | Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread | July 17, 2020 | December 2026 |
| NCT04808466 | Recruiting | Phase 2 | Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy | September 18, 2021 | September 1, 2025 |
| NCT04807673 | Recruiting | Phase 3 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) | December 1, 2021 | May 2028 |
| NCT04804696 | Recruiting | Phase 2 | Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma | February 10, 2021 | December 2024 |
| NCT06072781 | Recruiting | Phase 3 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | March 18, 2024 | February 9, 2031 |
| NCT04794699 | Recruiting | Phase 1 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | April 14, 2021 | March 30, 2027 |
| NCT05577702 | Recruiting | Phase 2 | Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer | February 15, 2023 | December 2026 |
| NCT04762953 | Recruiting | Phase 2 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis | February 18, 2021 | June 2025 |
| NCT06094296 | Recruiting | Phase 2 | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | November 27, 2023 | October 27, 2027 |
| NCT03574779 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer | November 15, 2018 | March 31, 2026 |
| NCT04736823 | Recruiting | Phase 2 | A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | February 1, 2021 | March 2025 |
| NCT05580887 | Recruiting | Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients | May 12, 2022 | August 2025 | |
| NCT04704934 | Recruiting | Phase 3 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | May 21, 2021 | February 1, 2026 |
| NCT06096844 | Recruiting | Phase 3 | Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | November 11, 2024 | June 1, 2026 |
| NCT02429700 | Recruiting | Phase 3 | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors | April 2015 | May 2030 |
| NCT05605535 | Recruiting | Phase 2 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | February 7, 2023 | May 15, 2026 |
| NCT06103864 | Recruiting | Phase 3 | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | November 23, 2023 | April 23, 2029 |
| NCT05613088 | Recruiting | Phase 2 | A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | February 1, 2023 | October 11, 2026 |
| NCT04682158 | Recruiting | Phase 2 | Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma | April 1, 2021 | April 1, 2027 |
| NCT04679064 | Recruiting | Phase 3 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | December 1, 2020 | January 1, 2025 |
| NCT02429687 | Recruiting | Phase 3 | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors | April 2015 | May 2030 |
| NCT05235542 | Recruiting | Phase 1/Phase 2 | A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors | July 12, 2022 | March 2024 |
| NCT05624996 | Recruiting | Phase 3 | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer | May 10, 2023 | October 15, 2036 |
| NCT06112379 | Recruiting | Phase 3 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | November 14, 2023 | August 28, 2030 |
| NCT06132958 | Recruiting | Phase 3 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | December 6, 2023 | January 10, 2028 |
| NCT04660760 | Recruiting | Phase 2 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | June 16, 2021 | May 31, 2026 |
| NCT05374512 | Recruiting | Phase 3 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | May 16, 2022 | December 3, 2025 |
| NCT06385080 | Recruiting | Phase 1/Phase 2 | A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer | April 22, 2024 | July 17, 2026 |
| NCT04615013 | Recruiting | Phase 1 | NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer | November 23, 2020 | October 31, 2025 |
| NCT01817452 | Recruiting | Phase 2 | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol | March 2014 | October 2024 |
| NCT03768063 | Recruiting | Phase 3 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | February 28, 2019 | July 5, 2028 |
| NCT04585490 | Recruiting | Phase 3 | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | August 25, 2021 | April 1, 2028 |
| NCT05654454 | Recruiting | Phase 3 | A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | May 31, 2023 | March 2027 |
| NCT04579224 | Recruiting | Phase 3 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | June 28, 2021 | August 15, 2027 |
| NCT04576143 | Recruiting | Phase 2/Phase 3 | Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer | September 20, 2020 | September 20, 2027 |
| NCT05394415 | Recruiting | Phase 1/Phase 2 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC | May 1, 2022 | April 30, 2025 |
| NCT06207305 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma | January 30, 2024 | January 2, 2028 |
| NCT03801876 | Recruiting | Phase 3 | Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | March 15, 2019 | December 21, 2031 |
| NCT06356311 | Recruiting | Phase 3 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | May 3, 2024 | May 5, 2028 |
| NCT04526470 | Recruiting | Phase 1/Phase 2 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | September 1, 2020 | December 2024 |
| NCT04516447 | Recruiting | Phase 1 | A Study of ZN-c3 in Patients With Ovarian Cancer | October 26, 2020 | February 28, 2027 |
| NCT05395910 | Recruiting | Phase 1 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis | August 4, 2023 | December 31, 2025 |
| NCT04495296 | Recruiting | Phase 1/Phase 2 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | August 13, 2020 | November 1, 2024 |
| NCT05664971 | Recruiting | Phase 1/Phase 2 | JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer | February 9, 2023 | November 17, 2024 |
| NCT04481256 | Recruiting | N/A | TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY | November 11, 2020 | June 1, 2023 |
| NCT06241235 | Recruiting | Phase 1/Phase 2 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | March 27, 2024 | May 2026 |
| NCT05227664 | Recruiting | Phase 2 | A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | March 23, 2022 | October 30, 2023 |
| NCT06245889 | Recruiting | Phase 2 | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | May 1, 2024 | June 2030 |
| NCT06246110 | Recruiting | Phase 2 | A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer | February 6, 2024 | December 2027 |
| NCT05415709 | Recruiting | Early Phase 1 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer | June 13, 2022 | December 31, 2024 |
| NCT04444921 | Recruiting | Phase 3 | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | November 17, 2020 | March 31, 2026 |
| NCT03872947 | Recruiting | Phase 1 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | April 26, 2019 | March 2025 |
| NCT06251973 | Recruiting | Phase 2 | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | February 1, 2024 | August 1, 2027 |
| NCT03876886 | Recruiting | Phase 3 | The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency | February 22, 2019 | December 2024 |
| NCT05189067 | Recruiting | Phase 2/Phase 3 | Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer | January 31, 2022 | June 30, 2025 |
| NCT05188313 | Recruiting | Phase 3 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | March 9, 2022 | February 2037 |
| NCT05325632 | Recruiting | Phase 2 | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | October 28, 2021 | January 31, 2025 |
| NCT03907475 | Recruiting | Phase 2 | Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) | July 16, 2019 | June 1, 2026 |
| NCT04443348 | Recruiting | Phase 2 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | December 16, 2020 | December 2024 |
| NCT03912415 | Recruiting | Phase 3 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) | October 1, 2019 | December 1, 2024 |
| NCT05681728 | Recruiting | Phase 2 | A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer | February 1, 2022 | June 1, 2024 |
| NCT04428151 | Recruiting | Phase 2 | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | August 6, 2020 | February 17, 2027 |
| NCT05185947 | Recruiting | Phase 2 | Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | October 13, 2022 | December 30, 2031 |
| NCT06346392 | Recruiting | Phase 3 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | March 4, 2024 | October 9, 2026 |
| NCT03921008 | Recruiting | Phase 1/Phase 2 | Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma | May 21, 2019 | August 31, 2027 |
| NCT04391049 | Recruiting | Phase 1 | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | June 29, 2020 | October 1, 2025 |
| NCT03932409 | Recruiting | Phase 1 | Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer | February 19, 2020 | September 2025 |
| NCT06304974 | Recruiting | Phase 3 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | March 19, 2024 | May 2026 |
| NCT06312137 | Recruiting | Phase 3 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | April 3, 2024 | October 23, 2034 |
| NCT03944304 | Recruiting | Phase 2 | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | May 27, 2019 | November 30, 2025 |
| NCT03944915 | Recruiting | Phase 2 | De-Escalation Therapy for Human Papillomavirus Negative Disease | August 26, 2019 | July 1, 2024 |
| NCT04332367 | Recruiting | Phase 2 | Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | August 1, 2020 | April 2025 |
| NCT05684276 | Recruiting | Phase 2 | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors | May 12, 2023 | June 1, 2028 |
| NCT03965468 | Recruiting | Phase 2 | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | November 19, 2019 | December 2026 |
| NCT02905591 | Recruiting | Phase 2 | A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC | November 16, 2018 | December 31, 2027 |
| NCT04329065 | Recruiting | Phase 2 | Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer | April 20, 2022 | June 30, 2027 |
| NCT05687266 | Recruiting | Phase 3 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | December 29, 2022 | February 22, 2027 |
| NCT05691010 | Recruiting | Early Phase 1 | A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | January 10, 2023 | January 10, 2025 |
| NCT04308837 | Recruiting | Phase 2 | A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation | December 3, 2018 | August 2025 |
| NCT05636111 | Recruiting | Phase 1 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | July 12, 2023 | July 31, 2026 |
| NCT04644068 | Recruiting | Phase 1/Phase 2 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | November 12, 2020 | December 15, 2026 |
| NCT03742102 | Recruiting | Phase 1/Phase 2 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | December 21, 2018 | November 14, 2024 |
| NCT05637268 | Recruiting | Phase 2 | Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma | November 26, 2020 | June 1, 2025 |
| NCT06161441 | Recruiting | Phase 2 | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery | June 7, 2024 | April 19, 2029 |
| NCT04638582 | Recruiting | Phase 2 | Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) | August 28, 2022 | December 27, 2025 |
| NCT06203600 | Recruiting | Phase 2/Phase 3 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | January 31, 2025 | October 31, 2027 |
| NCT04656041 | Recruiting | Phase 2 | Folfox+Irinotecan+Chemort In Esophageal Cancer | June 29, 2021 | December 2027 |
| NCT04652076 | Recruiting | Phase 1/Phase 2 | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab | December 14, 2020 | July 30, 2026 |
| NCT05633667 | Recruiting | Phase 2 | Study of Novel Treatment Combinations in Patients With Lung Cancer | March 16, 2023 | January 2027 |
| NCT00781612 | Recruiting | Phase 2 | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | October 16, 2008 | September 20, 2029 |
| NCT03721744 | Recruiting | Phase 2/Phase 3 | A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | October 25, 2018 | September 2025 |
| NCT05635708 | Recruiting | Phase 2 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | March 7, 2023 | July 2025 |
| NCT06161025 | Recruiting | Phase 2/Phase 3 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | February 27, 2024 | December 31, 2029 |
| NCT03731442 | Recruiting | Phase 3 | Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients | November 1, 2018 | October 31, 2027 |
| NCT03604991 | Suspended | Phase 2/Phase 3 | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery | May 3, 2019 | January 31, 2026 |
| NCT04711161 | Suspended | Phase 1 | First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. | December 21, 2020 | March 2025 |
| NCT02037529 | Suspended | Phase 3 | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer | January 17, 2014 | December 31, 2023 |
| NCT03002103 | Suspended | Phase 3 | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer | November 23, 2016 | June 2027 |
| NCT00278122 | Suspended | Phase 2 | Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | July 2005 | |
| NCT05554341 | Suspended | Phase 2 | Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial | July 14, 2023 | July 1, 2025 |
| NCT05673200 | Suspended | Phase 1 | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | September 25, 2023 | February 23, 2027 |
| NCT02560038 | Terminated | Phase 2 | Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer | October 2015 | September 14, 2017 |
| NCT00929162 | Terminated | Phase 2 | ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer | June 2009 | June 2011 |
| NCT00883116 | Terminated | Phase 3 | A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer | August 2009 | February 2014 |
| NCT02593708 | Terminated | Phase 1 | Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | November 3, 2015 | July 31, 2017 |
| NCT00850577 | Terminated | Phase 2 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | June 2009 | August 2013 |
| NCT00003086 | Terminated | Phase 1/Phase 2 | Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer | March 1997 | January 28, 2001 |
| NCT00811993 | Terminated | Phase 1 | A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | February 2009 | December 2012 |
| NCT05493501 | Terminated | Phase 3 | Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer | December 14, 2022 | August 31, 2023 |
| NCT02629848 | Terminated | Phase 3 | Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer | July 2012 | March 2015 |
| NCT02661815 | Terminated | Phase 1 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | June 15, 2016 | July 28, 2017 |
| NCT00003054 | Terminated | Phase 2 | Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus | August 1997 | |
| NCT02711137 | Terminated | Phase 1/Phase 2 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | May 18, 2016 | February 13, 2019 |
| NCT02718417 | Terminated | Phase 3 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | May 19, 2016 | May 16, 2019 |
| NCT00807612 | Terminated | Phase 1/Phase 2 | QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer | January 2009 | August 2010 |
| NCT02756013 | Terminated | Phase 2 | Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0 | April 20, 2016 | January 24, 2019 |
| NCT02761694 | Terminated | Phase 1 | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | June 26, 2016 | March 10, 2021 |
| NCT02824575 | Terminated | Phase 1 | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | July 2016 | December 27, 2021 |
| NCT02826161 | Terminated | Phase 3 | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | November 2016 | April 24, 2017 |
| NCT02834975 | Terminated | Phase 2 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | December 22, 2016 | December 1, 2022 |
| NCT00756470 | Terminated | Phase 2 | Phase II Neoadjuvant in Inflammatory Breast Cancer | October 2008 | October 2013 |
| NCT00738699 | Terminated | Phase 2 | An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer | September 2008 | January 2012 |
| NCT00728845 | Terminated | Phase 1/Phase 2 | Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer | June 16, 2008 | December 21, 2010 |
| NCT02920450 | Terminated | Phase 1/Phase 2 | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | September 25, 2017 | April 4, 2019 |
| NCT02923739 | Terminated | Phase 2 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | May 5, 2017 | September 27, 2022 |
| NCT00679029 | Terminated | Phase 2 | Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer | May 2, 2008 | November 18, 2010 |
| NCT00002819 | Terminated | Phase 3 | Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer | November 1996 | |
| NCT00662597 | Terminated | Phase 3 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer | April 2008 | May 2010 |
| NCT00662311 | Terminated | Phase 1/Phase 2 | Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery | March 2008 | September 2011 |
| NCT03019588 | Terminated | Phase 3 | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) | February 16, 2017 | June 29, 2021 |
| NCT03029611 | Terminated | Phase 2 | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery | April 3, 2017 | December 10, 2019 |
| NCT03064854 | Terminated | Phase 1 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | May 24, 2017 | July 28, 2021 |
| NCT00626561 | Terminated | Phase 2 | Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix | February 2008 | July 2011 |
| NCT00622466 | Terminated | Phase 2 | Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer | April 23, 2008 | October 2016 |
| NCT00618917 | Terminated | Phase 1/Phase 2 | MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) | November 11, 2005 | August 11, 2011 |
| NCT00603941 | Terminated | Phase 1/Phase 2 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | January 2008 | December 2011 |
| NCT03138889 | Terminated | Phase 1/Phase 2 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | June 9, 2017 | August 24, 2022 |
| NCT00596830 | Terminated | Phase 3 | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | April 2008 | September 2012 |
| NCT00589238 | Terminated | Phase 2 | Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery | January 2008 | |
| NCT00585052 | Terminated | Phase 2 | A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer | August 2003 | June 2013 |
| NCT00570531 | Terminated | Phase 2 | Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma | June 2007 | June 2013 |
| NCT00568451 | Terminated | Phase 2 | Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma | June 2006 | April 2012 |
| NCT00566540 | Terminated | Phase 2 | Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer | December 11, 2007 | February 25, 2010 |
| NCT00551733 | Terminated | Phase 3 | Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | August 2007 | December 25, 2007 |
| NCT03329378 | Terminated | Phase 2 | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | January 24, 2019 | March 7, 2021 |
| NCT03348904 | Terminated | Phase 3 | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | December 27, 2017 | May 22, 2018 |
| NCT03367871 | Terminated | Phase 2 | Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | September 6, 2018 | January 30, 2023 |
| NCT00539331 | Terminated | Phase 1 | Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients | September 2007 | September 2008 |
| NCT00537173 | Terminated | Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer | September 2007 | August 2009 | |
| NCT00536939 | Terminated | Phase 2 | Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | November 2007 | March 2008 |
| NCT00531687 | Terminated | Phase 2 | Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer | September 2007 | October 2016 |
| NCT00526890 | Terminated | Phase 2 | Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | October 2006 | September 2010 |
| NCT00522834 | Terminated | Phase 3 | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | August 2007 | June 2009 |
| NCT00520975 | Terminated | Phase 3 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU | November 2007 | October 2015 |
| NCT00507429 | Terminated | Phase 2/Phase 3 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer | August 2007 | November 2011 |
| NCT00506779 | Terminated | Phase 1/Phase 2 | Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | December 29, 2003 | April 2015 |
| NCT00505492 | Terminated | Phase 2 | Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy | February 2002 | December 2010 |
| NCT00493025 | Terminated | Phase 2 | Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery | April 2005 | March 2013 |
| NCT00476827 | Terminated | Phase 2 | A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain | May 2007 | May 2011 |
| NCT00460317 | Terminated | Phase 3 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | July 2007 | August 2013 |
| NCT00459121 | Terminated | Phase 2 | Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery | July 2007 | October 2008 |
| NCT00002772 | Terminated | Phase 3 | S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | July 1996 | February 2004 |
| NCT00434356 | Terminated | Phase 2 | A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | March 2007 | |
| NCT00434226 | Terminated | Phase 2 | A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) | March 2007 | |
| NCT00408070 | Terminated | Phase 2 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | October 2006 | October 2009 |
| NCT03690739 | Terminated | Phase 3 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | August 9, 2019 | March 3, 2021 |
| NCT00373217 | Terminated | Phase 2 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | April 13, 2006 | February 7, 2008 |
| NCT03707028 | Terminated | Phase 1/Phase 2 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | October 1, 2018 | August 24, 2021 |
| NCT00369551 | Terminated | Phase 1 | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer | June 2006 | |
| NCT00369070 | Terminated | Phase 2 | A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | January 31, 2007 | August 3, 2011 |
| NCT00358163 | Terminated | Phase 1 | Trial of PTK787/ZK 222584 Plus Paclitaxel | April 26, 2006 | May 29, 2008 |
| NCT00356681 | Terminated | Phase 2 | A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | December 2006 | August 2012 |
| NCT00334763 | Terminated | Phase 2 | Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer | May 2006 | November 2007 |
| NCT00331422 | Terminated | Phase 2 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | October 2005 | March 2009 |
| NCT00322881 | Terminated | Phase 2 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | April 2006 | April 2010 |
| NCT00290537 | Terminated | Phase 2 | Phase II Study of ZD6474 in Advanced NSCLC | January 2006 | April 2008 |
| NCT00272987 | Terminated | Phase 3 | ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | December 13, 2005 | October 21, 2019 |
| NCT00269828 | Terminated | Phase 3 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. | December 2005 | December 2006 |
| NCT03840902 | Terminated | Phase 2 | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | April 16, 2019 | February 17, 2023 |
| NCT03852979 | Terminated | Phase 2 | Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility | November 1, 2018 | January 1, 2020 |
| NCT00268450 | Terminated | Phase 2 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | September 21, 2005 | April 2012 |
| NCT00201734 | Terminated | Phase 1/Phase 2 | Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary | June 2005 | June 2013 |
| NCT03871153 | Terminated | Phase 2 | Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer | August 2, 2019 | March 9, 2022 |
| NCT00194792 | Terminated | Phase 2 | Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer | August 2005 | July 2011 |
| NCT03887442 | Terminated | Phase 2 | Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy | February 16, 2011 | October 2, 2012 |
| NCT03894007 | Terminated | Phase 2 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | May 23, 2019 | June 30, 2021 |
| NCT03894540 | Terminated | Phase 1 | Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours | March 22, 2019 | December 21, 2020 |
| NCT00176241 | Terminated | Phase 1 | Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer | December 2005 | November 2008 |
| NCT00161278 | Terminated | Phase 2 | Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling | December 2004 | August 2006 |
| NCT00138151 | Terminated | Phase 2 | Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer | March 2001 | November 2010 |
| NCT00113399 | Terminated | Phase 3 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery | April 2005 | |
| NCT00102622 | Terminated | Phase 1 | Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | December 1, 2004 | July 2012 |
| NCT00088829 | Terminated | Phase 2 | Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer | April 2001 | December 2012 |
| NCT00084448 | Terminated | Phase 2 | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | April 2004 | |
| NCT00072215 | Terminated | Phase 3 | Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors | April 2004 | April 2005 |
| NCT00063258 | Terminated | Phase 2 | Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer | June 2003 | April 2008 |
| NCT00054210 | Terminated | Phase 3 | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | January 2003 | October 2004 |
| NCT00048893 | Terminated | Phase 1/Phase 2 | Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer | November 2002 | June 2011 |
| NCT00042835 | Terminated | Phase 1 | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer | May 2002 | |
| NCT00041470 | Terminated | Phase 1/Phase 2 | Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial | March 2001 | August 2008 |
| NCT01303679 | Terminated | Phase 3 | 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer | June 2010 | May 2018 |
| NCT01367301 | Terminated | N/A | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer | July 8, 2011 | August 15, 2018 |
| NCT01372202 | Terminated | Phase 2 | CHFR Methylation Status Esophageal Cancer Study | June 2011 | October 1, 2014 |
| NCT01279291 | Terminated | Phase 1 | Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | January 2011 | November 2012 |
| NCT01395537 | Terminated | Phase 1/Phase 2 | Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) | August 2011 | December 2014 |
| NCT01407562 | Terminated | Phase 1 | Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors | September 17, 2010 | March 29, 2016 |
| NCT01413750 | Terminated | Phase 1/Phase 2 | Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer | November 2010 | April 2013 |
| NCT00031577 | Terminated | Phase 1 | Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma | August 1999 | September 2006 |
| NCT04210037 | Terminated | Phase 1/Phase 2 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | August 20, 2020 | May 15, 2022 |
| NCT00025298 | Terminated | Phase 2 | Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx | July 2001 | |
| NCT01457846 | Terminated | Phase 2 | Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer | November 2011 | February 2015 |
| NCT00023907 | Terminated | Phase 2 | Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | July 2001 | |
| NCT04251169 | Terminated | Phase 2 | Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression | July 21, 2020 | April 30, 2024 |
| NCT01493505 | Terminated | Phase 3 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | January 2012 | December 2016 |
| NCT01495247 | Terminated | Phase 1/Phase 2 | Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | January 30, 2012 | May 19, 2014 |
| NCT00022633 | Terminated | Phase 2 | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract | July 2001 | July 2011 |
| NCT01512199 | Terminated | Phase 1/Phase 2 | Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) | November 2011 | January 28, 2015 |
| NCT01558492 | Terminated | Phase 2 | Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer | March 2011 | November 2013 |
| NCT01268059 | Terminated | Phase 1/Phase 2 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | December 16, 2010 | September 11, 2013 |
| NCT01578551 | Terminated | Phase 2 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | May 2012 | January 2017 |
| NCT01579578 | Terminated | Phase 2 | Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer | April 2012 | March 2013 |
| NCT04325698 | Terminated | Phase 3 | A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC | June 11, 2020 | May 10, 2021 |
| NCT01249443 | Terminated | Phase 1 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | November 2013 | December 2017 |
| NCT00016341 | Terminated | Phase 3 | Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer | May 2001 | |
| NCT00016276 | Terminated | Phase 3 | Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer | May 2001 | |
| NCT01238133 | Terminated | Phase 1 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | December 2010 | August 2015 |
| NCT01688791 | Terminated | Phase 1 | A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001) | December 2012 | September 2014 |
| NCT01697293 | Terminated | Phase 1/Phase 2 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | January 2012 | June 2020 |
| NCT01705483 | Terminated | Phase 1 | A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies | August 28, 2012 | June 11, 2014 |
| NCT01732640 | Terminated | Phase 1/Phase 2 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | December 2012 | January 2017 |
| NCT01745367 | Terminated | Phase 2 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | November 2012 | June 2014 |
| NCT00006472 | Terminated | Phase 2 | Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer | January 2000 | September 10, 2002 |
| NCT01774851 | Terminated | Phase 2 | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | January 2013 | December 2015 |
| NCT01779050 | Terminated | Phase 2 | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | December 19, 2013 | September 1, 2021 |
| NCT01220128 | Terminated | Phase 2 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | April 11, 2011 | November 14, 2014 |
| NCT01215136 | Terminated | Phase 2 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | December 2010 | April 24, 2018 |
| NCT00005612 | Terminated | Phase 1/Phase 2 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer | August 1999 | February 2004 |
| NCT01820325 | Terminated | Phase 1 | Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | September 9, 2013 | June 18, 2014 |
| NCT01200342 | Terminated | Phase 2 | Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | December 2010 | September 2013 |
| NCT01822496 | Terminated | Phase 2 | Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | November 4, 2013 | June 4, 2018 |
| NCT01830270 | Terminated | Phase 2 | Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer | May 2011 | July 2016 |
| NCT01847677 | Terminated | Phase 2 | Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin | May 6, 2013 | May 17, 2019 |
| NCT01852292 | Terminated | Phase 2 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | October 1, 2013 | March 30, 2017 |
| NCT01194869 | Terminated | Phase 2 | Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer | June 2010 | June 2015 |
| NCT01868984 | Terminated | Phase 2 | Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis | May 2013 | June 2015 |
| NCT01182610 | Terminated | Phase 2 | Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma | April 2011 | March 2012 |
| NCT01891357 | Terminated | Phase 2 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer | September 30, 2013 | November 16, 2016 |
| NCT01912625 | Terminated | Phase 1 | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | October 28, 2013 | February 24, 2023 |
| NCT01930292 | Terminated | Phase 1 | Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies | April 2013 | March 2016 |
| NCT00004859 | Terminated | Phase 3 | Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer | January 2000 | March 2010 |
| NCT01953926 | Terminated | Phase 2 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | September 30, 2013 | January 2, 2023 |
| NCT04729608 | Terminated | Phase 3 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer | April 22, 2021 | August 4, 2023 |
| NCT01962948 | Terminated | Phase 1/Phase 2 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | October 9, 2013 | July 6, 2018 |
| NCT04761601 | Terminated | Phase 1 | First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors | March 3, 2021 | February 29, 2024 |
| NCT00004221 | Terminated | Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | November 1999 | |
| NCT00004159 | Terminated | Phase 1/Phase 2 | Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor | February 2000 | February 2000 |
| NCT01147016 | Terminated | Phase 2 | Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery | July 2010 | July 26, 2017 |
| NCT02012192 | Terminated | Phase 1/Phase 2 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | July 4, 2014 | December 4, 2017 |
| NCT01144442 | Terminated | N/A | WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer | July 27, 2010 | May 1, 2015 |
| NCT00004093 | Terminated | Phase 1/Phase 2 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | August 1999 | March 2002 |
| NCT00003880 | Terminated | Phase 2/Phase 3 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | February 1999 | August 2001 |
| NCT04906382 | Terminated | Early Phase 1 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | July 1, 2021 | September 1, 2022 |
| NCT00003852 | Terminated | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | March 1998 | March 2000 |
| NCT02112552 | Terminated | Phase 2 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer | April 10, 2014 | December 1, 2017 |
| NCT02134067 | Terminated | Phase 1 | Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | August 2014 | July 2018 |
| NCT01120158 | Terminated | Phase 2 | Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer | September 2009 | January 2017 |
| NCT02138812 | Terminated | Phase 1 | Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel | May 9, 2014 | October 2, 2017 |
| NCT00003624 | Terminated | Phase 2 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | December 1998 | |
| NCT01110603 | Terminated | Phase 1 | A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) | July 2010 | July 2011 |
| NCT02204345 | Terminated | Phase 1/Phase 2 | A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology | October 2014 | March 2016 |
| NCT01083537 | Terminated | Phase 1/Phase 2 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | February 2010 | June 2012 |
| NCT01069796 | Terminated | Phase 2 | Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer | April 2010 | June 2014 |
| NCT02252796 | Terminated | Phase 1 | Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer | July 2014 | September 2017 |
| NCT01055028 | Terminated | Phase 2 | Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma | February 2010 | June 24, 2016 |
| NCT01041027 | Terminated | Phase 2 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer | January 16, 2009 | October 1, 2019 |
| NCT02279576 | Terminated | Phase 2 | Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) | January 2015 | September 2016 |
| NCT02297230 | Terminated | Phase 1/Phase 2 | Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics | June 2002 | December 2, 2014 |
| NCT00003386 | Terminated | Phase 2 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | July 1999 | |
| NCT02322814 | Terminated | Phase 2 | A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread | March 12, 2015 | September 17, 2021 |
| NCT02358200 | Terminated | Phase 1 | Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer | February 23, 2015 | January 8, 2019 |
| NCT02367352 | Terminated | Phase 1 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | March 19, 2015 | May 23, 2017 |
| NCT00003378 | Terminated | Phase 1 | Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer | August 1998 | |
| NCT02379585 | Terminated | Phase 1/Phase 2 | Fasting on Newly Diagnosed Breast Cancer | January 2013 | August 2015 |
| NCT02389985 | Terminated | Phase 1/Phase 2 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | July 2015 | October 18, 2018 |
| NCT01009983 | Terminated | Phase 2 | Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer | March 2010 | December 2013 |
| NCT02392377 | Terminated | Phase 2 | Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy | February 2015 | December 2015 |
| NCT02403895 | Terminated | Phase 2 | AZD2014 and Weekly Paclitaxel in Squamous NSCLC | April 15, 2015 | December 29, 2016 |
| NCT02412371 | Terminated | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | April 30, 2015 | August 5, 2019 |
| NCT01006252 | Terminated | Phase 3 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma | December 2009 | March 2011 |
| NCT00976677 | Terminated | Phase 2 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer | January 2010 | November 2013 |
| NCT02449655 | Terminated | Phase 2 | Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy | February 12, 2015 | July 16, 2018 |
| NCT02470585 | Terminated | Phase 3 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | June 29, 2015 | October 5, 2023 |
| NCT02474173 | Terminated | Phase 1 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | January 15, 2016 | October 26, 2022 |
| NCT00960297 | Terminated | Phase 2 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC | August 2009 | May 2013 |
| NCT00955305 | Terminated | Phase 2 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | March 2010 | November 2016 |
| NCT00954512 | Terminated | Phase 1/Phase 2 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | September 25, 2009 | June 7, 2011 |
| NCT00946712 | Terminated | Phase 3 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | July 15, 2009 | February 8, 2022 |
| NCT02530437 | Terminated | Phase 1/Phase 2 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | March 7, 2017 | January 7, 2022 |
| NCT00933426 | Terminated | Phase 1 | Lenalidomide and Paclitaxel in Prostate Cancer | August 2009 | December 2015 |
| NCT02551055 | Terminated | Phase 1 | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma | October 15, 2015 | February 17, 2017 |
| NCT00933374 | Terminated | Phase 2 | Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma | July 2009 | September 2013 |
| NCT01755845 | Unknown status | Phase 3 | Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients | January 2011 | December 2016 |
| NCT01756170 | Unknown status | Phase 3 | Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients | January 2011 | December 2016 |
| NCT00008021 | Unknown status | Phase 1 | Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma | February 2001 | |
| NCT02526953 | Unknown status | Phase 3 | Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients | January 2016 | October 2022 |
| NCT01366183 | Unknown status | Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | August 15, 2011 | ||
| NCT03237507 | Unknown status | Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer | July 1, 2017 | June 1, 2020 | |
| NCT00003064 | Unknown status | Phase 1/Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | January 1997 | |
| NCT02545010 | Unknown status | Phase 1 | Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer | September 2015 | August 2018 |
| NCT00039039 | Unknown status | Phase 3 | Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer | February 2000 | |
| NCT01405235 | Unknown status | Phase 3 | Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma | September 2006 | January 2015 |
| NCT03206177 | Unknown status | Phase 1 | Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | August 20, 2017 | August 19, 2023 |
| NCT04164238 | Unknown status | Phase 2 | Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients | November 7, 2019 | November 7, 2021 |
| NCT03195569 | Unknown status | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer | March 1, 2017 | December 10, 2018 | |
| NCT01428414 | Unknown status | Phase 2 | Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer | August 2011 | February 2015 |
| NCT00025688 | Unknown status | Phase 3 | Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer | January 2001 | |
| NCT03154294 | Unknown status | Phase 1 | Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors | July 6, 2017 | July 2022 |
| NCT00024310 | Unknown status | Phase 1 | Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors | September 2001 | |
| NCT04073537 | Unknown status | Phase 3 | Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer | October 31, 2019 | June 30, 2022 |
| NCT00616031 | Unknown status | Phase 2 | Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer | January 2008 | |
| NCT03095001 | Unknown status | Phase 2 | Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion | June 1, 2017 | June 1, 2020 |
| NCT01471132 | Unknown status | Phase 2 | Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis | September 2011 | September 2015 |
| NCT04072263 | Unknown status | Phase 1/Phase 2 | Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer | August 1, 2018 | December 1, 2021 |
| NCT04054531 | Unknown status | Phase 2 | Study of KN046 With Chemotherapy in First Line Advanced NSCLC | September 4, 2019 | June 1, 2021 |
| NCT01487226 | Unknown status | Phase 2 | Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer | January 2008 | January 2015 |
| NCT01491217 | Unknown status | Phase 1/Phase 2 | A Study of Oraxol® in Gastric Cancer Patients | May 2009 | December 2012 |
| NCT04261465 | Unknown status | Phase 2 | NUVOLA TRIAL Open-label Multicentre Study | December 1, 2019 | December 1, 2022 |
| NCT04053205 | Unknown status | Phase 1/Phase 2 | A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer | August 2019 | December 2020 |
| NCT03053856 | Unknown status | Phase 2 | Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients | February 14, 2017 | August 13, 2021 |
| NCT01507428 | Unknown status | Phase 2 | Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer | February 22, 2012 | August 1, 2021 |
| NCT00629278 | Unknown status | Phase 3 | Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer | December 2007 | |
| NCT00070278 | Unknown status | Phase 3 | Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer | January 2005 | |
| NCT00077220 | Unknown status | Phase 3 | Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer | June 2002 | |
| NCT04000295 | Unknown status | Phase 3 | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | August 16, 2019 | July 2022 |
| NCT00083083 | Unknown status | Phase 2 | Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer | March 2005 | |
| NCT03990103 | Unknown status | Phase 2 | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | November 1, 2017 | April 30, 2022 |
| NCT01547741 | Unknown status | Phase 3 | Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer | April 2012 | November 2023 |
| NCT00003558 | Unknown status | Phase 3 | Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin | August 1998 | |
| NCT00108745 | Unknown status | Phase 3 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | March 21, 2005 | February 22, 2022 |
| NCT01034189 | Unknown status | Phase 2 | Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer | October 2008 | June 2012 |
| NCT00964626 | Unknown status | Phase 2 | Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer | April 2009 | |
| NCT00820690 | Unknown status | Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer | July 2008 | September 2017 | |
| NCT03966118 | Unknown status | Phase 2 | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma | April 1, 2019 | September 2023 |
| NCT00022217 | Unknown status | Phase 2 | Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer | November 2000 | |
| NCT03949634 | Unknown status | Phase 3 | Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD) | September 1, 2017 | October 31, 2020 |
| NCT01599078 | Unknown status | N/A | Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention | January 2012 | January 2014 |
| NCT03045770 | Unknown status | N/A | mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA | February 10, 2017 | December 30, 2019 |
| NCT00017303 | Unknown status | Phase 2 | Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer | January 2001 | |
| NCT04342910 | Unknown status | Phase 3 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | September 21, 2020 | September 1, 2022 |
| NCT00634595 | Unknown status | Phase 2 | Trial of E10A in Head and Neck Cancer | March 2008 | December 2010 |
| NCT03925233 | Unknown status | Breast Cancer Treatment Based on Organ-like Culture | January 2, 2019 | December 15, 2021 | |
| NCT04416035 | Unknown status | Phase 3 | A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC | August 17, 2020 | November 10, 2021 |
| NCT00011921 | Unknown status | Phase 3 | Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer | September 1997 | |
| NCT01650376 | Unknown status | Phase 1/Phase 2 | Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer | August 2012 | December 2019 |
| NCT04426955 | Unknown status | Phase 3 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer | June 30, 2020 | December 2023 |
| NCT01654146 | Unknown status | Phase 3 | ICON8: Weekly Chemotherapy in Ovarian Cancer | June 2011 | |
| NCT00168883 | Unknown status | Phase 2 | Study for Patients With Non Small Cell Lung Cancer (NSCLC) | October 2002 | December 2006 |
| NCT04435652 | Unknown status | Phase 2/Phase 3 | A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer. | July 1, 2020 | November 30, 2022 |
| NCT02611700 | Unknown status | Phase 3 | Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma | November 2015 | June 2019 |
| NCT03912402 | Unknown status | Phase 2 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA) | December 25, 2018 | July 7, 2020 |
| NCT01024712 | Unknown status | Phase 2 | Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer | May 2009 | |
| NCT00652119 | Unknown status | Phase 1 | Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin | February 2008 | August 2021 |
| NCT03026881 | Unknown status | Phase 1 | A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | January 2017 | June 2018 |
| NCT01224652 | Unknown status | Phase 3 | Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy | ||
| NCT00009932 | Unknown status | Phase 1 | Combination Chemotherapy in Treating Patients With Solid Tumors | January 2001 | |
| NCT01711697 | Unknown status | Phase 1 | An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | September 4, 2012 | May 31, 2022 |
| NCT00009776 | Unknown status | Phase 1 | Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma | March 2001 | |
| NCT00009763 | Unknown status | Phase 1 | Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer | March 2001 | |
| NCT00009750 | Unknown status | Phase 1 | Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | March 2001 | |
| NCT00008047 | Unknown status | Phase 1/Phase 2 | Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus | August 1999 | |
| NCT02934464 | Unknown status | Phase 3 | Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers | December 2016 | December 2021 |
| NCT04520035 | Unknown status | Phase 2 | Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell | August 1, 2020 | December 31, 2021 |
| NCT01220154 | Unknown status | Phase 1 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | October 2010 | |
| NCT01752205 | Unknown status | Phase 3 | Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma | November 2012 | November 2014 |
| NCT00002627 | Unknown status | Phase 1/Phase 2 | Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer | November 1994 | |
| NCT03810872 | Unknown status | Phase 2 | An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation | June 21, 2017 | December 2022 |
| NCT00006120 | Unknown status | Phase 2 | Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer | May 2000 | |
| NCT00006118 | Unknown status | Phase 2 | Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer | July 1999 | |
| NCT00003253 | Unknown status | Phase 2 | Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer | July 1997 | |
| NCT00006049 | Unknown status | Phase 3 | ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | May 2000 | |
| NCT00289263 | Unknown status | Phase 3 | Maintenance Chemotherapy in Metastatic Breast Cancer | April 1998 | October 2003 |
| NCT01015339 | Unknown status | Phase 3 | Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | November 2009 | August 2015 |
| NCT03792074 | Unknown status | Phase 3 | To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer | February 2019 | January 2022 |
| NCT03791905 | Unknown status | Phase 2 | PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma | January 15, 2019 | December 2023 |
| NCT00838656 | Unknown status | Phase 2 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | October 2007 | |
| NCT00686114 | Unknown status | Phase 3 | Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer | May 2008 | December 2014 |
| NCT02879513 | Unknown status | Phase 3 | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | January 2014 | December 2022 |
| NCT03763123 | Unknown status | Phase 1 | A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. | April 24, 2018 | December 31, 2020 |
| NCT02879097 | Unknown status | Phase 3 | Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC | December 2016 | May 2018 |
| NCT00005581 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer | June 2000 | |
| NCT00323583 | Unknown status | Phase 2 | Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer | May 2006 | |
| NCT00004887 | Unknown status | Phase 3 | Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery | January 1999 | |
| NCT03756090 | Unknown status | N/A | The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer | December 1, 2018 | November 30, 2020 |
| NCT03735082 | Unknown status | Phase 2 | Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer | November 1, 2018 | June 1, 2020 |
| NCT01843829 | Unknown status | Phase 2 | A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer | October 2013 | May 2016 |
| NCT03718624 | Unknown status | Phase 2 | A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | October 30, 2018 | October 30, 2020 |
| NCT02595554 | Unknown status | Phase 3 | Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer | November 2015 | December 2020 |
| NCT01848197 | Unknown status | N/A | Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer | May 2013 | December 2020 |
| NCT01850628 | Unknown status | NSABP Biospecimen Discovery Project | July 2013 | February 2022 | |
| NCT00003251 | Unknown status | Phase 1/Phase 2 | Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer | December 1997 | |
| NCT02866370 | Unknown status | Phase 2 | Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | April 2015 | March 2021 |
| NCT03648489 | Unknown status | Phase 2 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | September 21, 2018 | December 2022 |
| NCT00373620 | Unknown status | Phase 2 | A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients | January 2006 | |
| NCT00003160 | Unknown status | Phase 2 | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | September 1997 | |
| NCT05189730 | Unknown status | Phase 2 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC | July 1, 2021 | December 31, 2023 |
| NCT02568033 | Unknown status | Early Phase 1 | Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer | October 2013 | October 2017 |
| NCT00002628 | Unknown status | Phase 1/Phase 2 | Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer | November 1994 | |
| NCT05213312 | Unknown status | Phase 2/Phase 3 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | June 1, 2022 | March 1, 2024 |
| NCT00453323 | Unknown status | Phase 2 | Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer | June 2006 | December 2010 |
| NCT00003327 | Unknown status | Phase 2 | Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer | September 1997 | |
| NCT00462397 | Unknown status | Phase 2 | Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer | June 2005 | |
| NCT03580395 | Unknown status | Phase 2/Phase 3 | Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer | June 1, 2017 | December 2022 |
| NCT02858206 | Unknown status | Phase 2 | Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma | June 2016 | November 2021 |
| NCT02579564 | Unknown status | Phase 3 | Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients | October 2016 | December 2018 |
| NCT05228743 | Unknown status | N/A | Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer | September 1, 2020 | October 31, 2023 |
| NCT00004265 | Unknown status | Phase 2 | Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer | February 1999 | |
| NCT03579004 | Unknown status | Phase 2 | Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer | July 10, 2017 | July 10, 2020 |
| NCT00004253 | Unknown status | Phase 2 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery | March 2000 | |
| NCT03570437 | Unknown status | Phase 2 | Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? | May 17, 2018 | June 30, 2023 |
| NCT00486668 | Unknown status | Phase 3 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | July 2007 | March 2017 |
| NCT02423603 | Unknown status | Phase 2 | PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer | May 2014 | June 2020 |
| NCT04768075 | Unknown status | Phase 3 | Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC | March 5, 2021 | April 30, 2024 |
| NCT00004173 | Unknown status | Phase 1 | Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer | October 1999 | |
| NCT04771871 | Unknown status | Phase 2 | MicroRNA Profiles in Triple Negative Breast Cancer | November 29, 2021 | August 2023 |
| NCT02743923 | Unknown status | Phase 3 | Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer | April 2016 | April 2024 |
| NCT02741856 | Unknown status | Phase 2/Phase 3 | Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation | November 4, 2016 | April 2023 |
| NCT00786110 | Unknown status | Phase 2 | Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients | April 2008 | October 2010 |
| NCT00499525 | Unknown status | Phase 2 | Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer | June 2007 | December 2022 |
| NCT04802980 | Unknown status | Phase 1 | A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor | April 28, 2020 | September 2023 |
| NCT02023710 | Unknown status | Phase 2 | Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma | December 2013 | December 2017 |
| NCT00499603 | Unknown status | Phase 2 | Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | July 2007 | April 2017 |
| NCT03544047 | Unknown status | N/A | Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model | January 1, 2019 | July 1, 2020 |
| NCT02036164 | Unknown status | Phase 3 | Adjuvant Chemotherapy for Locally Advanced Cervical Cancer | January 2014 | January 2019 |
| NCT03539328 | Unknown status | Phase 2 | Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer | June 2018 | April 2022 |
| NCT02038621 | Unknown status | Phase 2 | The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer | January 2014 | December 2017 |
| NCT00004097 | Unknown status | Phase 1 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer | August 1999 | |
| NCT04843098 | Unknown status | Phase 1/Phase 2 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | April 2021 | January 2024 |
| NCT02039791 | Unknown status | Phase 2 | Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer | January 2013 | August 2016 |
| NCT02041338 | Unknown status | Phase 2 | Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer | January 2014 | December 2017 |
| NCT03512834 | Unknown status | Phase 2 | Paclitaxel-Avelumab for Angiosarcoma | June 1, 2018 | May 2023 |
| NCT03503604 | Unknown status | Phase 1 | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | May 1, 2018 | March 1, 2019 |
| NCT03475615 | Unknown status | Phase 3 | A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites | March 16, 2018 | December 31, 2020 |
| NCT03467178 | Unknown status | Phase 2 | Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. | July 30, 2018 | December 2021 |
| NCT02051868 | Unknown status | Phase 2 | International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel | December 2013 | February 2018 |
| NCT00004094 | Unknown status | Phase 2 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx | August 1999 | |
| NCT03429972 | Unknown status | Phase 2 | Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients | September 2016 | June 2020 |
| NCT02065687 | Unknown status | Phase 2/Phase 3 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | March 17, 2014 | September 13, 2023 |
| NCT02432365 | Unknown status | Phase 2 | Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy | February 2015 | December 2023 |
| NCT00533936 | Unknown status | Phase 2 | Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer | September 2006 | |
| NCT02435186 | Unknown status | Phase 2 | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | June 2015 | August 2018 |
| NCT02437812 | Unknown status | Phase 2 | Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma | January 2014 | April 2021 |
| NCT02713386 | Unknown status | Phase 1/Phase 2 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | November 14, 2016 | September 30, 2022 |
| NCT03348098 | Unknown status | Phase 2 | Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer | September 6, 2017 | December 6, 2018 |
| NCT00003733 | Unknown status | Phase 2 | Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer | December 1997 | |
| NCT00003717 | Unknown status | Phase 2 | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | October 1998 | |
| NCT03328234 | Unknown status | Phase 3 | Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03 | September 1, 2017 | December 31, 2022 |
| NCT02694224 | Unknown status | Phase 2 | Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients | April 2016 | December 2018 |
| NCT00003326 | Unknown status | Phase 2 | Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus | September 1997 | |
| NCT03314740 | Unknown status | Phase 2 | Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib | June 1, 2017 | November 30, 2019 |
| NCT00003696 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer | October 1998 | |
| NCT00003643 | Unknown status | Phase 2/Phase 3 | Combination Chemotherapy in Treating Men With Germ Cell Cancer | October 1998 | |
| NCT02446652 | Unknown status | Phase 3 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | July 2015 | August 2018 |
| NCT04973904 | Unknown status | Phase 2 | Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer | August 1, 2021 | December 1, 2023 |
| NCT03308552 | Unknown status | Phase 3 | Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02 | December 1, 2017 | August 30, 2021 |
| NCT03292822 | Unknown status | Early Phase 1 | Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line | November 1, 2017 | April 1, 2019 |
| NCT00003284 | Unknown status | Phase 2 | High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer | January 1998 | |
| NCT01084876 | Unknown status | Phase 3 | Demonstrate Efficacy and Safety of Metastatic Breast Cancer | June 2010 | December 2017 |
| NCT04986098 | Unknown status | Clinical Study on the Effectiveness and Safety Evaluation of Directional Atherectomy Combined With Drug-coated Balloons | August 1, 2021 | December 31, 2023 | |
| NCT02514681 | Unknown status | Phase 3 | A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer | August 1, 2015 | December 2021 |
| NCT01084863 | Unknown status | Phase 1/Phase 2 | Evaluate Safety, Efficacy and Pharmacokinetics | February 2010 | December 2020 |
| NCT00807768 | Unknown status | Phase 3 | Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer | March 23, 2009 | |
| NCT03282825 | Unknown status | Phase 1 | Clinical Study of Decitabine and Paclitaxel Combination Therapy | March 28, 2017 | May 2018 |
| NCT02644863 | Unknown status | Phase 2 | Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer | December 2015 | May 2019 |
| NCT02230319 | Unknown status | Phase 2 | Prevention of Paclitaxel Neuropathy With Cryotherapy | October 2014 | March 2017 |
| NCT00551122 | Unknown status | Phase 1/Phase 2 | Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors | November 2006 | |
| NCT02244502 | Unknown status | Phase 1/Phase 2 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | September 2014 | December 2016 |
| NCT02250599 | Unknown status | Phase 2 | Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma | August 2014 | December 2016 |
| NCT03273595 | Unknown status | Phase 2 | Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer | July 2016 | December 2019 |
| NCT00954174 | Unknown status | Phase 3 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | August 17, 2009 | |
| NCT01042522 | Unknown status | Phase 2 | Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors | February 8, 2010 | November 2, 2022 |
| NCT03264547 | Unknown status | Phase 3 | A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | August 28, 2017 | October 31, 2023 |
| NCT03262948 | Unknown status | Phase 3 | Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer | December 1, 2017 | October 1, 2020 |
| NCT04190745 | Unknown status | Phase 2 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | November 29, 2019 | June 2024 |
| NCT00039546 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery | August 2001 | |
| NCT01295502 | Unknown status | Phase 1 | Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer | April 4, 2011 | |
| NCT00006374 | Withdrawn | Phase 2 | Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | October 1999 | June 2001 |
| NCT01156961 | Withdrawn | Phase 4 | A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX) | October 2010 | December 2012 |
| NCT04252768 | Withdrawn | Phase 1 | A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel | June 2023 | February 2026 |
| NCT02569489 | Withdrawn | Phase 1 | Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer | December 2015 | December 2015 |
| NCT03841747 | Withdrawn | Phase 2 | Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer | December 2020 | June 2025 |
| NCT04561817 | Withdrawn | Phase 2 | To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer | October 1, 2020 | October 1, 2023 |
| NCT05177796 | Withdrawn | Phase 2 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | March 11, 2022 | July 26, 2023 |
| NCT02929576 | Withdrawn | Phase 3 | Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer | September 2016 | |
| NCT00547443 | Withdrawn | Phase 1/Phase 2 | Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | July 2007 | July 2009 |
| NCT03806049 | Withdrawn | Phase 3 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | December 2019 | December 2024 |
| NCT01702714 | Withdrawn | Phase 1 | A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease | July 2014 | February 2016 |
| NCT02013453 | Withdrawn | Phase 2 | A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer | December 2013 | |
| NCT02274012 | Withdrawn | Phase 2 | Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment | May 29, 2014 | August 12, 2015 |
| NCT01205217 | Withdrawn | Phase 2 | Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer | December 2010 | December 2010 |
| NCT03554109 | Withdrawn | Phase 2 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | September 2018 | December 2021 |
| NCT03770299 | Withdrawn | Phase 2 | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | January 15, 2021 | March 14, 2024 |
| NCT03766607 | Withdrawn | Phase 2 | Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer | September 30, 2019 | June 30, 2022 |
| NCT04203511 | Withdrawn | Phase 3 | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | July 31, 2020 | January 31, 2025 |
| NCT04806945 | Withdrawn | Phase 3 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | September 30, 2022 | October 30, 2024 |
| NCT03872505 | Withdrawn | Phase 2 | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer | July 2022 | July 2027 |
| NCT04611776 | Withdrawn | Phase 2 | A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer | July 1, 2021 | January 8, 2026 |
| NCT00084565 | Withdrawn | Phase 2 | Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer | November 2003 | November 2004 |
| NCT05791097 | Withdrawn | Phase 3 | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. | July 28, 2023 | December 26, 2027 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |
| NCT02312804 | Withdrawn | Phase 1 | Ph Ib/BGJ398/Cervix and Other Solid Tumors | January 2015 | January 2015 |
| NCT02598687 | Withdrawn | Phase 1 | Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer. | December 2015 | April 2016 |
| NCT04262869 | Withdrawn | Phase 2 | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | March 27, 2020 | October 18, 2021 |
| NCT03058939 | Withdrawn | Phase 2 | Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer | November 2018 | June 2019 |
| NCT03285607 | Withdrawn | Phase 1 | MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | September 30, 2018 | February 28, 2021 |
| NCT04989283 | Withdrawn | Phase 2 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | September 9, 2021 | May 10, 2031 |
| NCT02040454 | Withdrawn | Phase 2 | Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis (PaciFIST-2) | March 2014 | October 2016 |
| NCT03197584 | Withdrawn | Phase 1/Phase 2 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | December 2017 | April 2019 |
| NCT00054392 | Withdrawn | Phase 3 | Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | September 2001 | September 2001 |
| NCT01419548 | Withdrawn | Phase 1 | ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems | July 29, 2011 | November 18, 2011 |
| NCT02044601 | Withdrawn | Phase 1/Phase 2 | Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) | June 2014 | |
| NCT00055887 | Withdrawn | Phase 3 | Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer | November 2002 | |
| NCT03704077 | Withdrawn | Phase 2 | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | October 31, 2019 | September 30, 2024 |
| NCT03699033 | Withdrawn | Phase 2 | Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer | October 1, 2018 | October 1, 2020 |
| NCT02050009 | Withdrawn | Phase 1 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | October 31, 2014 | |
| NCT00022230 | Withdrawn | Phase 1/Phase 2 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | January 2000 | January 2007 |
| NCT04038489 | Withdrawn | Phase 2 | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer | October 18, 2019 | April 30, 2023 |
| NCT02053597 | Withdrawn | Phase 2 | TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen | October 2014 | July 2015 |
| NCT05295589 | Withdrawn | Phase 2 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | June 30, 2022 | March 17, 2023 |
| NCT01169870 | Withdrawn | Phase 2 | Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients | July 2007 | October 2008 |
| NCT01163929 | Withdrawn | Phase 2 | A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer | July 2010 | March 2012 |
| NCT02059967 | Withdrawn | Phase 1 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | March 2014 | January 2015 |
| NCT03607955 | Withdrawn | Phase 1 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | June 30, 2021 | August 31, 2029 |
| NCT00009828 | Withdrawn | Phase 1 | Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors | December 1999 | |
| NCT04466917 | Withdrawn | Phase 3 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | May 15, 2021 | November 13, 2022 |
| NCT00458315 | Withdrawn | Phase 2 | Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor | May 2007 | May 2012 |
| NCT02637375 | Withdrawn | N/A | A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | May 2016 | December 2018 |
| NCT01031212 | Withdrawn | Phase 1 | ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors | January 2010 | June 2013 |
| NCT03400306 | Withdrawn | Phase 1 | A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer | November 15, 2021 | November 16, 2021 |
| NCT00057928 | Withdrawn | Phase 3 | S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer | April 2003 | July 2003 |
| NCT01953445 | Withdrawn | Phase 2 | Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer | August 2014 | July 2015 |
| NCT01138137 | Withdrawn | Phase 1 | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | June 2010 | December 2014 |
| NCT01000896 | Withdrawn | Phase 1 | Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | January 2010 | March 2011 |
| NCT02985333 | Withdrawn | Phase 2 | Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | January 2014 | June 2019 |
| NCT05233696 | Withdrawn | Phase 2 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | January 4, 2022 | December 1, 2022 |
| NCT03920839 | Withdrawn | Phase 1 | INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | July 15, 2019 | November 4, 2019 |
| NCT00003622 | Withdrawn | Phase 2 | Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy | January 1999 | February 22, 2017 |
| NCT01137994 | Withdrawn | Phase 2 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | October 2011 | March 2018 |
| NCT04754815 | Withdrawn | Phase 2 | Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC | April 1, 2021 | April 1, 2026 |
| NCT01159236 | Withdrawn | N/A | Molecular Triaging of Newly Diagnosed Breast Cancer | September 2010 | |
| NCT00768131 | Withdrawn | Phase 2 | A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel | October 2008 | October 2008 |
| NCT04762901 | Withdrawn | Phase 1 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | April 1, 2021 | January 2026 |
| NCT05809895 | Withdrawn | Phase 2 | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | September 15, 2023 | July 18, 2029 |
| NCT02272699 | Withdrawn | Phase 2/Phase 3 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | November 2014 | December 2020 |
| NCT03818997 | Withdrawn | Phase 2 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | December 2019 | April 2022 |
| NCT03834571 | Withdrawn | Phase 2 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | May 31, 2022 | January 2025 |